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CHAPTER 1: BACKGROUND AND LITERATURE REVIEW 
 
Introduction 
Valentine’s Day celebrations in 2003 did not stop the World Health Organization from releasing 
its Weekly Epidemiological Record (World Health Organization, 2003). The bulk of that week’s 
issue was unremarkable—an update on the global status of immunization safety—but five 
sentences were devoted to several hundred cases of an acute respiratory syndrome in China’s 
Guangdong Province. The document is written in dry, scientific language, and it does not set off 
any alarm bells. In fact, nothing suggests that these were the first rumblings of a worldwide 
threat. Over the ensuing weeks, case reports continued to climb—1000 by March 27, 3000 by 
April 14, 7000 by May 8—and the WHO’s reporting became steadily grimmer. The disease had 
earned an ominous moniker, severe acute respiratory syndrome (SARS). Global, national, and 
local health officials scrambled to contain, identify, and trace the unknown pathogen causing 
SARS, and the world waited anxiously. Was this the pandemic we had long feared? 
 
Without knowing the cause of SARS, containment and quarantine were the primary weapons for 
its control. In a cruel twist, these strategies meant that those tasked with caring for the sick, 
healthcare workers, were one of the most highly infected groups. By the time the outbreak was 
stopped, in early June 2003, SARS had reached every inhabited continent except South America 
and caused 8096 cases and 774 deaths. The infectious agent had also been identified—SARS 
was caused by a coronavirus (Drosten et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003b; Rota, 
2003). 
In and of itself, isolating a coronavirus that caused human respiratory illness was unremarkable. 
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As early as the 1960’s, coronaviruses were known causes of the “common cold” but were of no 
unusual threat to the world’s population (Mäkelä et al., 1998; McIntosh et al., 1973; 1970). In 
fact, before SARS, members of this single-stranded RNA virus family were much more 
important economically than clinically. The first identified coronavirus, infectious bronchitis 
virus (IBV), causes devastating respiratory disease in commercial chickens (Cavanagh, 2007). 
Transmissible gastroenteritis virus (TGEV) and porcine epidemic diarrhea virus (PEDV), 
predictably, cause severe diarrhea in pigs. PEDV alone may cause between $900 million and 
$1.8 billion in annual economic losses in the United States (Annamalai et al., 2015). Cattle are 
not exempt from coronaviral illnesses, either—newborn calves are susceptible to both enteric 
and respiratory disease from bovine coronavirus infections. Adult cattle are susceptible to 
shipping fever and the colorfully-named “winter dysentery with hemorrhagic diarrhea syndrome” 
(Saif, 2010). Murine hepatitis virus (MHV), the focus of this dissertation, is a scourge of animal 
research facilities across the globe (National Research Council (US), 2000). Coronaviruses have 
also been found in a broad range of other non-commercial mammalian and avian species (Brister 
et al., 2014; Leibowitz et al., 2011). The emergence of a highly pathogenic human coronavirus 
changed the paradigm. Rapidly transmitted, terrifyingly lethal, and nearly untreatable, SARS-
CoV ignited a new era of research into coronavirus biology, ecology, and countermeasures. 
 
In the 15 years since SARS made its mark on the public memory and the global health network, 
intensive study of SARS-CoV and its relatives has revealed fascinating aspects of coronaviral 
biology. Coronaviruses carry some of the largest single-strand RNA genomes in existence and 
encode an array of enzymes rarely found in RNA viral systems (Gorbalenya et al., 2006; Smith 
et al., 2014; Snijder et al., 2016; 2003). Worldwide networks of global health officials, 
epidemiologists, zoologists, and virologists have identified numerous coronaviruses poised for 
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emergence into humans (Becker et al., 2008; Ge et al., 2013; Lau et al., 2005; Li et al., 2005; 
Poon et al., 2005), and collaborative efforts between coronavirologists, chemists, structural 
biologists, and pharmaceutical companies have explored diverse strategies for countermeasures 
against CoV disease (Modjarrad, 2016; Rabaan et al., 2017). In this time, as well, three new 
human coronaviruses have been identified (van der Hoek et al., 2004; Woo et al., 2004; Zaki et 
al., 2012), two of which cause mild respiratory disease. The third, MERS-CoV, emerged from 
bat and camel populations to cause the Middle East respiratory syndrome and remains a public 
health threat 6 years after its identification (Arabi et al., 2017; Zaki et al., 2012). 
 
In this dissertation, I describe my contribution to this compendium of work. I focus on an 
enzyme rarely found in RNA viral biology: a proofreading exoribonuclease. In particular, I 
examine the importance of this enzyme for coronavirus replication, and I assess the evolutionary 
consequences of its disruption. Along the way, I have adapted experimental methods from other 
viral systems for the detailed study of coronaviruses. 
 
Coronavirus genome organization and replication cycle 
The phylogeny of coronaviruses was recently updated to accommodate newly discovered viral 
species (Gorbalenya et al., 2017). The family Coronaviridae remains classified within the order 
Nidovirales, suborder Cornidoviridae, and is now divided into two subfamilies: 
Orthocoronavirinae and Alphaletovirinae. All coronaviruses discussed in this dissertation are 
Orthocoronavirinae, divided into four genera: Alphacoronavirus, Betacoronavirus, 
Deltacoronavirus, and Gammacoronavirus. Of the six coronaviruses infecting humans, two are 
alphacoronaviruses (HCoV-229E and HCoV-NL63), and four are betacoronaviruses (SARS-
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CoV, MERS-CoV, HCoV-OC43, and HCoV-HKU1). Murine hepatitis virus, the focus of this 
dissertation, is also a betacoronavirus. The recently described microhyla letovirus 1 (MleV) is 
the sole member of the Alphaletovirinae subfamily (Bukhari et al., 2018). From this point 
forward, “coronavirus” will refer only to the Orthocoronavirinae, as little is known about MleV. 
 
Coronavirus genomes are single strands of positive-sense RNA (that is, directly translatable by 
the ribosome) that range from 26-32 kilobases in length (Brister et al., 2014) (Figure 1). Like 
cellular mRNA, coronavirus genomes have 5¢ caps and 3¢ poly(A)-tails, and the termini fold into 
conserved RNA secondary structures essential for replication (Goebel et al., 2007; 2004a; 2004b; 
Masters, 2006). Coronaviruses encode 16 nonstructural proteins (nsps), a minimum of four 
structural proteins, and a species-dependent array of accessory proteins (Perlman and Netland, 
2009). In general, nonstructural proteins are involved in modifying cell membranes, cleaving 
viral proteins, and replicating the genome, while structural and accessory proteins promote viral 
assembly and dissemination. Nonstructural proteins are translated from two overlapping open-
reading frames (ORFs) covering the first two-thirds of the genome. Structural and accessory 
proteins are encoded in separate ORFs in the final third of the genome and are translated from a 
nested set of subgenomic mRNA species (sgmRNA). Each sgmRNA contains the same 5¢ and 3¢ 
terminal sequences as the full genome, including the cap and poly(A)-tail. Although most 
sgmRNAs contain multiple protein-coding regions, only the 5¢-most ORF is translated (Masters, 
2006). Transcriptional regulatory sequences (TRS) precede each ORF. 
 
Coronavirus replication begins when the spike fusion glycoprotein (hereafter, spike protein) 
interacts with its cellular receptor (Figure 2). Host receptor distribution is a critical determinant  
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Figure 1. Murine hepatitis virus genome organization. 
 
 
 
 
 
 
 
 
Figure 1. Murine hepatitis virus (MHV) genome organization. The MHV genome is a 31.4 
kilobase, capped (dark circle), and polyadenylated positive-sense RNA molecule. The first two thirds 
of the genome encode 16 nonstructural proteins translated as a single polyprotein with a ribosomal 
frameshift. The final one-third encodes the structural proteins (spike – S, envelope – E, matrix – M, 
and nucleocapsid – N) and several accessory proteins. Transcriptional regulatory sequences (red 
arrows) at the 5¢ end and upstream of the structural and accessory ORFs drive transcription of a nested 
set of subgenomic mRNAs. Other coronavirus genomes differ from MHV primarily in the number and 
identity of accessory proteins. 
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of viral tropism, and structural variation in receptors between species is one of the key challenges 
to developing animal models for human coronavirus infections (Agrawal et al., 2015; van 
Doremalen et al., 2014; Zhao et al., 2014). The receptors for MHV and SARS-CoV are 
carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM-1) and angiotensin-
converting enzyme-2 (ACE2), respectively (Dveksler et al., 1993; Li et al., 2003). Dipeptidyl 
peptidase 4 (DPP4), in concert with CEACAM-5, permits MERS-CoV entry (Chan et al., 2016; 
Raj et al., 2013). Receptor engagement triggers the spike protein to fuse viral and cellular 
membranes, releasing nucleoprotein-coated genomes into the cytoplasm. Host ribosomes 
immediately translate the first open-reading frame, ORF1, which covers the first two-thirds of 
the genome. Approximately 60% of translation events terminate at around nucleotide 13,000, 
yielding polyprotein 1a (pp1a). In the remaining 40%, the ribosome slips backwards by one 
nucleotide and continues to synthesize polyprotein in a new frame (a -1 ribosomal frameshift) to 
yield pp1ab (Brierley et al., 1987; 1989; Irigoyen et al., 2016). Virus-encoded proteases cleave 
individual nsps from the polyprotein (Masters, 2006). Once matured, nsps 3, 4, and 6 convert the 
host endoplasmic reticulum into a network of double-membrane vesicles and convoluted 
membranes (Knoops et al., 2008; Oudshoorn et al., 2017). The remaining nsps then assemble 
into the replicase-transcriptase complex (RTC) and initiate genome replication and sgmRNA  
transcription. The RTC will be discussed in greater detail in subsequent sections. 
 
Schematically, genome replication is straightforward (Figure 3A,B). Full-length negative-sense 
RNAs are generated and serve as the template for genomic RNA production. The mechanism of 
sgmRNA transcription remains controversial, but data to date support a model of discontinuous 
transcription (Figure 3C,D) (Sawicki et al., 2007). During negative-strand synthesis, the RTC  
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Figure 2. Coronavirus replication cycle. 
 
 
Figure 2. Coronavirus replication cycle. Coronavirus spike proteins facilitate viral entry and virion 
uncoating. Genomic RNA is immediately recognized and translated by host ribosomes in the 
cytoplasm, and the resulting polypeptide is cleaved by viral proteases into mature nonstructural 
proteins (nsps). The replicase-transcriptase complex assembles on virus-induced double-membrane 
vesicles, where they replicate genomic RNA and transcribe subgenomic mRNAs (sgmRNAs). 
Coronavirus structural proteins are translated from the sgmRNAs and assemble into full virions in the 
endoplasmic reticulum golgi-intermediate complex (ERGIC). Progeny virions are trafficked and 
released by non-lytic exocytic pathways. This figure is reproduced from Case, 2018 and de Wit et al., 
2016, with permission. 
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Figure 3. Coronavirus genomic replication and subgenomic mRNA transcription. 
 
 
 
 
 
 
Figure 3. Coronavirus genomic replication and subgenomic mRNA transcription. The 
coronavirus replicase-transcriptase complex (RTC) generates a full-length antigenome (A) that serves 
as the template for synthesis of positive-sense RNA genomes (B). During negative-strand synthesis, 
the RTC jumps between transcriptional regulatory sequences (TRS) to generate subgenomic RNA 
species (C) that are templates for subgenomic mRNA synthesis (D).  
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may leap between a TRS and a homologous sequence at the 5¢ end of the genome, fusing the 
ORF with the 5¢ untranslated region. The RTC then uses these negative-strand templates to 
generate positive-sense sgmRNAs that are translated to form the structural and accessory 
proteins. The frequency with which the individual sgmRNAs are generated determines the yield 
of individual proteins, which has important implications for genome assembly and packaging. 
Once structural proteins are generated, virion assembly begins. Within the endoplasmic 
reticulum golgi-intermediate complex (ERGIC), coronavirus genomes are coated with protective 
layer of the viral nucleoprotein (N) and encapsulated within a cell-derived lipid envelope 
decorated with the spike protein (S) (Perlman and Netland, 2009) (Figure 2). In negative-stain 
microscopy, spike proteins form a characteristic halo of flare-like projections that resembles a 
solar corona—hence, the name coronavirus (Estola, 1973). The matrix (M) and envelope (E) 
proteins are also embedded in the viral envelope, and progeny virions are released by cellular 
secretory pathways. 
 
Human coronaviruses: origins, epidemiology, pathogenesis, clinical manifestations, and 
countermeasures 
Origins. Six coronaviruses are known to infect humans, and all are proposed to be of zoonotic 
origin. Molecular clock analyses and epidemiological studies suggest that coronavirus 
emergence into humans occurred recently by evolutionary timescales. HCoV-NL63 emerged the 
earliest between 1190-1449 CE (Huynh et al., 2012), followed by HCoV-229E between 1501-
1883 CE (Pfefferle et al., 2009), and HCoV-OC43 between 1866-1918 CE (Vijgen et al., 2005b). 
The emergence of HCoV-HKU1 has not been well-studied, but available evidence suggests that 
it may have entered humans in the 1950’s (Al-Khannaq et al., 2016a). SARS-CoV emerged in 
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late 2002 and was traced to civet cats in animal markets in Guanzhou province, China (de Wit et 
al., 2016; Guan et al., 2003). MERS-CoV was first identified from a patient in Saudi Arabia in 
2012, and later cases were subsequently linked to dromedary camels, where MERS-CoV-like 
viruses have circulated for at least 30 years (Cui et al., 2018; de Wit et al., 2016; Müller et al., 
2014). HCoV-229E, HCoV-NL63, SARS-CoV, and MERS-CoV precursors likely originated in 
bats, while HCoV-OC43 and HCoV-HKU1 likely arose from rodents (Corman et al., 2018; Cui 
et al., 2018; Forni et al., 2016a). 
 
Epidemiology. The four endemic human coronaviruses, HCoV-229E, -OC43, -HKU1, and -
NL63, are distributed worldwide (Arden et al., 2005; Bastien et al., 2005; Ebihara et al., 2005; 
Fouchier et al., 2004; Gerna et al., 2006; Kin et al., 2016; Kuypers et al., 2007; Moës et al., 2005; 
Pyrc et al., 2007; Sloots et al., 2006; Vabret et al., 2006a). CoVs are estimated to cause 10-30% 
of mild respiratory infections (“common colds”), but these figures may be skewed by frequent 
coinfection with other respiratory pathogens like respiratory syncytial virus, human 
metapneumovirus, rhinovirus, and adenovirus (Dominguez et al., 2009; Gaunt et al., 2010; 
Kuypers et al., 2007; McIntosh et al., 1970). HCoV epidemics display marked seasonality, with 
peaks of incidence in the winter and early spring and few or no infections detected in the summer 
(Gaunt et al., 2010; Hodinka, 2016). Individual HCoV species cause epidemics every 2-3 years, 
and reinfection is common even in the presence of pre-existing immunity (Bradburne and 
Somerset, 1972; Bradburne et al., 1967; McIntosh et al., 1970; Reed, 1984). All ages are 
susceptible, but elderly populations may be at greater risk for severe disease requiring 
hospitalization (Falsey et al., 1997; 2002). Volunteer studies have demonstrated that transmission 
is predominantly through respiratory droplets (Bradburne and Somerset, 1972; Bradburne et al., 
1967; Reed, 1984). 
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No cases of SARS-CoV have been reported since 2004, but the mechanisms of introduction, 
spread, and disease remain important for potential animal-to-human transmission and disease. 
Although the virus appears to have been introduced into humans though animal contact, the 
clustering of cases is more consistent with human-to-human spread than with thousands of 
independent animal exposures. Indeed, nosocomial transmission was a common feature of the 
outbreak, likely related to the fact that peak viral shedding occurs when respiratory symptoms 
are most severe (Cheng et al., 2004; Peiris et al., 2003a). These observations are consistent with 
droplet exposure as the primary mode of SARS-CoV transmission. Fomite transmission has also 
been implicated, as SARS-CoV RNA was found on hospital surfaces (Booth et al., 2005; Xiao et 
al., 2017a). Subsequent studies have demonstrated that viable SARS-CoV can persist on surfaces 
for a week at room temperature (Chan et al., 2011; Geller et al., 2012; Rabenau et al., 2004).  
SARS-CoV RNA can be detected in stool, and fecal-oral transmission may have occurred in the 
setting of profuse diarrhea (Booth et al., 2005; Xiao et al., 2017a). Aerosol transmission is 
implicated in several “superspreading” events, in which a small number of infected individuals 
transmitted infection to a much larger number of persons (Yu et al., 2004). 
 
Since its identification in 2012, MERS-CoV has continued to emerge within and spread outside 
of the Arabian Peninsula. As of January 27, 2019, the World Health organization has recorded 
2,279 laboratory-confirmed cases of MERS-CoV from 27 countries, all of which are linked to 
exposures in the Arabian Peninsula (approximately 80% in Saudi Arabia). As with SARS-CoV, 
the majority of reported MERS-CoV cases are linked to nosocomial transmission of respiratory 
droplets (Arabi et al., 2017). However, in contrast to the SARS-CoV epidemic, no sustained 
human-to-human transmission has been observed. Instead, as many as 40% of primary cases are 
linked to exposure to dromedary camels (Alraddadi et al., 2016). Camels carry great cultural 
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significance in the Middle East, hindering efforts to contain MERS-CoV. Higher levels of 
MERS-CoV RNA are detected in lower respiratory tract samples and can persist in some patients 
for more than a month (Memish et al., 2014; Song et al., 2015). MERS-CoV is also frequently 
detected in blood and stool and can survive at least 48 hours on environmental surfaces (Kim et 
al., 2016; van Doremalen et al., 2013). Most outbreaks of MERS-CoV are relatively small, but at 
least one superspreading event resulted in 186 cases and 36 deaths in Korea (Ki, 2015).  
 
Pathogenesis of SARS and MERS. Severe disease in SARS and MERS likely results from 
direct virologic damage and subsequent immunopathology. SARS-CoV and MERS-CoV 
replicate to high titers in respiratory epithelial cells early during infection, ravaging the 
pulmonary lining (Channappanavar et al., 2016; Chu et al., 2004; Oh et al., 2016; Peiris et al., 
2003a). Both viruses encode multiple innate immune antagonists that delay and dysregulate host 
responses to infection (reviewed in (Channappanavar and Perlman, 2017)). High virus titers 
eventually initiate an inflammatory cascade that leads to a vicious cycle of cytokine elaboration, 
vascular leakage, and inflammatory cell infiltration (Channappanavar et al., 2016; Gralinski and 
Baric, 2015; Totura and Baric, 2012). Overexuberant immune responses impair viral clearance 
and lead to acute respiratory distress syndrome, the primary cause of death from severe CoV 
disease (Arabi et al., 2017). Infection of distant organs has been observed for SARS-CoV (Gu et 
al., 2005) but not for MERS-CoV. Recapitulation of human clinical features in animal models of 
MERS-CoV infection remains challenging, but promising new models are in development. 
 
Clinical manifestations. Endemic human coronaviruses. The clinical presentations of endemic 
HCoV-OC43 and HCoV-229E are indistinguishable from the “common cold” symptoms of other 
respiratory viruses. The average incubation period is 2-4 days, with symptoms typically lasting 
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4-7 days. Rhinorrhea, cough, sore throat, malaise, and headache are the most common 
symptoms. Fever occurs in up to 60% of cases (Bradburne and Somerset, 1972; Bradburne et al., 
1967; McIntosh et al., 1970; Reed, 1984). Clinical manifestations of HCoV-HKU1 and HCoV-
NL63 are presumed to be similar but have not been well-studied, though HCoV-NL63 has been 
associated with croup in children (van der Hoek et al., 2005). HCoV infections are linked to 
episodes of wheezing and asthma attacks in both adults and children (McIntosh et al., 1973; 
Nicholson et al., 1993). Severe lower respiratory tract infections have been reported across 
various demographics but may be more likely in older adults and in immunocompromised 
patients. Whereas coronaviruses are known causes of severe diarrhea in animals (Annamalai et 
al., 2015; Saif, 2010), evidence is mixed on whether HCoVs contribute to enteric disease (Esper 
et al., 2010; Jevšnik et al., 2016; 2013). Similarly, although coronaviruses are important models 
for neurological diseases like multiple sclerosis (Bailey et al., 1949; Perlman et al., 1987), their 
role in similar disease processes in humans remains unproven. Diagnostic testing for endemic 
HCoVs is available (e.g. BioFire FilmArray Respiratory Panel; www.biofiredx.com/filmarrayrp), 
but its clinical value remains to be determined. 
 
Severe acute respiratory syndrome. The prodrome of SARS-CoV infection lasts three to seven 
days and is non-specific, consisting of fever, malaise, headache, and myalgias with a notable lack 
of upper respiratory symptoms. Respiratory symptoms develop during the second week of 
infection, including nonproductive cough progressing to dyspnea, chest pain, and, in 
approximately 20% of cases, acute respiratory distress syndrome. As many as 25% of SARS 
patients required mechanical ventilation in the intensive care unit. Risk factors for severe disease 
included diabetes, cancer, cardiovascular disease, and chronic obstructive pulmonary disease. 
Extrapulmonary manifestations including gastrointestinal symptoms (nausea, vomiting, diarrhea) 
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were common, and approximately 7% of patients developed acute kidney injury (Booth et al., 
2003; Leung et al., 2004; Peiris et al., 2003a). Several patients developed neuromuscular 
symptoms, though it is not clear whether these derived specifically from SARS-CoV infection or 
were sequelae of chronic illness (Tsai et al., 2004). The case fatality rate from SARS-CoV 
infection during the 2003 outbreak was 9.6%. The case definition for SARS is provided in Table 
1 (World Health Organization, 2009). 
 
Middle East respiratory syndrome. The clinical presentations of reported MERS cases were 
thoroughly collated and presented in Arabi et al., 2017. Briefly, the incubation period of MERS-
CoV is between 2-14 days and typically presents with nonspecific clinical features typical of 
acute respiratory illnesses, including low-grade fever, rhinorrhea, sore throat, and myalgia. 
Severe disease is characterized by the acute respiratory distress syndrome with multilobe 
involvement visible by radiography. Risk factors for severe disease include age >50 years and 
comorbidities like obesity, diabetes, COPD, end-stage renal disease, cancer, and 
immunosuppression. Extrapulmonary manifestations are common in severe MERS disease and 
include gastrointestinal symptoms (nausea, vomiting, diarrhea), acute kidney injury, and 
encephalitis-like neurological findings. Laboratory analyses typically detect leukopenia and 
lymphopenia with occasional thrombocytopenia, anemia, and aminotransferase elevations. The 
case fatality rate remains at 35%, though the true incidence of MERS-CoV infection is likely 
underestimated by existing data due to a potentially high incidence of asymptomatic infection. 
The case definition for MERS is provided in Table 2 (World Health Organization, 2017; 2018). 
 
Countermeasures. Coronavirus infections of humans are acute and self-limited. No effective  
antivirals are approved to treat human coronaviruses. The nucleoside analogue ribavirin was  
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Table 1. Clinical case definition of severe acute respiratory syndrome. 
 
 
 
 
 
 
 
 
Table 1. Clinical case definition of severe acute respiratory syndrome. World Health Organization, 
2009. 
 
 
 
Definition 
 
Clinical data 
 
• Documented fever AND 
• Symptoms of lower respiratory tract illness (cough, shortness of 
breath, difficult breathing) AND 
• Radiographic or autopsy evidence consistent with pneumonia or 
acute respiratory distress syndrome 
• No alternative diagnosis fully explaining the illness 
 
Laboratory data 
 
Diagnosis must be confirmed with one or both of: 
• Detection of viral RNA by RT-PCR from two separate samples 
OR virus culture from any specimen 
• Detection of rise in antibody titer 
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Table 2. Clinical case definition of Middle East respiratory syndrome. 
 
 
 
Table 2. Clinical case definition of Middle East respiratory syndrome. World Health Organization, 
2017 and 2018. 
 
 
 
Definition 
 
Confirmed Case 
 
Laboratory confirmation of infection irrespective of clinical signs and 
symptoms 
 
Probable case 
 
Three definitions: 
 
• Acute febrile respiratory illness with clinical, radiographic, or 
histopathologic evidence of pneumonia or acute respiratory 
distress syndrome AND 
• Direct epidemiologic link with confirmed MERS case AND 
• Testing for MERS-CoV is unavailable, negative on inadequate 
specimen, or inconclusive 
 
OR 
• Acute febrile respiratory illness with clinical, radiographic, or 
histopathologic evidence of pneumonia or acute respiratory 
distress syndrome AND 
• Person resides in or traveled to Middle East or country with 
known recent human/dromedary infections AND 
• Testing for MERS-CoV is inconclusive 
 
OR 
• Acute febrile respiratory illness of any severity AND 
• Direct epidemiologic link with confirmed MERS case AND 
• Testing for MERS-CoV is inconclusive 
 
Laboratory data 
 
• Detection of viral nucleic acid by RT-PCR for at least two 
specific genomic targets OR one genomic target with 
sequencing of a second target 
• Evidence of seroconversion by acute and convalescent antibody 
titers taken at least 14 days apart 
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used extensively and empirically during the 2003 SARS-CoV outbreak, but ribavirin-associated 
adverse events outweighed any measurable clinical benefits (Booth et al., 2003; Chiou et al., 
2005; Muller et al., 2007; Stockman et al., 2006). The ineffectiveness of ribavirin has been 
attributed both to its effects on host immune responses and to the SARS-CoV proofreading 
exoribonuclease (Barnard et al., 2006; Ferron et al., 2018; Smith et al., 2013). However, recent 
studies in our lab have identified a nucleoside analogue, remdesivir, with potent activity against 
epidemic and zoonotic coronaviruses that is proceeding towards clinical trials (Agostini et al., 
2018; Sheahan et al., 2017). Non-specific immune modulators including systemic corticosteroids 
may be associated with increased mortality in SARS-CoV and MERS-CoV and are thus not 
recommended unless indicated for another clinical condition (Arabi et al., 2017; Auyeung et al., 
2005; Stockman et al., 2006). However, host-directed therapies intended to promote antiviral 
immunity or prevent inflammatory damage are under consideration (Zumla et al., 2015). Meta-
analysis of observational studies suggests that human convalescent plasma may reduce SARS 
mortality (Mair-Jenkins et al., 2014), but the use of blood products has not been well-studied in 
MERS due, in part, to the challenge of harvesting large quantities of human hyperimmune serum 
(Arabi et al., 2016). Several polyclonal and monoclonal antibody preparations have shown 
positive results against SARS- and MERS-CoV in animal studies (Beigel et al., 2018; Luke et 
al., 2016; Pascal et al., 2015; Traggiai et al., 2004; Wang et al., 2018; Zhu et al., 2007), but high 
cost and the potential for antibody-enhanced disease may limit their clinical utility (Wang et al., 
2014).  
 
Challenges for development of effective vaccines targeted against HCoV-OC43, -229E, -HKU1, 
and -NL63 include the fact that infections are rarely life-threatening and reinfection is the rule, 
even in the presence of natural immunity from previous infections (Bradburne and Somerset, 
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1972; Bradburne et al., 1967; McIntosh et al., 1970; Reed, 1984). The durability of immunity to 
SARS-CoV and MERS-CoV is poorly understood. Nevertheless, effective vaccines for SARS-
CoV and MERS-CoV are highly desirable but not yet available. A potential vaccine target is the 
viral spike protein, which recognizes and penetrates host cells. In MERS-CoV-infected patients, 
the production of anti-spike IgG is correlated with survival, and anti-spike antibody levels 
inversely correlate with viral load in the respiratory tract (Corman et al., 2016a). Comprehensive 
discussion of existing vaccine development efforts for CoVs is beyond the scope of this 
dissertation and has been reviewed elsewhere (Choi et al., 2017; Rabaan et al., 2017; 
Schindewolf and Menachery, 2019). Briefly, candidate vaccine platforms include delivery of 
recombinant spike protein immunogens (Li et al., 2013; Pallesen et al., 2017); delivery of spike-
encoding nucleic acid (Kim et al., 2014; Muthumani et al., 2015; Song et al., 2013; Wang et al., 
2015a); and attenuation of live virus by disrupting critical protein functions or genetic 
architectures (Almazan et al., 2013; Fett et al., 2013; Graham et al., 2012; 2018; Lamirande et 
al., 2008; Menachery et al., 2018; 2014). Of particular relevance to this dissertation is the 
observation that a live, recombinant SARS-CoV mutant lacking exoribonuclease activity is 
attenuated and protective (Graham et al., 2012; Menachery et al., 2018). Nevertheless, despite 
promising results in preclinical studies, no vaccines have yet been approved for human 
coronaviruses. Thus, approaches for rapid development of stably attenuated live viruses or 
broadly immunogenic and cross-protective protein immunogens continues to be a key area for 
future research. 
 
Reservoirs for emerging coronaviruses 
Within a few months after SARS-CoV was identified, the epidemic had been traced to wet 
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markets in Guangzhou province, China. Virus was detected in captive civet cats but not in wild 
populations, indicating that these animals were incidental hosts rather than true reservoirs for 
SARS-CoV (Guan et al., 2003; Kan et al., 2005; Wang et al., 2006). Subsequent field studies 
implicated Chinese horseshoe bats as the likely origin of SARS-CoV (Lau et al., 2005; Li et al., 
2005). Since then, the search for prepandemic coronaviruses has focused on bats. 
 
Bats are a common starting point in any search for potentially zoonotic viruses, as bats are 
excellent hosts for evolving viruses. In part, this is a numbers game – with bats constituting more 
than 20% of all mammalian species, we would expect to find many different viruses among 
them. However, several other properties contribute to the viral diversity maintained within bat 
populations (reviewed in (Calisher et al., 2006)). Bats are exposed to a wide variety of viruses as 
they traverse wide geographic regions, with some individual animals migrating more than 800 
miles annually. Viral infections in bats are commonly asymptomatic and persistent, with virus 
shedding sometimes continuing for several months (Baker et al., 2013). Within massive and 
dense communities of bats (e.g. several million bats roosting at ~300 animals per square foot), 
viruses likely transmit rapidly and frequently. Together, these factors provide extensive 
evolutionary time to viruses and allow frequent shuffling of genetic elements that may drastically 
alter tropism and pathogenicity.  
 
Studies of bat populations since 2003 have determined that viruses phylogenetically related to 
SARS-CoV (SARSr-CoV) are distributed across Europe, Africa, and Southeast Asia (Cui et al., 
2018; de Wit et al., 2016). In one cave in Yunnan province, China, researchers found all the 
genetic elements needed to form SARS-CoV (Hu et al., 2017; Wang et al., 2016). Two SARSr-
CoV are capable of infecting human cells without adaptation and are immediately poised for 
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emergence (Ge et al., 2013; Menachery et al., 2016), while several more are on the precipice 
(Cui et al., 2018; Hu et al., 2017; Menachery et al., 2015). Numerous MERS-CoV-related viruses 
(MERSr-CoV) have been identified in bats (Annan et al., 2013; Corman et al., 2014a; 2014b; 
Lau et al., 2013; Yang et al., 2014), though none are an immediate progenitor of circulating 
dromedary and human viruses (Cui et al., 2018). Viruses related to endemic HCoV-229E and 
HCoV-NL63 have also been identified in bats (Corman et al., 2015; Drexler et al., 2010). The 
preponderance of CoV sequences in bat populations suggests that bats are likely the major 
natural reservoirs for coronaviruses. 
 
The focus on bats as coronaviral reservoirs is valuable but neglects the larger trends in 
coronavirus emergence. Contact between humans and bats is relatively rare compared with our 
exposure to other coronavirus-susceptible species such as dogs, cats, pigs, chickens, turkeys, 
rodents, and camels (Brister et al., 2014; Leibowitz et al., 2011). Accordingly, bat exposures 
have not been implicated directly in transmission of any endemic or zoonotic coronaviruses. 
Instead, the evidence indicates that coronaviruses enter humans after amplification (and perhaps 
evolution) within domesticated, intermediate hosts: civet cats for SARS-CoV, dromedary camels 
for MERS-CoV, and cattle for HCoV-OC43. In a mechanism paralleling that of MERS-CoV, 
precursors to HCoV-229E evolved towards the human genotype within camels before entering 
human populations (Corman et al., 2016b; 2015). Curiously, no host-specific coronaviruses have 
been found in any primate species, further suggesting that exposure to domesticated animals may 
be essential for human acquisition of coronaviruses (Corman et al., 2018). In addition, the 
financial costs of field studies of bats has stifled examinations of other potential reservoir hosts, 
such as rodents. Recent studies have identified rodent coronaviruses closely related to HCoV-
OC43 and HCoV-HKU1 (Lau et al., 2015; Wang et al., 2015b), and a relative of MERS-CoV 
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was identified in European hedgehogs (Corman et al., 2014b). Thus, while bats may be a genuine 
incubator for potentially pandemic coronaviruses, predictive models for coronavirus emergence 
should be bolstered by data regarding other potential reservoirs and zoonotic sources. 
 
SARS-CoV and MERS-CoV have clearly established the potential for zoonotic coronaviruses to 
cause outbreaks, but coronaviruses already circulating in humans could be the source of the next 
pandemic. Coronaviruses continue to evolve within their human hosts. SARS-CoV isolates from 
early in the outbreak have complete ORF8 coding sequences, but most viral genomes from 
middle- and late-epidemic patients have a 29-nucleotide deletion in ORF8 (Chinese SARS 
Molecular Epidemiology Consortium, 2004). Some genomes isolated in the very late stages of 
the epidemic lack ORF8 entirely, indicating that SARS-CoV was evolving even during the few 
months of the outbreak. Deletions potentially reflecting adaptation to the human host (or the 
release of selective pressure in a reservoir) have also been identified in MERS-CoV isolated in 
Jordan and Korea (Lamers et al., 2016; Payne et al., 2018; Xie et al., 2017). The impact of 
MERS-CoV deletions on viral fitness is unclear, but the SARS-CoV ORF8 deletions are 
attenuating in multiple model systems (Muth et al., 2018). Extensive positive selection has been 
detected in the nonstructural proteins of MERS-CoV during four years of circulation (Forni et 
al., 2016b), strongly suggesting adaptation to the human host. Endemic human coronaviruses 
also evolve over time, demonstrating that coronaviruses are not static in human populations (Al-
Khannaq et al., 2016b; Gerna et al., 2006; St-Jean et al., 2004; Vabret et al., 2006b; Vijgen et al., 
2005a). Thus, the next pandemic human coronavirus could emerge not from an animal, but from 
our own lungs. 
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Evolution of RNA viruses 
The remarkable diversity of coronaviruses worldwide is a small example of a much larger truth: 
RNA viruses are the most diverse group of biological entities on the planet (Holmes, 2016). 
RNA viruses replicate with some of the highest mutation rates known, contributing to their 
enormous and notorious adaptability (Duffy et al., 2008; Sanjuán et al., 2010). High mutation 
rates are both a blessing and a curse for RNA viruses, promoting rapid replication and adaptation 
but also constraining genome size and complexity. In this section, I will discuss the sources and 
importance of mutation rates in RNA viruses and establish general principles that determine the 
outcomes of viral evolution. 
 
How do viruses generate diversity? Genomic mutations are the ultimate source of all viral 
diversity. A key driver of mutation rates in RNA viruses is the intrinsic fidelity of their 
replication. Replication fidelity describes the accuracy with which nucleic acids are copied 
relative to the template strand. In cellular DNA replication, fidelity is regulated at multiple 
levels: selection and incorporation of correct bases by the polymerase, detection and editing of 
mismatches during replication by proofreading exonucleases, and repair of errors after 
replication. The confluence of these mechanisms means that, on average, DNA replication errors 
only occur at a rate of 10-11 to 10-9 mutations per nucleotide per replication cycle (approximately 
one error per billion bases copied) (Smith et al., 2014). In contrast, RNA virus fidelity is 
regulated almost exclusively by RNA-dependent RNA polymerases (RdRp) or retroviral reverse 
transcriptases (RT). Although the intrinsic fidelity of RdRps does not differ significantly from 
DNA polymerases (Arnold and Cameron, 2004), RNA viruses typically lack proofreading or 
post-replicative repair mechanisms and thus have mutation rates of approximately 10-6 to 10-4
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mutations per nucleotide per cell infection (Arnold and Cameron, 2004; Sanjuán et al., 2010; 
Steinhauer et al., 1992). Other viral proteins, such as the chikungunya helicase, West Nile virus 
N7-methyltransferase, and yellow fever envelope and pre-membrane proteins, can modulate viral 
fidelity but do not drastically change mutation rates (Collins et al., 2018; Stapleford et al., 2015; 
Van Slyke et al., 2015). A key exception is the proofreading exoribonuclease encoded by 
coronaviruses, which is discussed in detail in later sections. 
 
Viral replication enzymes do not operate in isolated biochemical systems, however, and thus 
their error rates also depend upon the cellular microenvironment. Reactive oxygen and nitrogen 
species produced in response to infection can damage viral nucleic acids, disrupting the 
interactions between Watson-Crick base pairs that are critical for accurate nucleotide selection 
(Seronello et al., 2011; Yoshitake et al., 2004). In addition, misincorporation frequencies can be 
altered by disrupting cellular nucleotide homeostasis (Diamond et al., 2002; Smith et al., 2013; 
Stapleford et al., 2015). Host-encoded protein families can directly mutate RNA viruses. 
Apolipoprotein B mRNA-editing catalytic peptide-like enzymes (APOBECs) convert cytosines 
to uracils in viral DNA from hepatitis B virus, papillomaviruses, and herpesviruses (Sanjuán et 
al., 2010). APOBECs are also packaged within HIV-1 virions and cause 98% of mutations in 
HIV-1 in vivo, a >40-fold increase over the virus-encoded RT (Cuevas et al., 2015). Adenosine 
deaminases (ADARs) convert adenosines to inosines in double-stranded RNA. In subsequent 
replication events, inosines pair with guanosines rather than thymines, causing A-to-G 
transitions. ADAR editing has been demonstrated in a variety of RNA and DNA viruses 
(Tomaselli et al., 2015). Additional undetermined host factors may affect mutation rates across 
cell types. For example, vesicular stomatitis virus (VSV) has higher mutation rates in 
mammalian cells compared to insect cells (Combe and Sanjuán, 2014), and the distribution of 
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mutation types in cucumber mosaic virus varies depending on the plant host (Pita et al., 2007). 
The precise mechanisms for these results have not yet been determined. Whether mutagenesis 
driven by the cellular microenvironment is pro- or antiviral remains controversial and may 
depend upon the particular model under study (Sanjuán and Domingo-Calap, 2016; Tomaselli et 
al., 2015).  
 
Once mutations generate initial variability in viral populations, recombination amplifies genetic 
diversity by shuffling genetic material. In RNA viruses, recombination occurs when the viral 
polymerase switches between different templates present within the same cell. By transferring 
large regions of viral sequence between templates, recombination can readily access evolutionary 
innovations that would be unattainable by mutation alone. Recombination is important within 
individual populations, where it can purge deleterious mutations or combine beneficial ones 
(Bentley and Evans, 2018; Sanjuán et al., 2010; Xiao et al., 2016). It is also important for global 
viral ecology, where large-scale transfer of whole genes (e.g. accessory proteins) or protein 
functional domains (e.g. spike protein receptor-binding motifs) facilitates new strain and species 
emergence (Arenas et al., 2018; Bentley and Evans, 2018; Mandary and Poh, 2018). 
Recombination occurs frequently in coronaviruses in tissue culture (Lai et al., 1985; Masters, 
2006), and hallmarks of recombination are frequently found in coronavirus ecological 
surveillance (Su et al., 2016). Recombination likely facilitated the emergence of both SARS-
CoV and MERS-CoV and has promoted vaccine failure for infectious bronchitis virus and 
porcine epidemic diarrhea virus (Chen et al., 2017; Feng et al., 2018; Forni et al., 2016a; Hon et 
al., 2008; Sabir et al., 2016). RNA-dependent RNA polymerases drive recombination in 
enteroviruses (Bentley and Evans, 2018), but the mechanism of coronavirus recombination is not 
fully understood. 
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Why is viral diversity important? High mutation rates in RNA viruses have profound 
biological consequences. Under logarithmic growth, RNA viruses can theoretically make one 
mutation at every site in the genome during every replication cycle (Lauring and Andino, 2010). 
Consequently, RNA viruses do not exist as collections of identical clones but as populations of 
closely-related but genetically distinct variants (mutant swarm) that interact to determine viral 
phenotypes. The importance of genetic diversity for virulence was elegantly demonstrated in 
poliovirus (Vignuzzi et al., 2006) (Figure 4). Wild-type poliovirus invades the central nervous 
system of mice to cause lethal paralysis, but a high-fidelity poliovirus with reduced genetic 
diversity was unable to reach the spinal cord. Treatment of the high-fidelity variant with a 
mutagenic compound restored wild-type-like diversity and neurovirulence. No consensus-level 
mutations were identified in the spinal cord, indicating that low-frequency variants cooperated to 
permit neural tropism. Several additional studies have demonstrated cooperation in measles 
virus, influenza virus, HIV-1, and coxsackievirus B3 (Bordería et al., 2015; 2010; Shirogane et 
al., 2012; Xue et al., 2016), and high-fidelity variants of diverse RNA viruses frequently show 
restricted tropism and virulence, suggesting that cooperation is likely a widespread phenomenon 
in viral mutant swarms (Arias et al., 2008; Arnold et al., 2005; Campagnola et al., 2015; Cheung 
et al., 2014; Coffey et al., 2011; Fitzsimmons et al., 2018; Liu et al., 2013; Meng and Kwang, 
2014; Pfeiffer and Kirkegaard, 2003; 2005; Rai et al., 2017; Sadeghipour et al., 2013; 
Sadeghipour and McMinn, 2013; Sierra et al., 2007; Vignuzzi et al., 2006; 2008; Xie et al., 2014; 
Zeng et al., 2014; 2013). The mechanisms underlying cooperation are poorly understood and 
likely highly variable, but they may require multiple genomes to be present inside individual 
cells (coinfection). Whether coinfection occurs due to multiple virions infecting the same cell or 
a single virion containing multiple genomes will likely depend upon the virus and host factors  
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Figure 4. Genetic diversity is important for virulence. 
 
 
 
 
 
 
 
 
 
Figure 4. Genetic diversity is important for virulence. Results from Vignuzzi et al. 2006 are 
presented. Mice inoculated with a diverse population of poliovirus succumb to paralytic disease, while 
those infected with a homogenous population survive. Figure modified from Lauring and Andino, 
2010 under a Creative Commons Attributions License. 
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(Bordería et al., 2015; Chen et al., 2015; Feng et al., 2013; Shirogane et al., 2012).  
 
High mutation rates also facilitate viral evolution. The standing genetic diversity within mutant 
swarms represents an enormous reservoir of potentially adaptive mutations. For example, 
mutations conferring resistance of HIV-1 and hepatitis C virus to antiviral compounds can be 
found in treatment-naïve patients, likely contributing to the rapid development of antiviral 
resistance (Jabara et al., 2014; 2011; Lech et al., 1996; Mzingwane et al., 2016; Takeda et al., 
2017; Telele et al., 2018). High mutation rates also allow RNA viruses to establish cell- and 
tissue-specific subpopulations within hosts (Koel et al., 2019; Riemersma et al., 2018; Xiao et 
al., 2017b). At global scales, high mutation rates allow influenza virus to circumvent vaccine-
induced immunity and drive rapid reversion of the live-attenuated oral poliovirus vaccine (OPV), 
which is now the greatest challenge to global poliovirus eradication (Kew, 2012; Minor, 2009). 
Finally, MERS-CoV emergence into humans was likely facilitated by two point mutations in a 
bat coronavirus spike protein (Yang et al., 2015). 
 
Although high mutation rates permit rapid adaptation, “more mutagenic” does not necessarily 
mean “more adaptable” (Elena and Sanjuán, 2005; Furió et al., 2005). RNA viruses are proposed 
to replicate close to their error threshold, beyond which deleterious mutations accumulate and 
disrupt essential genetic information. RNA viruses are therefore always close to “error 
catastrophe” (Figure 5) (Domingo et al., 2012; Holmes, 2003). Most mutations in RNA viruses 
are detrimental (Acevedo et al., 2014; Elena and Moya, 1999; Malpica et al., 2002; Peris et al., 
2010; Sanjuán et al., 2004a; Theys et al., 2018; Visher et al., 2016), so even marginal increases 
in mutation rates are expected to reduce viral fitness. Accordingly, altered-fidelity variants with 
increased mutation rates are generally attenuated (Campagnola et al., 2015; Eckerle et al., 2010; 
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2007; Gnädig et al., 2012; Kautz et al., 2018; Korboukh et al., 2014; Rai et al., 2017; Riemersma 
et al., 2018; Rozen-Gagnon et al., 2014; Sexton et al., 2016; Smith et al., 2013; 2015). 
Therapeutic exploitation of error thresholds with mutagenic compounds is termed lethal  
mutagenesis (Bull et al., 2007; Crotty et al., 2001; 2002; Moreno et al., 2011; 2012; Smith et al., 
2013). The error threshold is thought to constrain RNA genome lengths, as increasing genome 
size without increasing replication fidelity could lead to error catastrophe (Bradwell et al., 2013). 
Thus, RNA virus genomes and replicases are evolutionarily fine-tuned to maximize genetic 
diversity (and concomitantly, replication speed) while maintaining sufficient genetic stability.  
 
What determines evolutionary outcomes? In the simplest view of viral evolution, natural 
selection drives a population towards high fitness by the canonical “survival of the fittest.” 
Simply defined, a virus’ fitness is its ability to replicate in a given environment and is 
determined by the aggregate effects of all mutations in its genome (its genotype) (Domingo and 
Holland, 1997; Wargo and Kurath, 2012). Most mutations in RNA viruses are detrimental or 
lethal, but others have minimal effects on viral fitness and are considered neutral. Relatively few 
mutations provide an adaptive advantage (Acevedo et al., 2014; Elena and Moya, 1999; Malpica 
et al., 2002; Peris et al., 2010; Sanjuán et al., 2004a; Theys et al., 2018; Visher et al., 2016). In 
this paradigm, the outcome of viral evolution is determined by the fitness of individuals within 
the population (deterministic evolution) (Figure 6). Beneficial mutations rise to fixation by 
positive selection, detrimental mutations are purged by negative selection, and neutral mutations 
are ignored by selection. These effects can be visualized as a rugged fitness landscape, with 
peaks of high fitness and valleys of low fitness, that determine the evolutionary trajectory of a 
viral population (Figure 7). 
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Figure 5. Model for a viral mutant swarm on the brink of error catastrophe. 
 
 
 
 
 
 
Figure 5. Model for a viral mutant swarm on the brink of error catastrophe. Black and blue lines 
represent histograms of mutations per genome in a normal or mutagenized population, respectively. 
The majority of variants in the normal population are live (white), but some proportion are nonviable 
due to random mutations (gray). An increase in the mutational load (mutagenized population) shifts 
the majority of variants over the error threshold, where the number of mutations per genome is high 
enough to extinguish most variants. 
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Figure 6. Deterministic evolution by natural selection. 
 
 
 
 
 
 
 
 
Figure 6. Deterministic evolution by natural selection. A diverse mutant swarm is propagated 
during multiple rounds of infection. A beneficial mutation (green circle) increases in frequency with 
each round of replication because it provides an adaptive advantage, while deleterious mutations (blue 
squares) are lost. New deleterious mutations are generated in each round of replication by chance. The 
beneficial mutation is not detected at consensus level until it is in greater than 50% of genomes. 
Horizontal lines indicate individual genomes, and shapes represent mutations. 
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Figure 7. Genotype-fitness landscape. 
 
 
 
 
 
 
 
 
 
 
Figure 7. Genotype-fitness landscape. From a starting point (gray dot), a virus explores the genetic 
landscape (x-y plane) through mutations. Natural selection drives evolution for increased fitness (z- 
axis) towards local fitness maxima (gray lines). Different trajectories vary in the achievable fitness. 
Figure from Dolan et al., 2018, with permission. 
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Natural selection is driven by differences in viral fitness, but fitness is not simply the sum of 
individual mutational effects. Instead, units of selection are complicated by the effects of 
epistasis and cooperation. Epistasis occurs when the phenotypic effect of a mutation depends 
upon other mutations in the genome. Epistatic interactions may make the genome inhospitable to 
the vast majority of mutations (Elena et al., 2010; Sanjuán et al., 2004b; Van den Bergh et al., 
2018). However, epistatic interactions can promote increases in viral fitness. Pauly et al. 
demonstrated epistasis in influenza virus during the evolution of drug resistance. Two mutations, 
PB1 T123A and PA T97I, confer 10- and 5-fold reductions in sensitivity to 5-fluorouracil, 
respectively, while the two in combination yield a 54-fold reduction (Pauly and Lauring, 2015; 
Pauly et al., 2017a). At larger scales, epistasis makes evolutionary trajectories dependent upon 
history. For example, the impact of mutations on receptor-binding and antigenicity of the 
influenza virus hemagglutinin is strain-dependent (Das et al., 2013; Koel et al., 2018; Nakajima 
et al., 2005). Thus, groups of mutations within individual genomes can be units of selection. 
Complicating the picture still further is the role of cooperation in determining the phenotype of a 
mutant swarm (described above), making the entire population a target of natural selection 
(Bordería et al., 2010; 2015; Shirogane et al., 2012; Xue et al., 2016). Cooperation allows 
detrimental mutations to be maintained at higher-than-predicted levels due to genetic piggy-
backing. Regardless of the scale at which viral fitness is determined—individual mutants, groups 
of mutations, or collections of genomes—the principles of deterministic evolution still apply.  
 
Though natural selection is important for viral evolution, viral populations are also subject to the 
stochastic effects of random genetic drift (probabilistic evolution) (Figure 8). All finite 
populations encounter bottlenecks during their evolutionary history. Bottlenecks cause a sharp 
reduction in the size of a population and can lead to the fixation of neutral or deleterious 
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Figure 8. Probabilistic evolution by random genetic drift. 
 
 
 
 
 
 
 
 
Figure 8. Probabilistic evolution by random genetic drift. A diverse mutant swarm contains 
beneficial (green circle), detrimental (cyan square), and neutral mutations (other shapes). When only a 
single genome is replicated during a stringent bottleneck, detrimental and neutral mutations can be 
fixed at the expense of beneficial mutants. Horizontal lines indicate genomes. 
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mutations at the expense of beneficial mutations. The relative contributions of deterministic and 
probabilistic evolution depend upon the population size. The smaller the population, the more the 
outcome is governed by random chance. In general, bottlenecks slow the rate of adaptation by 
reducing the likelihood that beneficial mutations are carried into the next generation (Sanjuán et 
al., 2005). In extreme cases like plaque-to-plaque passage, where only a single infectious unit 
initiates each generation, mutations accumulate rapidly and cause error catastrophe, an effect 
known as Muller’s ratchet (Duarte et al., 1992). Viruses typically replicate to very high titers 
within their hosts, but sharp reductions in population size frequently occur during inter-host and 
cross-species transmission (McCrone and Lauring, 2017). High mutation rates allow viruses to 
restore genetic diversity and recover fitness after genetic bottlenecks, potentially explaining why 
high-fidelity mutants are typically attenuated in animal models (Xiao et al., 2017b). 
 
Why study viral evolution? Predictive models for infectious disease emergence are one of the 
most important goals of biomedical science (Holmes, 2013). Emerging zoonotic infections will 
always be a risk at the limits of human civilization, which are constantly changing due to climate 
change, population dynamics, and economic incentives (Geoghegan and Holmes, 2017). 
Predicting viral evolution remains a significant challenge at multiple scales, from global 
evolutionary dynamics, to inter-host transmission, to interhost evolution, and to single cells 
(Dolan et al., 2018a; 2018b; Geoghegan and Holmes, 2017). Thus, understanding the processes 
that dictate viral evolution are important for anticipating future outbreaks of zoonotic disease, 
including coronaviruses. Further, disrupting evolutionary dynamics is a well-described approach 
for developing viral countermeasures. Most altered-fidelity variants described to date are 
attenuated in vivo and protect against reinfection, highlighting their potential utility as live-
attenuated vaccines (Graham et al., 2012; Kautz and Forrester, 2018; Korboukh et al., 2014; Lee 
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et al., 2016; Smith et al., 2014; Vignuzzi et al., 2008; Weeks et al., 2012). Similarly, altering 
genetic recombination affects evolutionary trajectories and virulence (Graham et al., 2018; 
Kempf et al., 2016; Xiao et al., 2016; 2017b), and recoding genomes to change genotype-fitness 
landscapes attenuates poliovirus, coxsackievirus B3, influenza virus, and respiratory syncytial 
virus (Lauring et al., 2012; Le Nouën et al., 2017; Moratorio et al., 2017; Stobart et al., 2016). 
These studies underscore the importance of understanding the molecular mechanisms by which 
RNA viruses generate diversity and the selective forces that drive RNA viral evolution. 
 
Coronaviruses encode a proofreading exoribonuclease 
A paradigm of RNA virus biology is error-prone genomic replication due the lack of 
proofreading or post-replicative repair mechanisms (Sanjuán et al., 2010; Steinhauer et al., 
1992). Mutation rates in RNA viruses are inversely correlated with genome length, suggesting 
that low-fidelity replication constrains genome size (Bradwell et al., 2013). Under this paradigm, 
the maintenance of large coronavirus genomes requires a corresponding increase in replication 
fidelity. The first indication that coronaviruses might replicate with higher fidelity than other 
RNA viruses was the discovery that SARS-CoV encodes a 3¢-to-5¢ exoribonuclease (ExoN) 
(Figure 9) (Snijder et al., 2003). The SARS-CoV ExoN is grouped with the DE-D-Dh 
superfamily of ExoNs that detect and excise nucleotide mismatches during DNA replication 
(proofreading) (Snijder et al., 2003; Zuo and Deutscher, 2001). A bonafide proofreading activity 
would be the first of its kind in an RNA virus, and the corresponding increase in replication 
fidelity could have allowed expansion of large coronavirus genomes. Consistent with this 
hypothesis, ExoN domains are found in all large members of the Nidovirus order (>20 kilobases) 
but not in those with smaller genomes (Gorbalenya et al., 2006; Lauber et al., 2013). 
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Figure 9. Schematic of MHV-nsp14-ExoN. 
 
 
 
 
 
 
 
 
Figure 9. Schematic of MHV-nsp14-ExoN. MHV-nsp14 encodes an exoribonuclease (blue) and an 
N7-methyltransferase (black) and has 3 zinc fingers (gray boxes) predicted from the solved SARS-
CoV nsp10/14 crystal structure (PDB 5C8U, Ma et al. 2015). Catalytic residues for ExoN are marked 
with white boxes, and the engineered mutations for MHV-ExoN(-) are shown below the genome.  
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The coronavirus ExoN is encoded within the N-terminal half of nonstructural protein 14 (Figure 
9) (Minskaia et al., 2006; Snijder et al., 2003). Bacterially expressed SARS-CoV nsp14 can 
remove 3¢ mismatched nucleotides, including ribavirin 5¢-monophosphate, from double-stranded 
DNA templates (Bouvet et al., 2012; Chen et al., 2007; Ferron et al., 2018; Minskaia et al., 
2006). Coronavirus ExoN activity depends on conserved magnesium-coordinating acidic amino 
acids in three motifs that together constitute the active site (DE-E-D) (Ferron et al., 2018; Ma et 
al., 2015) (Figure 9). Alanine substitution of CoV motif I DE residues (DEàAA) reduces 
biochemical ExoN activity in SARS-CoV (Bouvet et al., 2012; Ferron et al., 2018; Ma et al., 
2015; Minskaia et al., 2006). Murine hepatitis virus A59 (MHV) and SARS-CoV lacking ExoN 
activity [ExoN(-)] display defective replication and RNA synthesis, 8- to 20-fold greater 
mutation frequencies than wild-type, and high susceptibility to nucleoside analogues (Eckerle et 
al., 2007; 2010; Sexton et al., 2016; Smith et al., 2013; 2015). Recombinant variants of HCoV-
229E and transmissible gastroenteritis virus (TGEV) lacking ExoN activity [ExoN(-)] are not 
viable (Becares et al., 2016; Minskaia et al., 2006). Thus, all data to date support the hypothesis 
that nsp14-ExoN is the first known proofreading enzyme encoded by an RNA virus and 
demonstrate the critical importance of this enzyme for coronaviral replication. 
 
The coronavirus replicase-transcriptase complex 
The coronavirus replicase-transcriptase complex (RTC) is an intricate, multi-subunit molecular 
machine reminiscent of DNA replication complexes (Smith et al., 2014) (Figure 10). The 
keystone of the complex is the RNA-dependent RNA polymerase in nsp12 that assembles the 
growing RNA strand. The crystal structure of nsp12-RdRp has not been solved, but 
computational modeling suggests that the catalytic core of the RdRp folds into the canonical  
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Figure 10. Model of the multi-subunit coronavirus replicase-transcriptase complex (RTC). 
 
 
 
 
 
Figure 10. Model for the multi-subunit coronavirus replicase-transcriptase complex (RTC). 
Coronaviruses encode a large RTC anchored by the nsp12 RNA-dependent RNA polymerase (RdRp) 
with an associated nucleotidylation domain (NiRAN). The nsp13 helicase (Hel, with attached NTPase) 
and nsp7+8 processivity factor directly interact with nsp12. The nsp14-exoribonuclease (ExoN) and 
its nsp10 co-factor increase replication fidelity. Nsp10 also binds and regulates the 2¢-O-
methyltransferase (2¢-OMT) in nsp16. Nsp9 is a single-stranded RNA binding protein. Nsp15 is an 
endoribonuclease but may not be associated directly with the RTC. This model is derived from the 
theoretical, biochemical, and virological evidence cited in the text and is used with permission from 
Sexton, 2017. 
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fingers-palm-thumb arrangement characteristic of viral RdRps (Sexton et al., 2016; Xu et al., 
2003). The CoV RdRp regulates fidelity by mechanisms similar to those in other RNA viruses 
but has lower overall fidelity (Ferron et al., 2018; Sexton et al., 2016). An accessory domain is 
encoded in the N-terminal half of nsp12, fused to the RdRp core. This domain is highly 
conserved among all nidoviruses, suggesting an important role in nidoviral biology. The role of 
this domain is poorly understood, in part because it has low predicted structural homology to 
known proteins and has therefore been difficult to model with high confidence. However, an 
essential nucleotidylation activity is encoded by this domain, now termed the nidovirus RdRp-
associated nucleotidylation domain (NiRAN) (Lehmann et al., 2015), and a small piece of the 
NiRAN domain is important for localizing nsp12 to replication sites (Brockway et al., 2003). 
 
Several additional proteins assist the CoV nsp12-RdRp in maintaining efficient and accurate 
RNA synthesis. Multimers of nsps7 and 8 assemble into a ring-like structure that increase 
nsp12’s RNA-binding efficiency and processivity (Subissi et al., 2014; Velthuis et al., 2012; 
Xiao et al., 2012). Nsp8 may also synthesize primers to initiate RNA synthesis (Imbert et al., 
2006). A helicase encoded by nsp13 unwinds double-stranded RNA, and nsp9 may protect the 
single-stranded RNA from reannealing or degrading (Adedeji et al., 2012; Egloff et al., 2004; 
Smith et al., 2014). The proofreading nsp14-ExoN can assemble into a complex with nsps7, 8, 
10, and 12 without disrupting polymerization or excision (Subissi et al., 2014). Nsp10 is a 
nonenzymatic cofactor that orients the catalytic DE-E-D motifs to stimulate nsp14-ExoN activity 
(Donaldson et al., 2007; Ferron et al., 2018; Subissi et al., 2014). The model of an RTC 
composed of nsps7-14 is supported by interaction studies and by genetic analyses showing 
strong purifying selection against mutations in these proteins, suggesting that they are highly 
coevolved and interdependent (Brunn et al., 2007; Forni et al., 2016b; Sawicki et al., 2005). 
  40 
 
Components of the RTC have additional functions beyond RNA synthesis. Viral mRNAs are 
capped by the sequential action of two enzymes: the N7-methyltransferase domain in the C-
terminal half of nsp14 and the nsp16 2¢-O-methyltransferase (Bouvet et al., 2010; Case et al., 
2016; Chen et al., 2009; Decroly et al., 2008; Sevajol et al., 2014). In addition to its role in 
regulating fidelity via nsp14-ExoN, nsp10 also promotes capping through its interaction with 
nsp16 (Bouvet et al., 2014; Decroly et al., 2011). The interaction surface is similar between 
nsp10-nsp14 and nsp10-16, though the former is substantially larger (Decroly et al., 2011; Ferron 
et al., 2018; Lugari et al., 2010; Ma et al., 2015). Additionally, nsp14 has been implicated in 
evading innate immune responses, perhaps by degrading used or damaged viral RNA to prevent 
host recognition (Becares et al., 2016; Case et al., 2017). Finally, nsp15 encodes a uridylate-
specific endoribonuclease involved in evasion of host immune responses, but it is not clear 
whether this protein should be considered part of the coronavirus RTC (Deng et al., 2017; 
Kindler et al., 2017; Snijder et al., 2003). 
 
Summary 
Faithful replication of large and complex coronavirus genomes requires correspondingly large 
and complex replication machinery, with the first known proofreading activity in the RNA 
world. Individual components of the coronavirus RTC have been studied in detail, revealing 
conceptually new strategies for live-attenuation of coronavirus vaccines (Graham et al., 2012; 
Menachery et al., 2014; 2018; Schindewolf and Menachery, 2019). However, studies examining 
complexes of coronavirus replicase proteins remain relatively scarce. Further, the coronavirus 
RTC likely lies in close proximity to most, if not all, coronavirus-encoded proteins (Brockway et 
al., 2004; 2003; Brunn et al., 2007; Kuo et al., 2016; Sawicki et al., 2005; V'kovski et al., 2019), 
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but to date, models of coronavirus replication have largely ignored potential interactions outside 
of nsps7-16. Unraveling the connections between coronavirus replicase proteins (and potential 
collaborators across the genome) is essential for understanding their evolutionary dynamics and 
may reveal new tactics to counter emerging coronavirus infections.  
 
In Chapter 2, I demonstrate that experimental evolution of MHV lacking proofreading activity 
compensates for the loss of ExoN activity in part through a high-fidelity polymerase. In Chapter 
3, I describe experiments to identify fidelity-regulating proteins outside of nsp12-RdRp and 
nsp14-ExoN. In Chapter 4, I tackle the remarkable observation that despite the critical 
importance of ExoN activity for viral fitness, ExoN(-) coronaviruses do not revert in tissue 
culture or in animals. In Chapter 5, I describe two new tools for detailed analysis of coronavirus 
diversity and fitness. In Chapter 6, I summarize the materials and methods used in this 
dissertation. Finally, in Chapter 7, I examine the broader implications of this work and outline 
avenues for continuing investigation. 
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CHAPTER 2: A PROOFREADING-DEFICIENT CORONAVIRUS ADAPTS FOR 
INCREASED FIDELITY AND FITNESS OVER LONG-TERM PASSAGE WITHOUT 
REVERSION OF EXORIBONUCLEASE-INACTIVATING MUTATIONS 
 
Introduction 
At the beginning of this dissertation research, the coronavirus exoribonuclease (ExoN) had been 
established as a critical regulator of efficient and accurate replication in both murine hepatitis 
virus (MHV) and SARS-CoV (Eckerle et al., 2007; 2010; Graham et al., 2012; Smith et al., 
2013). Yet, despite the fitness costs associated with disruption of ExoN motif I, neither MHV-
ExoN(-) or SARS-CoV-ExoN(-) had reverted under any experimental conditions. MHV-ExoN(-) 
and SARS-CoV-ExoN(-) motif I were genetically stable during 17 and 20 passages in cell 
culture, respectively, and during treatment with RNA mutagens (Eckerle et al., 2007; 2010; 
Sexton et al., 2016; Smith et al., 2013; 2015). We also had not detected motif I reversion in 
SARS-CoV-ExoN(-) after eight acute passages in aged BALB/c mice and 60 days of persistent 
infection in immunodeficient Rag-/- mice (Graham et al., 2012). To test the stability of the 
ExoN(-) genotype and phenotype, we subjected MHV-ExoN(-) to long-term passage (250 
passages over one year; P250). We demonstrate that MHV-ExoN(-) did not extinguish during 
passage and adapted for increased replication. MHV-ExoN(-) concurrently evolved reduced 
susceptibility to multiple nucleoside and base analogues, consistent with selection for increased 
replication fidelity. Importantly, the ExoN-inactivating substitutions did not revert. The evolved 
mutations in MHV-ExoN(-) nsp14 and nsp12, which encodes the RdRp, accounted for only part 
of the increased nucleoside analogue resistance of MHV-ExoN(-) P250, implicating multiple 
replicase proteins in adaptation for viral fitness. These data support the proposed link between 
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CoV fidelity and fitness, demonstrate the surprising stability of the ExoN-inactivating 
substitutions, and identify additional proteins outside of nsp12 and nsp14 that may contribute to 
CoV fidelity regulation. 
 
Coauthor contributions 
Xiaotao Lu and Brett Case completed the P250 passage series. Xiaotao cloned and recovered all 
recombinant viruses except for the ExoN(-) silent reference, which Nicole Sexton generated. 
Clint Smith and Xiaotao obtained the full-length sequence data for the P250 viruses. Clint Smith 
and I performed at least one independent experiment for each panel, with few exceptions: Clint 
performed all replication curves, and I performed the competitive fitness and specific infectivity 
assays. Tia Hughes prepared PrimerID libraries. 
 
Results 
Long-term passage of WT-MHV and MHV-ExoN(-). We serially passaged WT-MHV and 
MHV-ExoN(-) in delayed brain tumor (DBT) cells 250 times (P250). Virus from each passage 
was harvested once 50-100% of the monolayer was involved in syncytia, which occurred 
between 8 and 24 hours post-infection. Passage conditions varied for WT-MHV and MHV-
ExoN(-) due to differences in replication kinetics between the two viruses. We stopped passage 
at P250 after observing reduced syncytia formation in MHV-ExoN(-)-infected flasks, likely 
resulting from a mutation in the MHV-ExoN(-) P250 spike protein cleavage site (discussed 
below). 
MHV-ExoN(-) and WT-MHV replicate with identical kinetics following 250 passages. 
MHV-ExoN(-) has a significant replication defect relative to WT-MHV (Eckerle et al., 2007). 
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We first tested whether replication of MHV-ExoN(-) P250 was affected by long-term passage by 
examining replication at two different multiplicities of infection (MOI). At both MOI = 1 and 
MOI = 0.01 PFU/cell, MHV-ExoN(-) P3 replication was delayed by ~2 hours and peak titer 
reduced by ~1 log10 relative to WT-MHV P3 (Figure 11A and B), consistent with our previous 
studies (Eckerle et al., 2007). By P250, both viruses replicated with identical kinetics (Figure 11, 
A and B, dotted lines). This represented a ~1 log10 increase in peak replication for WT-MHV and 
a ~2 log10 increase for MHV-ExoN(-), compared with the respective parental virus. At MOI = 
0.01 PFU/cell, we also measured replication of MHV-ExoN(-) at P10, P50, P100, and P160. 
Replication kinetics gradually increased over passage, reaching P250-like levels by P100 (Figure 
11B). To determine whether the increased replication of MHV-ExoN(-) P250 was affected by the 
presence of potential defective viral genomes or by some other population-based phenomenon, 
both WT-MHV P250 and MHV-ExoN(-) P250 were plaque purified three times (Figure 12). The 
plaque-purified viruses replicated indistinguishably from the parent populations (Figure 11C). 
Together, these data demonstrate that WT-MHV and MHV-ExoN(-) populations adapted for 
increased replication and that either individual genomes or those derived from a single virus 
plaque encoded the adaptive changes required by the total population. 
 
MHV-ExoN(-) accumulated 8-fold more mutations than WT-MHV but did not revert 
ExoN-inactivating substitutions. To determine whether the increased replication of MHV- 
ExoN(-) P250 resulted from primary reversion of ExoN(-) motif I, we sequenced nsp14 from 
infected-cell total RNA. MHV-ExoN(-) P250 retained the motif I DEàAA substitutions, 
demonstrating that primary reversion of ExoN(-) motif I did not occur. To identify potentially 
adaptive consensus mutations, we performed full-genome di-deoxy sequencing of MHV-ExoN(-) 
P250 and WT-MHV P250. Within WT-MHV P250, we identified 23 mutations, of which 17  
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Figure 11. MHV-ExoN(-) evolved increased replicative capacity over long-term passage 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. MHV-ExoN(-) evolved increased replicative capacity over long-term passage. 
Replication kinetics were examined for the indicated viruses at MOI = 1 PFU/cell (A) and MOI = 0.01 
PFU/cell (B). (C) Replication kinetics of plaque-purified WT-MHV P250 and MHV-ExoN(-) P250 in 
parallel with the full population (MOI = 0.01 PFU/cell). Supernatants were collected at the indicated 
times post infection, and titers were determined by plaque assay. Data for A-C represent mean and 
standard deviation of n = 3. 
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Figure 12. Plaque purification of viral populations 
 
 
 
 
 
 
Figure 12. Plaque purification of viral populations. A viral population contains distinct but closely-
related genomes. When viruses are cultured under semi-solid media, they are unable to disperse 
through the supernatant and can only infect adjacent cells. Over multiple replication cycles, they form 
distinct plaques derived, in principle, from a single infectious particle. Propagating virus from 
individual plaques yields distinct populations. Horizontal lines represent individual genomes, and 
shapes represent mutations. 
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were nonsynonymous (NS) (Figure 13A). In contrast, MHV-ExoN(-) P250 had 171 total 
mutations (74 NS) (Figure 13B). The full-genome sequences have been deposited in GenBank, 
and the mutations for both viruses are listed in Appendix A.1 and A.2. We identified only one 
mutation shared by both viruses (nsp1 A146T), though it was present in approximately 50% of 
the WT-MHV P250 population by di-deoxy sequencing. Both viruses deleted most of the 
hemagglutinin esterase (HE). In MHV-A59, HE mRNA is not transcribed in vitro (Luytjes et al., 
1988; Yokomori and Lai, 1991; Yokomori et al., 1991), and HE protein expression is detrimental 
to MHV-A59 fitness in cell culture (Lissenberg et al., 2005). WT-MHV P250 also deleted ORF 
4a, which is dispensable for MHV replication in cell culture (Gadlage et al., 2008). The C-
terminal region of ns2 within MHV-ExoN(-) P250 was truncated and fused to HE with a -1 
frameshift. Ns2 is a phosphodiesterase (PDE) that protects viral RNA by degrading 2¢à5¢ 
oligoadenylate, the activating factor for cellular RNase L (Li and Weiss, 2016; Zhang et al., 
2013; Zhao et al., 2012). The portion of ns2 deleted in MHV-ExoN(-) P250 lies outside the PDE 
catalytic domain, in a region of unknown function. C-terminally truncated ns2 retains enzymatic 
activity (Sui et al., 2016), but whether this specific deletion and fusion disrupts PDE activity 
remains to be tested. Nevertheless, ns2 is dispensable for MHV replication in immortalized cells 
(Schwarz et al., 1990; Zhao et al., 2011). Details about the deletion sites are provided in Figure 
14. Within proteins predicted to be part of the replicase-transcriptase complex (nsp7-16 and  
nucleocapsid) (Smith et al., 2014), WT-MHV P250 had only one NS change, located in the 
nsp13-helicase (Figure 13A and Appendix A.1). In contrast, MHV-ExoN(-) P250 had 17 NS 
changes within this region (Figure 13B and Appendix A.2). 
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Figure 13. Mutations within P250 viruses. 
 
 
 
Figure 13. Mutations within P250 viruses. Mutations present at >50% by di-deoxy sequencing at 
passage 250 in WT-MHV (A) and MHV-ExoN(-) (B). Nonsynonymous mutations (red), noncoding 
mutations (cyan), and deletions (green boxes) are plotted above the schematic, and synonymous 
mutations (purple) are below. 
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Figure 14. Deleted region within WT-MHV P250 and MHV-ExoN(-) P250 
 
 
 
 
Figure 14. Deleted regions within WT-MHV P250 and MHV-ExoN(-) P250. 
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MHV-ExoN(-) P250 displays increased genomic RNA accumulation and increased 
resistance to 5-fluorouracil. Coronaviruses lacking ExoN consistently display defects in RNA 
synthesis relative to WT (Eckerle et al., 2007; Minskaia et al., 2006; Smith et al., 2013). To 
determine whether the increased replication of MHV-ExoN(-) P250 was associated with restored 
genomic RNA (gRNA) production, we measured gRNA accumulation over time using two-step 
real-time quantitative PCR (Smith et al., 2013; 2015). MHV-ExoN(-) P250 accumulated similar 
levels of gRNA to WT-MHV P3 and WT-MHV P250 at early time points, while gRNA levels 
for MHV-ExoN(-) P3 were ~1 log10 lower (Figure 15A). MHV-ExoN(-) P250 gRNA levels fell 
below those of WT-MHV and WT-MHV P250 after 8 hours and were similar to those of MHV-
ExoN(-) P3 at 10 hours post-infection. Normalizing to the gRNA abundance at four hours for 
each virus demonstrated that the rates of gRNA accumulation were similar for all four viruses 
(Figure 15B). These data suggest that the increased replication of P250 viruses relative to WT-
MHV is not fully accounted for by increased RNA synthesis. In addition to RNA synthesis 
defects, ExoN(-) CoVs have up-to 20-fold increased mutation frequencies and profoundly 
increased sensitivity to nucleoside and base analogues relative to WT CoVs (Eckerle et al., 2007; 
2010; Graham et al., 2012; Sexton et al., 2016; Smith et al., 2013). To determine whether 
nucleoside analogue sensitivity of MHV-ExoN(-) was altered by long-term passage, we treated 
cells infected with parental and passaged viruses with the base analogue, 5-fluorouracil (5-FU). 
5-FU is converted intracellularly into a nucleoside analogue that incorporates into growing RNA 
strands and causes A:G and U:C mutations. For simplicity, I hereafter refer to 5-FU as a 
nucleoside analogue. Incorporation of 5-FU is increased in the absence of ExoN activity (Smith 
et al., 2013). All viruses displayed a concentration-dependent decrease in viral titer but differed 
greatly in their susceptibility to 5-FU (Figure 15C). At 120µM, WT-MHV P3 titers were reduced  
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Figure 15. MHV-ExoN(-) evolved WT-like genomic RNA accumulation and increased resistance to multiple nucleoside analogs over passage. 
 
 
 
 
Figure 15. MHV-ExoN(-) evolved WT-like genomic RNA accumulation and increased resistance 
to multiple nucleoside analogues over passage. (A) Cells were infected with the indicated viruses at 
MOI = 1 PFU/cell, and intracellular RNA was harvested using TRIzol at the indicated times post 
infection. MHV genomic RNA was detected using SYBR green and primers directed to nsp10, and 
values were normalized to intracellular GAPDH. (B) Same data as in panel (A) normalized to RNA 
level for each virus at 4 hours post infection. Data represent mean and standard error for n = 9 (3 
triplicate experiments). (C-F) Sensitivity of passaged viruses to nucleoside analogues at MOI = 0.01 
PFU/cell. Cells were treated with the indicated concentrations of 5-FU (C), RBV (D), AZC (E), or 
CMeA (F) for 30 minutes prior to infection, and supernatants were harvested at 24 hours post-
infection and titered by plaque assay. Data represent change in titer relative to untreated control and 
are plotted as mean and standard error of n = 6 (two triplicate experiments). For panel C-F, statistical 
significance for change in titer of MHV-ExoN(-) P3 relative to MHV-ExoN(-) P250 was determined 
using Mann-Whitney test (**P<0.01).  
  52 
 
by ~1 log10, while MHV-ExoN(-) P3 titers were undetectable (> 5 log10-fold reduction). WT-
MHV 5-FU sensitivity was not altered by passage. MHV-ExoN(-) P250 was less susceptible than 
MHV-ExoN(-) P3 to 5-FU treatment, with only a ~1.5 log10 decrease in titer at 120 µM. MHV-
ExoN(-) P250 remained more sensitive to 5-FU than WT-MHV, suggesting that WT-like 
resistance requires an intact ExoN. These data demonstrate that MHV-ExoN(-) P3 evolved 
resistance to 5-FU through mutations outside of ExoN(-) motif I.  
 
Spike mutations in MHV-ExoN(-) P250 do not increase resistance to 5-FU. Bacteriophage 
ϕX174 acquired resistance to 5-FU by delaying cell lysis, thereby reducing the number of 
replication cycles in which 5-FU can be incorporated (Pereira-Gómez and Sanjuán, 2014). 
MHV-ExoN(-) P250 had multiple mutations in the spike glycoprotein, including one in the spike 
furin cleavage site that reduced syncytia formation. To test whether the spike mutations 
manifested in resistance to 5-FU, we cloned the spike gene from MHV-ExoN(-) P250 into the 
isogenic MHV-ExoN(-) background. The recombinant virus demonstrated intermediate 
replication kinetics between MHV-ExoN(-) P3 and MHV-ExoN(-) P250 (Figure 16A) and did 
not form syncytia. Spike-P250 also increased the specific infectivity of viral particles (Figure 
16B). However, the MHV-ExoN(-) P250 spike did not affect sensitivity of the recombinant virus 
to 5-FU (Figure 16C). Thus, any adaptive increase in 5-FU resistance must be located elsewhere 
in the genome.  
 
MHV-ExoN(-) passage resulted in unique mutations in nsp12 and nsp14. To date, three 
proteins have been shown to alter CoV sensitivity to 5-FU: nsp12-RdRp, nsp14-ExoN, and 
nsp10, which stimulates ExoN activity (Sexton et al., 2016; Smith et al., 2014; 2015). Neither  
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Figure 16. Mutations in the spike envelope protein from MHV-ExoN(-) P250 increase replicative capacity but do not affect sensitivity to 5-fluorouracil. 
 
 
 
Figure 16. Mutations in the spike envelope protein from MHV-ExoN(-) P250 increase replicative 
capacity but do not affect sensitivity to 5-fluorouracil. (A) Replication kinetics of indicated viruses 
(MOI = 0.01 PFU/cell) plotted as mean and standard deviation with n = 3. (B) Specific infectivity of 
indicated viruses 12 hours post-infection (MOI = 1 PFU/cell). Data represent mean and standard error 
of n = 6 (two triplicate experiments). (C) Sensitivity of indicated viruses to 5-fluorouracil at MOI = 
0.01 PFU/cell, as described in Fig. 4. Data represent mean and standard error of n = 6 (two triplicate 
experiments). For panel B, statistical significance was determined using one-way ANOVA. For Panel 
C, statistical significance for change in titer of MHV-ExoN(-) spike-P250 relative to MHV-ExoN(-) 
P3 was determined using Mann-Whitney test (**P<0.01, ***P<0.001, ns = not significant). 
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WT-MHV nor MHV-ExoN(-) P250 contained a NS mutation in nsp10, and WT-MHV P250 had 
no mutations within either nsp12 or nsp14. In contrast, MHV-ExoN(-) P250 had 7 NS mutations 
in nsp12 and 6 NS mutations in nsp14 (Figure 13 and Figure 17), none of which have been 
described previously in vitro or in viable viruses. Within nsp12, six mutations were in the 
predicted RdRp fingers, palm, and thumb domains (Figure 17A) (Ng et al., 2008). Four residues 
(H709, F766, S776, and M814) can be visualized on a Phyre2-modeled structure of the MHV-
nsp12 RdRp, while the remainder lie outside the modeled core RdRp (Figure 17A) (Sexton et al., 
2016). One mutation, M288T, lies in the CoV-specific domain, which is conserved among 
nidoviruses. This domain has been implicated in membrane targeting in MHV-A59 (Brockway et 
al., 2003) and performs an essential nucleotidylation activity in the arterivirus, equine arteritis 
virus (Lehmann et al., 2015). However, M288T is not predicted to catalyze nucleotidylation. 
Within nsp14, 4 NS mutations were identified in the ExoN domain, and 2 NS mutations were in 
the C-terminal N7-methyltransferase domain (Figure 17B). We next modeled the structure of 
MHV nsp14 using Phyre2 software (Kelley et al., 2015), resulting in highest-probability 
similarity to the SARS-CoV nsp14-nsp10 complex (PDB: 5C8S) (Ma et al., 2015) with high-
confidence (i.e. the calculated probability of true homology between the structures) of 100% for 
residues 3-519 of MHV-nsp14. The model predicts that five mutations are located close to 
surface of the protein (Figure 17B). All three modeled zinc finger domains contain one NS 
mutation (F216Y, Y248H, L473I). Two mutations, D128E and F216Y, are located near the 
interface between nsp10 and nsp14, though neither site has previously been implicated in nsp10-
nsp14 interaction (Bouvet et al., 2014; Donaldson et al., 2007; Smith et al., 2015). One NS 
mutation resulted in a D272E substitution in ExoN motif III, a metal-coordinating active site 
residue. We previously reported that alanine substitution of D272 results in an ExoN(-) 
phenotype (Eckerle et al., 2007), but the viability or phenotype of a D272E substitution was not  
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Figure 17. The timing of fixation of mutations in nsp12-RdRp and nsp14-ExoN within MHV-ExoN(-). 
 
 
 
Figure 17. The timing of fixation of mutations in nsp12-RdRp and nsp14-ExoN within MHV-
ExoN(-). (A) A schematic of nsp12-RdRp with the CoV-specific region and the canonical fingers, 
palm, and thumb domains of RdRps is shown. The nsp12-RdRp coding region was sequenced at the 
indicated passage, and the nonsynonymous changes are plotted; gray boxes indicate consensus 
changes, and hatched boxes indicate variants present at <50% of the population by di-deoxy 
sequencing. At right, mutations are marked in orange on a Phyre2-modeled structure of MHV-nsp12, 
with the active site residues marked in yellow (Sexton et al., 2016). RdRp domains are colored 
according to the linear schematic. M288T, L376P, and D913E lie outside the modeled region and thus 
are not marked. (B) A schematic of nsp14 with the ExoN and N7-methyltransferase domains is shown, 
with mutation plotting as in panel A. The black box denotes a mutation to ExoN motif III. At right, 
mutations are marked in orange on a Phyre2-modeled structure of the MHV-nsp14/nsp10 complex. 
Domains are colored according to the linear schematic. 
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tested in that study. These data suggest that a network of residues evolved to regulate nsp12 and 
nsp14 activity or stability in the ExoN(-) background. 
 
Fixed mutations in nsp12 and nsp14 in MHV-ExoN(-) P250 directly correlate with 
increased resistance to multiple nucleoside analogues. To determine approximately when the 
mutations in nsp12 and nsp14 arose, we performed di-deoxy sequencing across these protein-
coding regions roughly every 20 passages (P10, 31, 50, 72, 90, 100, 120, 140, 160, 180, 200, 
220, 240). By this method, we detected consensus NS mutations at P10, P50, and P160 for 
nsp12, and at P50 and P160 for nsp14 (Figure 17). Both nsp12 and nsp14 carried their full 
complement of P250 consensus mutations by P160, except for a minority variant (D913E) in 
nsp12 maintained at <50% of the population between P200 and P250. These passage levels 
correlated with increased replication of MHV-ExoN(-) (Figure 11B) and with decreasing 
sensitivity to 5-FU (Figure 15C). Neither replication nor 5-FU sensitivity of MHV-ExoN(-) 
changed substantially between P160 and P250. To determine whether MHV-ExoN(-) evolved 
increased resistance to multiple nucleoside analogues, we treated virus-infected cells with three 
additional analogues that are substrates for viral RdRps: ribavirin (RBV), a guanine analogue 
that inhibits viral replication through multiple mechanisms, including mutagenesis and inhibition 
of purine biosynthesis (Crotty et al., 2002); 5-azacytidine (AZC), an RNA mutagen (Pathak and 
Temin, 1992); and 2’-C-methyladenosine (CMeA), which is proposed to incorporate in viral 
RNA and terminate nascent transcripts (Carroll et al., 2003). As with 5-FU, we observed dose-
dependent sensitivity to RBV, AZC, and CMeA in all MHV-ExoN(-) viruses that decreased with 
increasing passage number (Figure 15D-F). Except against AZC, MHV-ExoN(-) sensitivity did 
not change between P160 and P250. Together, these data demonstrate that MHV-ExoN(-) 
evolved increased resistance to multiple nucleoside analogues that correlated with the length of 
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passage and the acquisition of mutations in nsp12 and nsp14. Importantly, this occurred in the 
absence of specific mutagenic selection and without reversion of ExoN motif I. This increased 
general selectivity towards all four classes of nucleotide strongly supports an overall increase in 
fidelity in MHV-ExoN(-) P250. 
 
Mutations in nsp12 partially account for increased resistance of MHV-ExoN(-) P250 to 
multiple nucleoside analogues. We hypothesized that mutations in MHV-ExoN(-) P250 nsp12 
and nsp14 were the most likely to impact replication and nucleoside analogue sensitivity based 
on their enzymatic activities and temporal association with phenotypic changes. To test this 
hypothesis, we engineered recombinant MHV-ExoN(-) to encode the P250 nsp12 and nsp14 
sequences, alone and together. Expression of nsp12-P250 and nsp14-P250, alone or in 
combination, altered replication kinetics of MHV-ExoN(-) without affecting peak titers (Figure 
18A) and increased gRNA levels above those of MHV-ExoN(-) P3 (Figure 18B). Nsp12-P250 
had a greater effect than nsp14-P250 on the sensitivity of MHV-ExoN(-) to all analogues tested, 
and the combination of nsp12- and nsp14-P250 did not increase resistance above nsp12-P250 
alone (Figure 18C-E). None of the recombinant viruses recapitulated the resistance phenotypes 
of the MHV-ExoN(-) P250 population. Together, these data demonstrate that nsp12-P250 
mutations only partially account for the nucleoside analogue resistance of MHV-ExoN(-) P250, 
and that adaptations in nsp12-P250 mask those in nsp14-P250. We also can conclude that the 
nsp14-P250 D272E active site mutation does not correct the defect caused by the motif I 
DEàAA substitutions. 
 
Nsp12-P250 is a high-fidelity polymerase. Mutations in nsp12-P250 increased resistance of 
MHV-ExoN(-) to multiple nucleoside analogues (Figure 18). Although resistance to a single  
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Figure 18. Mutations in nsp12-RdRp and nsp14-ExoN from MHV-ExoN(-) P250 incompletely increase resistance to nucleoside analogs through high-fidelity replication. 
 
 
 
 
 
 
Figure 18. Mutations in nsp12-RdRp and nsp14-ExoN from MHV-ExoN(-) P250 incompletely 
increase resistance to nucleoside analogues through high-fidelity replication. (A) Replication 
kinetics of recombinant P250 viruses (MOI = 0.01 PFU/cell) plotted as mean and standard deviation 
with n = 3. (B) Genomic RNA accumulation relative to intracellular GAPDH, as described in Fig. 4. 
Data represent mean and standard error for n = 6-9 (2-3 triplicate experiments). (C-E) Sensitivity of 
recombinant MHV-ExoN(-) viruses to 5-FU (C), ribavirin (D), and 5-azacytidine (E) at MOI = 0.01 
PFU/cell, as described in Fig. 4. Data represent mean and standard error of n = 6. (F) Mutation 
frequencies were measured using PrimerID. For panels C-E, statistical significance for change in titer 
of swapped viruses relative to MHV-ExoN(-) P3 at highest drug concentration tolerated was 
determined using Mann-Whitney test (*P<0.05, **<0.01, ns = not significant). Boxed points have the 
same P value. 
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nucleoside analogue can evolve without increasing overall fidelity, resistance to multiple 
nucleoside analogues strongly suggests a broadly increased capacity to discriminate nucleotides, 
or high-fidelity replication (Arias et al., 2008; Sierra et al., 2007; Smith et al., 2015; Zeng et al., 
2013). To determine whether nsp12-P250 is a bona fide high-fidelity RdRp, I measured mutation 
frequencies of WT-MHV, MHV-ExoN(-) P3, and MHV-ExoN(-) nsp12-P250 by PrimerID 
(Chapter 5). In this strategy, individual genomic RNA templates are tagged with unique barcode 
sequences (PrimerIDs) during reverse transcription. During analysis, these barcodes are used to 
generate consensus sequences for individual cDNA species, correcting for PCR and base-calling 
artifacts commonly introduced during deep sequencing experiments (Zhou et al., 2015). We 
isolated supernatant genomic RNA from each virus after approximately two rounds of replication 
and generated libraries with duplicate reactions containing 50,000 genomic templates. We 
obtained >2 million raw reads that condensed to >40,000 consensus sequences representing 40.8-
43.1% of input templates. The mutation frequencies for WT-MHV and MHV-ExoN(-) P3 were 
3.38 x 10-5 and 3.24 x 10-4 mutations per nucleotide sequenced, respectively, a difference of 9.6-
fold and consistent with previous findings (Eckerle et al., 2007; Sexton et al., 2016). The 
mutation frequency of ExoN(-) nsp12-250 was 1.92 x 10-4, which is 1.7-fold lower than MHV-
ExoN(-) P3 and 5.7-fold higher than WT-MHV, demonstrating that nsp12-250 is a high-fidelity 
polymerase (Figure 18F).  
 
Resistance to nucleoside analogues correlates with MHV-ExoN(-) fitness. I hypothesized that 
mutations in nsp12 and nsp14 provided a fitness advantage to MHV-ExoN(-) P250. I competed 
the recombinant viruses with a reference MHV-ExoN(-) virus (P1 stock) containing 10 silent 
mutations in the nsp2 coding region. I detected mutant and reference viruses from the mixed 
infection by real-time quantitative PCR using dual-labeled probes specific for each virus. MHV- 
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Figure 19. Mutations in nsp12-RdRp and nsp14-ExoN from MHV-ExoN(-) P250 increase the fitness of MHV-ExoN(-). 
 
 
 
 
 
 
 
 
Figure 19. Mutations in nsp12-RdRp and nsp14-ExoN from MHV-ExoN(-) P250 increase the 
fitness of MHV-ExoN(-). Recombinant viruses were competed against a reference MHV-ExoN(-) 
containing 10 silent mutations within nsp2. The ratio of viral genome copies relative to the MHV-
ExoN(-) reference is plotted. Data represent mean and standard error of n = 6. MHV-ExoN(-) P250 
data set contains 4 replicates at passage 3 and a single replicate at passage 4 due to undetectable levels 
of MHV-ExoN(-) silent. Statistical significance for the indicated comparisons was determined using 
Mann-Whitney test (**P<0.01). 
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ExoN(-) P3 showed a modest fitness advantage over the reference P1 MHV-ExoN(-) silent 
(Figure 19, solid green). MHV-ExoN(-) P250 profoundly outcompeted MHV-ExoN(-) silent, 
with >1000-fold more MHV-ExoN(-) P250 genomes present at the end of passage 1 (Figure 19, 
dotted green). MHV-ExoN(-) nsp12-P250 had greater relative fitness than MHV-ExoN(-) nsp14-
P250, and MHV-ExoN(-) nsp12/14-P250 was intermediate between the single recombinants, 
implicating a complex evolutionary interaction between these two proteins. The measured fitness 
correlated with the patterns of nucleoside analogue resistance and RNA synthesis associated with 
mutations in nsp12 and nsp14, suggesting a link between the evolution of these phenotypes. The 
result also confirms that nsp12 and nsp14 are important but not sufficient to account for the 
significantly increased fitness of MHV-ExoN(-) P250 relative to MHV-ExoN(-) P3. 
 
Discussion 
This chapter describes the experimental adaptive evolution of WT-MHV and MHV-ExoN(-) 
during long-term passage in cell culture. WT-MHV evolved increased replication kinetics over 
250 passages, with few consensus mutations arising in the WT-MHV P250 genome. In contrast, 
MHV-ExoN(-) accumulated 8-fold more mutations than WT-MHV, none of which occurred at 
the ExoN-inactivating substitutions (Figure 13). Nevertheless, MHV-ExoN(-) P250 
demonstrated increased replication kinetics and fitness, as compared to MHV-ExoN(-) P3 
(Figure 11 and Figure 19). Our previous studies demonstrate that ExoN-mediated proofreading is 
required for CoV fitness (Graham et al., 2012; Sexton et al., 2016; Smith et al., 2013). Thus, 
MHV-ExoN(-) was likely under selective pressure for restoration of high-fidelity replication or 
for tolerance of the increased mutational load. Consistent with this hypothesis, MHV-ExoN(-) 
P250 exhibited increased resistance to multiple nucleoside analogues, a phenotype strongly 
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associated with high-fidelity viruses (Arias et al., 2008; Sierra et al., 2007; Smith et al., 2015; 
Zeng et al., 2013). Our results raise two important questions. In the face of selection for 
increased fidelity, why didn’t MHV-ExoN(-) revert? Can MHV replicase proteins mediate high-
fidelity replication without ExoN proofreading?  
 
In the face of selective pressure for increased fidelity, why didn’t MHV-ExoN(-) revert? 
Although our data suggest that MHV-ExoN(-) was under selective pressure for increased 
fidelity, we detected no primary reversion at the DEàAA substitutions in MHV-ExoN(-) at any 
passage tested. These data are consistent with and significantly extend previous studies reporting 
genotypic stability of ExoN(-) motif I in MHV and SARS-CoV (Eckerle et al., 2007; 2010; 
Graham et al., 2012; Sexton et al., 2016; Smith et al., 2013). Complete reversion within ExoN(-) 
motif I to DE would require four nucleotide changes. This likely represents a high genetic barrier 
to reversion, especially given that fitness can be increased by mutations outside of nsp14-ExoN 
(Figure 19) (Eckerle et al., 2010). Single and double nucleotide changes within motif I could 
restore acidic charge to individual residues (e.g. motif I EA, AD, ED, etc). However, the active 
site compositions of DEDDh exonucleases, such as the Klenow fragment, are so stringent that 
even conservative mutations (D-to-E or E-to-D) reduce ExoN activity by >96% (Derbyshire et 
al., 1991). Thus, intermediate amino acid changes may not have a selective advantage compared 
to motif I AA, limiting the evolutionary pathways to reversion. However, nsp14-P250 had 
detectable effects on RBV and AZC resistance as well as the competitive fitness of MHV-
ExoN(-) (Figure 18 and Figure 19), demonstrating a modest capacity for fitness adaptation in 
nsp14 outside of the catalytic residues. Whether these mutations resulted from genetic drift or 
positive selection remains unclear. Nevertheless, our data show that MHV-ExoN(-) can adapt for 
increased fitness without fully restoring exoribonuclease activity. While some mutations in 
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MHV-ExoN(-) P250 likely confer DBT cell-specific selective advantages, others may represent 
generalizable strategies for overcoming ExoN(-) defects in other cell types and in other 
coronaviruses. Thus, understanding the mechanisms by which MHV-ExoN(-) P250 compensated 
for ExoN activity could allow recovery of ExoN(-) variants of other CoVs, such as transmissible 
gastroenteritis virus and human CoV 229E, which to date have been nonviable as ExoN(-) 
recombinants (Becares et al., 2016; Minskaia et al., 2006). 
 
Can MHV replicase proteins mediate high-fidelity replication without ExoN proofreading? 
MHV-ExoN(-) P250 exhibits increased resistance to four nucleoside analogues after passage 
(Figure 15). Although resistance to a single nucleoside analogue can evolve without increasing 
overall fidelity, resistance to multiple nucleoside analogues strongly suggests a broadly increased 
capacity to discriminate nucleotides, or high-fidelity replication (Arias et al., 2008; Sierra et al., 
2007; Smith et al., 2015; Zeng et al., 2013). Increased-fidelity variants in RNA viruses have most 
frequently been mapped to RdRps (Cameron et al., 2016; Coffey et al., 2011; Pfeiffer and 
Kirkegaard, 2003; Vignuzzi et al., 2008). Thus, if increased fidelity contributes to nucleoside 
analogue resistance in MHV-ExoN(-) P250, the most likely protein involved would be nsp12-
P250. Four findings are consistent with the hypothesis that mutations within nsp12-P250 
increase RdRp fidelity. First, nonsynonymous mutations to nsp12 arose in the low-fidelity MHV-
ExoN(-) but not in the presence of proofreading (WT-MHV). Second, five of the mutations lie in 
or near structural motifs important for fidelity regulation in other RdRps. Amino acid 
substitutions in the fingers and palm domains have been repeatedly shown to affect viral RdRp 
fidelity (Campagnola et al., 2015; Pfeiffer and Kirkegaard, 2003), and we have recently reported 
a fingers mutation (nsp12-V553I) that likely increases the fidelity of the MHV RdRp (Sexton et 
al., 2016). Our modeled structure predicts that nsp12-P250 contains three mutations in the palm 
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domain and one in the fingers domain, with the M814K thumb domain mutation lying near the 
palm (Figure 17A). Third, exchange of nsp12-P250 alone into the background of MHV-ExoN(-) 
reduced the susceptibility of MHV-ExoN(-) to three different nucleoside analogues (Figure 18). 
Finally, nsp12-P250 reduced the mutation frequency of MHV-ExoN(-) P3 by 1.7-fold, 
respectively, consistent with high-fidelity RdRps in other viruses (Figure 18) (Smith et al., 
2014). Thus, all data support the hypothesis that nsp12-P250 is a high-fidelity RdRp. 
 
Importantly, nsp12-P250 only partially accounts for the MHV-ExoN(-) P250 nucleoside 
analogue resistance phenotype (Figure 18), suggesting a possible limit to the compensation 
achievable by mutating the RdRp alone. Further, the effects of mutations in nsp12-P250 and 
nsp14-P250 are not additive and may be antagonistic when isolated from the whole passaged 
virus (Figure 18), indicating that the relationships between nsp12- and nsp14-P250 mutations are 
likely evolutionarily linked with those in other MHV proteins. In fact, a substantial component of 
the evolved resistance to nucleoside analogues cannot be explained by nsp12-P250 and nsp14-
P250, alone or together. In support of this hypothesis, we identified several nonsynonymous 
mutations in other replicase proteins, such as nsps 8, 9, 13, and 15. SARS-CoV nsp8 and nsp13 
have functional interactions with nsp12, acting as a primase/processivity factor (Imbert et al., 
2006; Subissi et al., 2014) and a helicase/NTPase, respectively (Adedeji et al., 2012). 
Processivity factors in herpes simplex virus and Mycobacterium tuberculosis regulate DNA 
polymerase fidelity by balancing polymerase extension and exonuclease activity (Chaudhuri et 
al., 2003; Gu et al., 2016), and helicases in chikungunya virus and foot-and-mouth disease virus 
can evolve to increase fidelity (Stapleford et al., 2015) and alter the frequency of ribavirin-
induced mutations (Agudo et al., 2016), respectively. SARS-CoV nsp9 has RNA-binding 
activities and is proposed to participate in the multi-protein replicase complex (Egloff et al., 
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2004; Smith et al., 2014), and MHV nsp15 is a uridylate-specific endoribonuclease (Bhardwaj et 
al., 2004). Both could plausibly be involved in modulating polymerase activity. Additionally, it 
remains possible that evolution for increased fidelity could involve proteins outside the canonical 
replication complex (nsps7-16), including those in the structural and accessory cassette. Thus, 
while immediate studies will focus on testing whether replicase proteins nsp8, 9, 13, and 15 
regulate fidelity, it is exciting to consider the possibility that this virus-directed discovery 
approach will reveal novel interactions between multiple MHV proteins. 
 
Conclusions. The proofreading activity of the nsp14 exoribonuclease is a critical determinant of 
CoV replication, fidelity, and fitness. I show that CoVs also have the capacity to compensate for 
loss of ExoN activity through a network of mutations in nsp12, nsp14, and elsewhere in the 
genome. Thus, while nsp14-ExoN appears to play a dominant role in CoV replication fidelity, its 
activity is likely closely tied to a highly evolved network of proteins. The demonstrated co-
adaptation for replication, competitive fitness, and likely increased fidelity within MHV-ExoN(-) 
supports the hypothesis that these roles are linked functionally and evolutionarily. It will be 
interesting to test whether evolution in other cell types derived from different species or with 
different innate immune environments would result in similar adaptive strategies. 
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CHAPTER 3: IDENTIFICATION OF FIDELITY-ALTERING MUTATIONS OUTSIDE 
OF THE MHV POLYMERASE AND EXORIBONUCLEASE  
 
Introduction 
Prior to this dissertation research, the proofreading exoribonuclease (ExoN) had been identified 
as a critical determinant of viral fitness (Eckerle et al., 2007; 2010; Graham et al., 2012; Smith et 
al., 2013; 2015). In the previous chapter, I demonstrated that a murine hepatitis virus lacking 
ExoN activity [MHV-ExoN(-), hereafter ExoN(-)] can adapt during long-term passage for 
increased replication and fitness without reverting the ExoN-inactivating mutations. Passage-
adapted ExoN(-) mutants also demonstrated increasing resistance to nucleoside analogues that is 
explained only partially by a high-fidelity RNA-dependent RNA polymerase (nsp12-250). These 
data suggested that high-fidelity coronaviral replication is mediated by the interplay of multiple 
replicase proteins and supported the proposed link between coronavirus fidelity and fitness. 
 
In this chapter, I describe my efforts to identify proteins outside of the nsp12-RdRp that 
contributed to the high-fidelity phenotype of ExoN(-) P250. As with experiments in Chapter 2, 
the general approach was to engineer recombinant ExoN(-) viruses containing passage-selected 
sequences of various proteins, alone and in combination, and screen for high-fidelity replication 
using nucleoside analogues. Using a large panel of recombinant viruses, I show that the high-
fidelity nsp12-RdRp is the only replicase protein that adapted to increase nucleoside analogue 
resistance in ExoN(-) P250. My data also suggests that structural and accessory protein 
mutations may contribute to nucleoside analogue resistance but indicates that the full phenotype 
of ExoN(-) P250 depends upon mutations across the genome that may be inseparable.  
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Co-author contributions 
I performed all molecular biology and all experiments described in this chapter with few 
exceptions. Xiaotao Lu was instrumental in cloning recombinant MHV fragments and assisted in 
virus recovery. Thayer Taft performed multiple replicates of 5-fluorouracil sensitivity assays 
reported in Figure 27. 
 
Results 
Selection of viruses for study. The experiments described in Chapter 2 focused on coding 
sequences from ExoN(-) P250. However, I chose to use coding sequences from ExoN(-) P160 in 
subsequent experiments for several reasons. First, ExoN(-) P160 and P250 have nearly 
indistinguishable replication and nucleoside analogue resistance (Figure 11, Figure 15, and 
reproduced in Figure 20). Genomic RNA accumulation was also similar for both viruses (Figure 
20C). Second, the nsp12 and nsp14 sequences of ExoN(-) P160 and P250 are identical (Figure 
17 and Appendices A.2, A.3). Third, the P160 consensus sequence has 20 fewer nonsynonymous 
mutations affecting four fewer proteins than P250, simplifying the matrix of testable interactions 
(Table 3 and Appenfix A.3). Finally, ExoN(-) P250 is challenging to use experimentally because 
it does not form distinct syncytia, while ExoN(-) P160 induces visible cytopathology. 
 
The infectious clone of ExoN(-) P160 cannot be recovered. Viral populations are complex, 
and the consensus sequence is not necessarily reflective of the population structure. I intended to 
use ExoN(-) P160 as a control in all experiments in this chapter, but I did not want minority 
variants in the passaged population to cloud my results. To circumvent this potential problem, I 
attempted to generate a full-length infectious clone of ExoN(-) P160 based on the consensus  
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Figure 20. Phenotypes of ExoN(-) P160 and ExoN(-) P250 are nearly identical. 
 
 
 
Figure 20. Phenotypes of ExoN(-) P160 and ExoN(-) P250 are nearly identical. ExoN(-) P160 and 
ExoN(-) P250 have nearly identical replication kinetics (A), sensitivity to 5-fluorouracil (B), and 
accumulation of genomic RNA (C). Note: Data in (A) and (B) are the same as presented in Figure 11 
and Figure 15. Data in (C) represent mean and standard deviation of n = 3. MOI was 0.01 PFU/cell in 
panels (A) and (B) and 1 PFUcell in panel (C). 
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Table 3. Comparison of ExoN(-) P160 and ExoN(-) P250 mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Comparison of ExoN(-) P160 and ExoN(-) P250 mutations. 
 
ExoN(-) passage level P160 P250 
Total # mutations 
          Nonsynonymous 
          Synonymous 
          Noncoding 
125 
54 
61 
7 
171 
74 
90 
7 
# proteins with 
nonsynonymous mutations 15 19 
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sequence (Appendix A.3). Xiaotao Lu used ExoN(-) P160 RNA to clone fragments C, D, and E 
from the MHV reverse genetics system, and I ordered fragments A, B, F, and G from a 
commercial supplier. ExoN(-) P160 sequence has a deletion of nucleotides 22286-23646. Not 
knowing the importance of this deletion for viral fitness, I generated two versions of the 
fragments. One set generates the native ExoN(-) P160 sequence, lacking nucleotides 22285-
23646 (ExoN(-) P160Δ in Figure 21). In the other, I inserted wild-type nucleotides 22285-23646 
(ExoN(-) P160ic in Figure 21). All fragments were confirmed by sequence analysis and 
restriction digests. Due to the high replicative capacity of ExoN(-) P160 (Figure 20), I expected 
that these viruses would be readily recoverable. However, I could not recover either ExoN(-) 
P160ic or ExoN(-) P160Δ despite six and three attempts, respectively, including protocol 
modifications intended for recovery of highly debilitated viruses. I did observe small foci of 
cytopathic effect (punctate syncytia) within 18-24 hours after plating, indicating that spike 
protein subgenomic mRNAs are transcribed and translated, but no viral particles were released. 
In general, the rate and yield of virus recovery correlates with their replicative fitness, and in my 
hands, even debilitated viruses (e.g. ExoN(-)-like) recover in <3 attempts. Thus, the inability to 
recover these viruses is more likely due to an intrinsic property of ExoN(-) P160 than to 
technical errors.   
 
Passaged ExoN(-) viruses are marginally restricted in BHK-R cells. Viral fitness is 
dependent upon the specific selective environment. Accordingly, mutations may be beneficial in 
one environment but maladaptive in others, and tissue culture-specific adaptations occur 
frequently in experimental evolution studies with viruses, including MHV (Baric et al., 1997; 
Iketani et al., 2018). I hypothesized that some ExoN(-) P160 mutations were DBT-specific and  
thus restricted ExoN(-) P160 replication in our recovery cell line, baby hamster kidney cells  
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Figure 21. Schematic of attempted recombinant ExoN(-) P160 infectious clones. 
 
 
 
 
 
 
 
 
 
 
Figure 21. Schematic of attempted recombinant ExoN(-) P160 infectious clones. Linear schematic 
of ExoN(-) P160 population with mutations marked (top). ExoN(-) P160 sequence is denoted in 
maroon, and wild-type sequence is in white. 
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 (BHK-R). To test this hypothesis, I measured replication of ExoN(-) P3, P160, and P250 in both 
DBT9 and BHK-R cells. As expected given their low passage number, WT P3 and ExoN(-) P3 
titers at 24 hours post-infection were identical in both cell lines (Figure 22). In contrast, ExoN(-) 
P160 and ExoN(-) P250 titers were reduced by 0.5 log10 and 1 log10, respectively, indicating that 
some DBT9-specific adaptation occurred. However, both passaged ExoN(-) viruses replicated to 
more than 107 PFU/mL in both cell lines, well above that achieved by ExoN(-) P3, suggesting 
that cell-type-specific adaptations do not restrict ExoN(-) P160 infectious clone recovery. 
Consistent with these results, co-plating of electroporated BHK-R cells with DBT9s did not yield 
infectious virus (not shown). Given these challenges, I used the ExoN(-) P160 passaged 
population as a control in all subsequent experiments. 
 
Replicase mutations outside of nsp12 and nsp14 do not affect nucleoside analogue 
sensitivity. In Chapter 2, I determined that mutations in nsp12-250 and nsp14-250 were likely 
evolutionarily linked with mutations in other MHV proteins. Intuitively, the most likely fidelity-
regulating proteins would be the remaining components of the proposed replicase machinery: 
nsps 7, 8, 9, 10, 13, 15, and 16 (Smith et al., 2014). Of these, only nsp8, nsp9, and nsp13 had 
nonsynonymous mutations in ExoN(-) P160. In SARS-CoV, nsp8 acts as a primase and 
processivity factor (Imbert et al., 2006; Subissi et al., 2014), nsp13 is a helicase (Adedeji et al., 
2012), and nsp9 binds to single-stranded RNA (Egloff et al., 2004). Processivity factors in herpes 
simplex virus and Mycobacterium tuberculosis regulate DNA polymerase fidelity by balancing 
polymerase extension and exonuclease activity (Chaudhuri et al., 2003; Gu et al., 2016), and 
helicases in chikungunya virus and foot-and-mouth disease virus can influence fidelity and 
susceptibility to nucleoside analogues (Agudo et al., 2016; Stapleford et al., 2015). Based on 
their known biochemical activities and association with the replicase-transcriptase, I selected  
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Figure 22. Viruses passaged in DBT9 cells are marginally restricted in BHK-R cells 
 
 
 
 
 
 
 
 
 
 
Figure 22. Viruses passaged in DBT9 cells are marginally restricted in BHK-R cells. 
Subconfluent monolayers of DBT9 cells or BHK-R cells were infected with the indicated viruses at 
MOI = 0.01 PFU/cell. Supernatants were harvested and titered after 24 hours. 
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these three mutants for initial testing. I cloned and recovered recombinant ExoN(-) viruses 
containing each of these three mutants individually (Figure 23). None of these variants had 
significant effects on the sensitivity of ExoN(-) to 5-fluorouracil, ribavirin, 5-azacytidine, or  2¢-
C-methyladenosine (Figure 24), indicating that the mutations in nsp8, 9, and 13 had no 
independent influence on replication fidelity. However, I suspected that they might be 
epistatically linked with nsp12-250 and nsp14-250 (that is, the effects of mutations in nsp8, 9, 
and 13 might depend upon interactions with nsp12-250 and nsp14-250). I cloned and recovered 
each mutation separately with nsp12- and nsp14-250, as well as a recombinant virus containing 
all five P160 replicase protein sequences (Figure 23 and Figure 26). However, no combination of 
replicase mutations increased the 5-fluorouracil sensitivity beyond that of nsp12-250 alone 
(Figure 25), indicating that the high-fidelity nsp12-RdRp is the sole ExoN(-) P160 replicase 
protein that evolved to resist nucleoside analogues. Interestingly, and in contrast to experiments 
in Chapter 2 (Figure 18), nsp12-250 was sufficient for the resistance phenotype of ExoN(-) P160 
to 5-azacytidine and 2´-C-methyladenosine (Figure 24). 
                           
Mutations in the structural and accessory proteins may affect 5-fluorouracil sensitivity. 
Although I considered nsp8, 9, and 13 to be the most likely candidates for fidelity regulation in 
ExoN(-) P160, proteins outside of the canonical replication complex could be important fidelity 
regulators (Collins et al., 2018). To identify potentially contributory mutations outside of the 
predicted replicase, I designed viruses to measure the collective effects of mutations in two 
additional genome regions: nsps1-6, which have various functions including interferon 
antagonism, polyprotein cleavage, and host membrane modification [ExoN(-) nsp1-6-160]; and 
the structural and accessory proteins, which primarily mediate virus assembly and dissemination  
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Figure 23. Schematic of P160 replicase mutants. 
 
 
 
 
Figure 23. Schematic of P160 replicase mutants. Linear schematic of ExoN(-) P160 population with 
mutations marked (top). The region containing components of the RTC is marked and expanded. 
Proteins containing nonsynonymous mutations from ExoN(-) P160 are filled in maroon and those 
without are white. 
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Figure 24. P160 mutations in nsp8, nsp9, and nsp13 do not affect sensitivity to nucleoside analogues 
 
 
 
Figure 24. P160 mutations in nsp8, nsp9, and nsp13 do not affect sensitivity to nucleoside 
analogues. Cells were incubated with 5-fluorouracil (A), ribavirin (B), 5-azacytidine (C), or 2’-C-
methyladenosine (D) for 30 minutes prior to infection with the indicated virus at 0.01 PFU/cell. 
Supernatants were harvested and titered by plaque assay at 24 hours post-infection. Data represent 
mean and standard deviation of n = 6. Statistical significance of individual replicase mutant relative to 
ExoN(-) was calculated using two-way ANOVA with Dunnett’s multiple comparisons testing. No 
comparisons were statistically significant. 
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Figure 25. Nsp12-250 is the primary determinant of 5-fluorouracil sensitivity in the P160-passaged replicase. 
 
 
 
 
 
 
Figure 25. Nsp12-250 is the primary determinant of 5-fluorouracil sensitivity in the P160-
passaged replicase. Cells were incubated with 5-fluorouracil for 30 minutes prior to infection with the 
indicated viruses at MOI = 0.01 PFU/cell. Supernatants were harvested and titered by plaque assay at 
24 hours post-infection. Panel (A) contains all data. Individual replicase mutant viruses are separated 
for ease of visualization in panel (B). Data for WT, ExoN(-) P3, ExoN(-) P160, ExoN(-) nsp12-250 
are identical in all 3 panels of (B). Data represent mean and standard deviation of n = 6. Statistical 
significance of individual replicase mutant relative to ExoN(-) was calculated using two-way ANOVA 
with Dunnett’s multiple comparisons testing. Only marked comparisons were performed. ns = not 
significant. 
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 [ExoN(-) structural-160] (Figure 26) (Perlman and Netland, 2009). I could not recover any virus 
containing P160 sequences in nsps1-6, suggesting that this region may have prevented recovery 
of ExoN(-) P160 infectious clones. However, I did readily recover ExoN(-) structural-160, which 
appears to increase resistance to 5-fluorouracil relative to ExoN(-) P3 (Figure 27). This 
difference was not statistically significant. 
 
Plaque clones of ExoN(-) P160 have identical 5-fluorouracil sensitivity to the full 
population. A foundational principle of viral dynamics is that groups of variants in viral 
populations cooperate and complement each other. Thus, the behavior of a viral population 
depends upon the full spectrum of variants found within it (Bordería et al., 2015; Dolan et al., 
2018b; Domingo et al., 2012; Vignuzzi et al., 2006). Population structures could influence 
nucleoside analogue resistance by a number of mechanisms, including absorption of the 
mutational load, complementation between distinct genomes, or recombination to purge 
deleterious mutations. To test for large-scale population effects, I plaque purified three clones of 
ExoN(-) P160 three times (Figure 12). Each clone is derived, theoretically, from a single 
infectious unit. During stock generation, each clone should develop a population structure that is 
distinct from the original passaged population. All three clones had identical 5-fluorouracil 
sensitivity to the passaged population (Figure 28), indicating that either individual genomes or 
those derived from a single virus plaque encoded the adaptive changes required for resisting 
nucleoside analogues. 
Discussion 
RNA viral susceptibility to mutagenic nucleoside analogues is determined by multiple factors, 
including polymerase fidelity, mutational robustness, and, in the case of coronaviruses,  
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Figure 26. Schematic of P160 regional swaps. 
 
 
 
 
 
 
 
Figure 26. Schematic of P160 regional swaps. Linear schematic of ExoN(-) P160 population with 
mutations marked (top). Proteins containing nonsynonymous mutations from ExoN(-) P160 are filled 
in maroon, and those without are white. 
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Figure 27. Passage-acquired mutations in structural and accessory proteins may contribute to 5-fluorouracil resistance. 
 
 
 
 
 
 
 
 
 
Figure 27. Passage-acquired mutations in structural and accessory proteins may contribute to 5-
fluorouracil resistance. Cells were incubated with 5-fluorouracil for 30 minutes prior to infection 
with the indicated viruses at MOI = 0.01 PFU/cell. Supernatants were harvested and titered by plaque 
assay at 24 hours post-infection. 
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Figure 28. Plaque-purified ExoN(-) P160 clones have identical 5-fluorouracil sensitivity to the full population. 
 
 
 
 
Figure 28. Plaque-purified ExoN(-) P160 clones have identical 5-fluorouracil sensitivity to the 
full population. Cells were incubated with 5-fluorouracil for 30 minutes prior to infection with the 
indicated viruses at MOI = 0.01 PFU/cell. Supernatants were harvested and titered by plaque assay at 
24 hours post-infection. Panel (A) contains all data. Individual replicase mutant viruses are separated 
for ease of visualization in panel (B). Data for WT, ExoN(-) P3, ExoN(-) P160, ExoN(-) nsp12-250 
are identical in all 3 panels of (B). Data represent mean and standard deviation of n = 3. Statistical 
significance of individual replicase mutant relative to ExoN(-) was calculated using two-way ANOVA 
with Dunnett’s multiple comparisons testing. Only marked comparisons were performed. ns = not 
significant. 
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replicative proofreading. Accordingly, disruption of proofreading in SARS-CoV and MHV 
leaves them highly susceptible to nucleoside analogues. In Chapter 2, I demonstrated that 
proofreading-deficient MHV is capable of restoring high-level resistance to nucleoside analogues 
without primary reversion of ExoN(-). Only part of the resistance phenotype of passaged MHV-
ExoN(-) could be accounted for by a high-fidelity polymerase, raising important questions about 
which other proteins or mechanisms mediate high-level nucleoside analogue resistance. In this 
chapter, I used a large panel of recombinant MHV containing passage-acquired sequences to 
examine potential sources of nucleoside analogue resistance in ExoN(-) P160. My results 
revealed a number of surprising findings. First, despite the high replication capacity of ExoN(-) 
P160, I could not recover its infectious clone, raising key questions about how it may interact 
with different cell types. Second, no replicase-transcriptase complex (RTC) proteins outside of 
nsp12-RdRp had any effect upon nucleoside analogue resistance, but mutations within the 
structural and accessory proteins increased resistance to 5-fluorouracil, indicating that the 
ExoN(-) P160 phenotype is complex and probably multifactorial. Finally, the high-level 
resistance of ExoN(-) P160 to nucleoside analogues did not depend upon a specific population 
architecture, strongly suggesting that the ExoN(-) P160 nucleoside analogue resistance 
phenotype likely depends upon a complex coevolution of mutations across the genome that may 
not be isolable. 
 
Why can’t an infectious clone of ExoN(-) P160 be recovered? In general, the replication 
kinetics of MHV variants correlate well with the ease of their recovery by reverse genetics. 
Given that ExoN(-) P160 replicates faster and to higher titers than wild-type (Figure 20), I 
expected that recovery of an infectious clone would be straightforward. However, despite 
evidence of viral protein synthesis (small puncta of cytopathic effect), I was unable to recover 
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viable virus from ExoN(-) P160ic or ExoN(-) P160Δ. The reasons for this restriction are unclear. 
The simplest explanation is that the full-genome sequence of ExoN(-) P160 lacks critical 
adaptive mutations or contains lethal artifacts. Comparing the full-genome sequences of plaque-
purified clones (Figure 28) to that of ExoN(-) P160 could reveal permissive or restrictive 
mutations. More interestingly, however, is the notion that long-term adaptation to DBT9 cells 
prevents efficient recovery in alternative cell lines. ExoN(-) P160 replication was not 
dramatically reduced in BHK-R cells (Figure 22), but mechanisms that subtly restrict 
experimental infections could be lethal in the setting of virus recovery. In the MHV reverse 
genetics system, full-length RNA genomes are electroporated into BHK-R cells along with 
nucleocapsid-encoding mRNA (Yount et al., 2002). In bypassing spike-mediated entry steps, the 
first event in the life cycle is translation of ORF1a (Figure 2). Thus, the first proteins that interact 
with the cellular microenvironment are nsps1-6, which establish a permissive environment for 
RNA synthesis. DBT9-specific adaptations in nsps1-6 could disrupt formation of replication 
organelles or other undefined structures and processes inside BHK-R cells. Consistent with this 
hypothesis, I could not recover a recombinant virus containing P160 sequence from nsps1-6 
[ExoN(-) nsp1-6-160, Figure 26]. If true, ExoN(-) P160 mutations could be scalpels for fine 
dissection of the virus-host interactions important for establishing MHV replication. 
 
Why does ExoN(-) P160 tolerate so many nonsynonymous mutations in the RTC? The 
predicted coronavirus replicase-transcriptase complex (RTC) contains, at minimum, nsps7-14 
and may include nsp15 and nsp16 (Figure 10) (Smith et al., 2014). Many of these proteins have 
multiple domains that perform distinct functions during replication (Snijder et al., 2016). In order 
to maintain their extensive interactions, RTC proteins must co-evolve in a cooperative manner. 
Mutations in these proteins are likely under strong purifying selection to preserve both their 
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essential individual functions and their interactions with the rest of the complex. Put another 
way, RTC proteins are so important for coronaviral fitness that mutations are unlikely to fixate 
by chance. Accordingly, phylogenetic analysis of lineage C Betacoronaviruses (including 
MERS-CoV) found evidence of strong negative selection in nsps 7, 8, 9, 12, 13, and 14 of 
ecological coronaviruses (Forni et al., 2016b). Over long-term passage, only one mutation was 
found in the replicase of WT-MHV, suggesting that most mutations were not tolerated (Figure 
13, Appendix A.1). Thus, it seems likely that the nonsynonymous mutations in the ExoN(-) P160 
RTC are important for viral fitness. Mutations in nsp12-250 clearly increase replication fidelity, 
RNA synthesis, and fitness in the ExoN(-) background (Figures 18, 19, 24, 25, and 27), but the 
effects of other replicase mutations remains unclear. To date, all fidelity-altering mutations in 
MHV have affected 5-fluorouracil sensitivity (Graepel et al., 2017; Sexton et al., 2016; Smith et 
al., 2013; 2015). No combination of P160 replicase mutations increased resistance to 5-
fluorouracil beyond that of nsp12-250 alone, strongly suggesting that they are not important for 
regulating fidelity in the absence of proofreading. However, these mutations are likely still 
important for viral fitness, perhaps by modulating interactions between nsp12-250 and nsp14-
250, which may be antagonistic without additional mutations (Figure 19). Such effects could be 
revealed by replication analyses and studies of RNA synthesis. Further, competitive fitness 
assays could aid in determining whether these mutants are indeed the result of positive selection 
or are artifacts of genetic drift. Finally, these mutations could mediate interactions with proteins 
outside of the canonical RTC, explaining why their effects were not detected as isolated 
recombinants. 
 
Do structural or accessory proteins regulate coronavirus fidelity? The paradigm of low-
fidelity replication in RNA viruses focuses on RdRps as the primary regulators of error rates. By 
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encoding a multi-subunit replicase complex that includes a co-factor-driven, proofreading 
exoribonuclease, coronaviruses have already broken the paradigm. My data suggest that, yet 
again, coronaviruses may be breaking the mold. Indeed, my results indicate that mutations in 
structural and/or accessory proteins may contribute to nucleoside analogue resistance in ExoN(-) 
P160 (Figure 27). We previously demonstrated that spike protein mutations, and the associated 
increase in replication kinetics, did not alter 5-fluorouracil sensitivity (Figure 16). However, we 
found single nonsynonymous mutations in both the envelope (E) and matrix (M) proteins of 
ExoN(-) P160, implicating these proteins in resistance to 5-fluorouracil. It is tempting, though 
perhaps far-fetched, to speculate that coronavirus structural proteins are direct fidelity regulators. 
Indeed, coronavirus structural proteins cannot be produced until after the replication machinery 
is assembled, as they are translated from subgenomic mRNAs (Figure 2 and Figure 3). Further, E 
and M are not closely associated with the RTC during MHV replication (V'kovski et al., 2019). 
However, the pre-membrane/membrane and envelope proteins of yellow fever virus partially 
control genetic diversity, though by an undefined mechanism (Collins et al., 2018). One potential 
explanation relates to the kinetics of replication. For example, mutations in the lysis protein of 
bacteriophage ϕX174 limit the accumulation of 5-fluorouracil-induced mutations by reducing the 
total number of replication cycles required for population expansion (Pereira-Gómez and 
Sanjuán, 2014). If a similar mechanism is at play in ExoN(-) structural-160, then these mutations 
should resist other mutagenic nucleoside analogues, such as 5-azacytidine or ribavirin, but not a 
non-obligate chain terminator like 2¢-C-methyladenosine. Deep sequencing experiments with 
PrimerID (Chapter 5) would also be useful to determine whether the 5-fluorouracil resistance of 
ExoN(-) structural-160 is driven by high-fidelity replication or an alternative mechanism. 
Regardless of whether structural and accessory proteins resist 5-fluorouracil by altering fidelity 
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or some other mechanism, examining their contributions to nucleoside analogue resistance will 
be important for understanding how coronaviruses can evolve in response to antiviral drugs. 
 
Which mechanisms other than increased fidelity might account for MHV-ExoN(-) P250 
nucleoside analogue resistance? Genomic mutations in RNA viruses are most commonly 
detrimental or lethal (Elena and Moya, 1999; Malpica et al., 2002; Peris et al., 2010; Sanjuán et 
al., 2004a; Visher et al., 2016). One strategy to prevent extinction by mutational load is to 
increase replication fidelity, as discussed above. An alternative strategy is to become more 
mutationally robust. Mutational robustness describes a virus’ capacity to buffer the fitness effects 
of mutations. In the setting of low-fidelity replication, as in MHV-ExoN(-), increased mutational 
robustness could have provided a selective advantage (Goldhill et al., 2014; Montville et al., 
2005; Sanjuán et al., 2007). Selection for increased robustness could explain the ~90 
synonymous changes in MHV-ExoN(-) P160. Synonymous changes can alter codons to reduce 
the probability of non-conservative amino acid changes (Lauring et al., 2012). Alternatively, the 
increased population size of MHV-ExoN(-) P160 could promote robustness by a “safety-in-
numbers” effect, allowing efficient purging of low-fitness mutants while maintaining population 
fitness (Lauring et al., 2013). Large populations also increase the likelihood of co-infection, 
allowing complementation between viral genomes. Although increased replication conferred by 
mutations in spike did not alter 5-fluorouracil resistance (Figure 16), a study with poliovirus 
suggests that mutagenized populations have elevated coinfection frequencies (Aguilera et al., 
2017). Thus, complementation may contribute to MHV-ExoN(-) P160 nucleoside analogue 
resistance. Conflicting evidence exists regarding whether mutational robustness itself affects the 
sensitivity to RNA mutagens (Graci et al., 2012; Lauring et al., 2012; O'Dea et al., 2010); 
nevertheless, the robustness of MHV-ExoN(-) P160 merits further investigation.  
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Conclusions. Coronaviruses are among the most genetically complex RNA viruses known, so it 
should come as no surprise that the interactions of mutations across the genome are equally 
complex. Despite the abundance of experimental data about coronavirus biology, our models for 
coronavirus replication probably lack critical details about how proteins across the genome 
interact during infection and about how genetic elements, including synonymous mutations, 
contribute to diverse phenotypes. My data indicate that even a phenotype as seemingly 
straightforward as resistance to nucleoside analogues, thought to be primarily driven by 
replication fidelity, may be multifactorial, and perhaps an accidental consequence of adaptation 
for other phenotypes. Accordingly, my data indicates that the high-level fitness of ExoN(-) P160 
is driven by complex genetic and functional interactions between proteins across the entire 
genome that may not be isolable. Genetic and biochemical testing of the rich mutational resource 
of ExoN(-) P160 could reveal new insights about diverse areas of coronaviral biology and inform 
countermeasures for endemic and emerging coronaviruses. 
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CHAPTER 4: FITNESS BARRIERS LIMIT REVERSION OF A PROOFREADING-
DEFICIENT CORONAVIRUS 
 
Introduction 
Prior to the start of this dissertation, a decade of work had demonstrated critical roles for the 
coronavirus ExoN in efficient and accurate RNA synthesis, fitness, and virulence. Given the 
defects associated with disruption of ExoN, ExoN(-) coronaviruses should be under strong 
selective pressure for primary reversion. In line with this expectation, ExoN motif III mutants of 
SARS-CoV and MHV rapidly and repeatedly revert ((Eckerle et al., 2010) and unpublished 
observations). In contrast, we have never detected partial or complete reversion of ExoN motif I 
mutants (ExoN-AA) in SARS-CoV or MHV during 10 years of study and hundreds of 
experiments. More specifically, we have not detected consensus or minority variants of any kind 
at the motif I AA codons in either virus strain during acute infections and prolonged passage in 
tissue culture and following treatment with multiple nucleoside analogues (Agostini et al., 2018; 
Case et al., 2017; Eckerle et al., 2007; 2010; Graepel et al., 2017; Sexton et al., 2016; Smith et 
al., 2013; 2015). SARS-CoV-ExoN-AA also is stable during acute and persistent animal 
infections in immunocompetent and immune-compromised mice (Graham et al., 2012). The lack 
of primary reversion is not due simply to reduced adaptive capacity, as both SARS-CoV- and 
MHV-ExoN-AA can adapt for increased replication (Eckerle et al., 2010; Graepel et al., 2017). 
Most strikingly, long-term passage of MHV-ExoN-AA (250 passages, P250) yielded a highly fit 
population that had directly compensated for defective proofreading through evolution of a likely 
high-fidelity RdRp (Graepel et al., 2017). Yet, where primary reversion would have required just 
four total consensus mutations, MHV-ExoN-AA-P250 contained more than 170.  
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In this chapter, I describe experiments to determine whether specific genetic or fitness barriers 
prevent primary reversion of ExoN motif I AA. To this end, I identified and engineered viable 
genetic pathways towards ExoN-AA motif I reversion in MHV (hereafter, ExoN-AA). My 
results show that partial reversion did not confer a selective advantage compared to ExoN-AA. 
Further, ExoN-AA adapted within 10 passages for greater fitness than any of the intermediate 
revertants. Finally, restoration of WT-ExoN-DE in the setting of passage-selected mutations in 
the nsp12 RNA-dependent RNA polymerase (RdRp) and nsp14-ExoN exacted profound fitness 
costs. Together, these data are the first observation of an ExoN(-) CoV genotype-fitness 
landscape and identify multiple genetic barriers underlying ExoN(-) motif I stability in MHV. 
Further, they suggest extensive coevolution between MHV replicase proteins during adaptation 
and reveal potential strategies for stabilizing ExoN mutant CoVs. 
 
Co-author contributions 
I performed all molecular biology and recovered all recombinant viruses described in this 
chapter, with two exceptions. Nicole Sexton generated ExoN(-) nsp12-M814K, and Xiaotao Lu 
recovered ExoN(+) nsp12-250 and isolated the ExoN(-) P10 plaque clone. Maria Agostini 
performed 5-fluorouracil sensitivity experiments in Figure 31 and Figure 32 and completed 
plaque assays for additional experiments. 
 
Results 
Primary reversion of ExoN(-) motif I. MHV-ExoN(-), hereafter ExoN-AA, contains two 
engineered substitutions in each codon of motif I, such that complete reversion to WT-ExoN-DE 
requires mutations to all four sites (Figure 29A). Viral mutation rates in the absence of 
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proofreading range from 10-4 to 10-6 mutations per nucleotide per round of replication (µ) 
(Sanjuán et al., 2010). Assuming an ExoN-AA mutation rate of 10-4 µ and accounting for codon 
degeneracy, the probability of restoring the native amino acid sequence in a single round of 
replication is 10-18. Only rarely do ExoN-AA titers exceed 106 PFU/mL, so it is unlikely that 
ExoN-AA could navigate this genetic barrier in a single infectious cycle. Thus, we hypothesized 
that ExoN-AA reversion, if possible, would proceed incrementally. To identify potential 
pathways towards ExoN-AA reversion, we examined the possible single-nucleotide substitutions 
surrounding A89 and A91 (Figure 29B). Three mutations are synonymous, and five mutations 
yield amino acids unlikely to coordinate with the positively-charged metals required for ExoN 
catalysis (glycine, valine, proline, threonine, and serine) (Chen et al., 2007; Ma et al., 2015; 
Minskaia et al., 2006; Steitz and Steitz, 1993). One mutation per site can restore the acidic 
charge (i.e. AA-to-ED) but not the native amino acid. These variants have not been tested in a 
CoV ExoN, but biochemical studies of E. coli DNA polymerase I ExoN mutants suggest that 
these conservative substitutions would not restore WT-like ExoN activity (Derbyshire et al., 
1991). We predicted stepwise pathways to ExoN-AAàDE reversion based on restoration of 
acidic charge followed by reversion to native amino acids (Figure 29C). We engineered and 
recovered variants in ExoN-AA requiring three mutations (3nt; ExoN-AD, ExoN-EA), two 
mutations (2nt; ExoN-DA, ExoN-ED, ExoN-AE), or one mutation (1nt; ExoN-DD, ExoN-EE) 
for reversion to WT-ExoN-DE (Table 4). We will hereafter refer to these mutants as intermediate 
revertants. All intermediate revertants generated viable progeny during recovery, demonstrating 
that reversion to WT-ExoN-DE along these pathways is theoretically possible. The 3nt and 2nt 
mutants were genetically stable during recovery, as confirmed by dideoxy sequencing. However, 
both 1nt mutants (ExoN-DD and ExoN-EE) reverted to WT-ExoN-DE during three independent  
  91 
 
 
Figure 29. Sequence landscape around ExoN-AA motif I. 
 
 
 
 
 
 
 
 
Figure 29. Sequence landscape around ExoN-AA motif I. (A) ExoN motif I nucleotide sequences. 
(B) Landscape of single-nucleotide substitutions within ExoN-AA motif I. (C) Predicted pathways to 
reversion of ExoN-AA. Variants marked with # reverted to WT during three independent recovery 
attempts. 
D89 E91
GAT GAA
A89 A91
GCA GCT
WT-ExoN-DE
ExoN-AA
A BExoN Motif I
C
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recovery attempts, suggesting that these two variants are less fit than WT-ExoN-DE and 
demonstrating that reversion by 1nt mutation is readily accessible. To test whether the 3nt or 2nt 
mutants would revert more rapidly than ExoN-AA (4nt), we passaged three lineages of each 
mutant 10 times at multiplicities of infection (MOI) of 0.5 and 0.01 PFU/cell. We harvested 
supernatants and screened for reversion by visual inspection of plaque phenotypes at each 
passage. WT-ExoN-DE and WT-like viruses produce uniform, large plaques, while ExoN-AA-
like viruses yield small, variably-sized plaques (Eckerle et al., 2007). When we observed mixed 
plaque phenotypes, we sequenced three large plaques from each lineage to confirm reversion. 
The 3nt (ExoN-AD and ExoN-EA) and 2nt (ExoN-DA and ExoN-ED) intermediate revertants 
showed no evidence of reversion over 10 passages at either MOI (Table 4). In contrast, the 2nt 
ExoN-AE contained WT-revertants by P2 in all lineages at MOI = 0.5 PFU/cell and by P8 in one 
lineage at MOI = 0.01 PFU/cell. Once observed, WT-revertants dominated the ExoN-AE 
population for the remaining passages. These data indicate that at least one 2nt mutation pathway 
can lead to full reversion in tissue culture. The probability of ExoN-AE arising during a single 
infectious cycle of ExoN-AA is low but theoretically achievable (~10-9), so ExoN-AA could 
conceivably revert within just two infectious cycles. However, complete reversion has never 
been observed even during prolonged passage or persistent infections, suggesting that additional 
barriers to the replication, fitness, or maintenance of intermediate revertants exist. 
 
Partial reversion of MHV-ExoN(-) motif I does not confer a selective advantage. Because 
the intermediate revertants are viable as recombinants but are not found in ExoN-AA 
populations, we hypothesized that they confer no selective advantage over ExoN-AA (Eckerle et 
al., 2007; Sexton et al., 2016; Smith et al., 2013). To test this hypothesis, we first analyzed 
replication of the 3nt and 2nt intermediate revertants (Figure 30A). All variants achieved similar  
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Table 4. Recovery and passage of intermediate revertants. 
 
 
 
 
 
 
 
Table 4. Recovery and passage of intermediate revertants. 
n.d.: not done. 
aBolded nucleotides must mutate to reach WT-ExoN-DE genotype. 
bRecovered viruses were subjected to 10 passages at the indicated MOI. Samples were screened for 
wild-type revertants by plaque assay, and revertant lineages were sequence-confirmed. 
 
Virus
# of mutations to 
WT-ExoN-DE Motif I sequencea
# of reverted lineages by passage 10b
MOI = 0.01 MOI = 0.5
ExoN-AA 4 GCA…GCT 0/3 0/3
ExoN-AD 3 GCA…GAT 0/3 0/3
ExoN-EA 3 GAA…GCT 0/3 0/3
ExoN-DA 2 GAT…GCT 0/3 0/3
ExoN-AE 2 GCA…GAA 1/3 (by P8) 3/3 (by P2)
ExoN-ED 2 GAA…GAT 0/3 0/3
ExoN-EE 1 GAA…GAA n.d. n.d.
ExoN-DD 1 GAT…GAT n.d. n.d.
WT-ExoN-DE 0 GAT…GAA n.d. n.d.
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peak titers to ExoN-AA, but detailed examination of their kinetics suggested a potential delay of 
up to 1.5 hours for all intermediate revertants compared to ExoN-AA. Of note, ExoN-AE was the 
most delayed, and we detected WT-ExoN-DE revertants in two of three replicates, suggesting 
increased selective pressure against this variant. We next measured the competitive fitness of 
each intermediate revertant relative to a recombinant ExoN-AA containing seven silent 
mutations in the nsp2 coding region (ExoN-AA-reference). Intermediate revertants were mixed 
with an equal titer of ExoN-AA-reference at a combined MOI = 0.05 PFU/cell and passaged four 
times. The ratio of each intermediate revertant to ExoN-AA-reference was quantified at each 
passage by RT-qPCR, and the change in ratio over time was used to calculate their relative 
fitness. WT-ExoN-DE was significantly more fit than ExoN-AA, whereas the intermediate 
revertants (ExoN-AD, -EA, -DA, and -ED) had no increased fitness relative to ExoN-AA (Figure 
30B). The apparent increased fitness of ExoN-AE resulted from all lineages reverting to WT-
ExoN-DE during the experiment. Finally, our previous studies have shown that adaptation of 
ExoN-AA includes partial compensation for the replication fidelity defect, as measured by 
reduced susceptibility to the mutagen 5-fluorouracil (5-FU) (Case et al., 2016; 2017; Graepel et 
al., 2017; Sexton et al., 2016; Smith et al., 2013; 2015). None of the intermediate variants 
demonstrated statistically significant differences in 5-FU sensitivity as compared to ExoN-AA 
(Figure 30C). Thus, with the exception of the ExoN-AEàDE revertants, no 3nt and 2nt 
intermediate genotypes along our predicted pathway demonstrated an advantage in replication, 
fitness, or fidelity that would favor their maintenance or expansion in the viral population. Thus, 
natural selection is unlikely to drive ExoN-AA down these pathways towards reversion. 
 
Secondary adaptations outside of ExoN-AA motif I increase fitness along alternative 
pathways. Although we did not find fitness advantages to intermediate revertants, we also did  
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Figure 30. Intermediate revertants of ExoN-AA motif I do not have selective advantages. 
 
 
 
 
Figure 30. Intermediate revertants of ExoN-AA motif I do not have selective advantages. (A) 
Replication kinetics at MOI = 0.01 PFU/cell plotted as mean ± SD of n = 3. (B) Competitive fitness of 
each variant relative to ExoN-AA. Viruses were competed with a tagged ExoN-AA-reference strain, 
and relative fitness was normalized to the mean of ExoN-AA. (C) 5-fluorouracil sensitivity at MOI = 
0.01 PFU/cell. Statistical significance of each variant relative to ExoN-AA was determined by one-
way ANOVA with multiple comparisons (Panel D) two-way ANOVA with Dunnett’s multiple 
comparisons (panel C). ****p<0.0001; ns = not significant. Data in (B) and (C) represent mean ± SD 
of n = 6. Boxed values have the same significance. #All lineages of ExoN-AE reverted to WT-ExoN-
DE during the experiment. 
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not identify profound fitness costs that would drive their immediate loss from populations. We 
have previously demonstrated that during 250 passages (P250), ExoN-AA can adapt for 
increased replication, fitness, and fidelity via secondary mutations outside of motif I (Graepel et 
al., 2017). We tested whether secondary adaptive mutations could exceed the fitness of ExoN-
AA and its intermediate revertants. To examine the early adaptation of ExoN-AA, we studied 
passage 10 from the P250 passage series (Figure 31). ExoN-AA-P10 retains the ExoN-AA motif 
I genotype but has increased replication and reduced susceptibility to 5-FU, altogether 
manifesting in greater relative fitness (Figure 31) (Graepel et al., 2017). We identified only six 
total mutations within ExoN-AA-P10 by dideoxy sequencing (Table 5), indicating that rapid 
adaptation of and compensation for ExoN-AA requires relatively few genetic changes at the 
consensus level. To test whether interactions between multiple mutations or population level 
effects contribute to ExoN-AA-P10 fitness, we isolated a plaque-purified clone of ExoN-AA-
P10. The clone replicated to higher titers than the ExoN-AA-P10 population but had identical 5-
FU sensitivity and relative fitness (Figure 31), indicating that genomes derived from a single 
virus plaque encode the adaptive changes required by the total population. Together, these data 
demonstrate that mutations outside of ExoN(-) motif I can confer greater fitness advantages than 
intermediate revertants even at early passages. These early adaptive mutations likely reduce the 
selective pressure for motif I reversion and place the intermediate revertants at a selective 
disadvantage. 
 
Adaptive mutations in nsp12 and nsp14 that increase ExoN-AA fitness confer significant 
fitness costs to WT-ExoN-DE. Mutational fitness effects are highly dependent upon the genetic 
background (Das et al., 2013; Koel et al., 2018; Nakajima et al., 2005). In addition to reducing 
selective pressure for reversion, mutations conferring increased fitness to ExoN-AA might also  
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Table 5. Mutations in ExoN(-) P10. 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Mutations in ExoN(-) P10. Data derived from dideoxy sequencing. 
aMutation present at approximately 50% of population. 
bMHV HE is not transcribed in tissue culture. 
cAmino acid numbers designate positions within cleaved nsps, not the polyprotein. 
 
 
 
Mutation 
number
Nucleotide 
change
Protein Amino acid 
changec
1 G2520Aa nsp2 D524N
2 A3080Ga nsp3 silent
3 T16017A nsp12 M814K
4 A17836Ga nsp13 I492M
5 G22673Aa HEb noncoding
6 A29298Ca M silent
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Figure 31. ExoN-AA adapts for increased fitness within 10 passages. 
 
 
 
 
 
 
 
 
 
Figure 31. ExoN-AA adapts for increased fitness within 10 passages. (A) Replication kinetics of 
indicated viruses at MOI = 0.01 PFU/cell plotted as mean ± SD of n = 3. (B) 5-fluorouracil sensitivity 
at MOI = 0.01 PFU/cell. (C) Competitive fitness of individual recombinants relative to ExoN-AA. 
Viruses were competed with a tagged ExoN-AA-reference strain, and relative fitness was normalized 
to the mean of ExoN-AA. Statistical significance of each virus relative to ExoN-AA was determined 
by two-way ANOVA with Dunnett’s multiple comparisons (panel B) or by one-way ANOVA with 
multiple comparisons (Panel C). ****p < 0.0001, ns = not significant. LOD = limit of detection. Data 
in (B) and (C) represent mean ± SD of n = 6. Boxed values have the same significance. 
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reduce the benefits of motif I reversion. We previously reported that long-term passage of ExoN-
AA selects for secondary adaptive mutations in the nsp12 RdRp and nsp14 (nsp12-P250 and 
nsp14-P250) (Graepel et al., 2017). Nsp12-P250 contains 7 nonsynonymous mutations that 
partially compensate for defective proofreading and increase ExoN-AA fitness. Nsp14-P250 
contains 6 nonsynonymous mutations, including a conservative D-to-E substitution in ExoN 
motif III, and increases ExoN-AA fitness without compensating for defective proofreading. To 
test whether the fitness effects of passage-associated mutations in nsp12-P250 and nsp14-P250 
depend upon the ExoN-AA genotype, we engineered a WT motif I (ExoN-DE) into viruses 
containing nsp12-P250 and nsp14-P250, alone and together, and analyzed replication, 5-FU 
sensitivity, and competitive fitness. Compared to WT-ExoN-DE, both ExoN-DE-nsp12-P250 
and ExoN-DE-nsp14-P250 displayed delayed and decreased replication (Figure 32A). In 5-FU 
sensitivity assays, ExoN-DE-nsp14-P250 was indistinguishable from WT-ExoN-DE, while both 
variants containing nsp12-P250 (ExoN-DE-nsp12-P250 and ExoN-DE-nsp12/14-P250) were 
significantly more sensitive to 5-FU (Figure 32B). Finally, the nsp12-P250 and nsp14-P250 
mutations significantly decreased fitness relative to WT-ExoN-DE (Figure 32C). We detected no 
statistical differences between the specific infectivity of WT-ExoN-DE and any of the nsp12-
P250 and nsp14-P250 variants in isolated infections (Figure 32D). Thus, mutations in nsp12 and 
nsp14 that arose in the ExoN-AA background were detrimental to replication, mutagen 
sensitivity, and competitive fitness in the presence of a fully-reverted ExoN-DE. These results 
support the conclusion that the adaptive pathways available to ExoN-AA may stabilize the 
ExoN-AA genotype, reducing both the selective pressure for, and the potential benefits of, 
primary reversion. 
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Figure 32. Mutations that increase ExoN-AA fitness are detrimental in the presence of WT-ExoN-DE. 
 
 
 
 
 
 
 
 
 
Figure 32. Mutations that increase ExoN-AA fitness are detrimental in the presence of WT-
ExoN-DE. (A) Replication kinetics of indicated viruses at MOI = 0.01 PFU/cell plotted as mean ± SD 
of n = 3. (B) 5-fluorouracil sensitivity at MOI = 0.01 PFU/cell, mean ± SD of n = 6. (C) Competitive 
fitness of individual recombinants relative to WT-ExoN-DE. Viruses were competed with a tagged 
WT-ExoN-DE reference strain, and relative fitness was normalized to the mean of WT-ExoN-DE, 
mean ± SD of n = 6. (D) Specific infectivity (genomes per PFU) from isolated infections, mean ± SD 
of n = 4.. Statistical significance of each virus relative to WT-ExoN-DE was determined with two-way 
ANOVA with Dunnett’s multiple comparisons test (panel B) or by ordinary one-way ANOVA with 
Dunnett’s multiple comparisons test (panels C and D). **p < 0.01; ***p < 0.001; ****p < 0.0001; ns 
= not significant. 
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Discussion 
In this study, we demonstrate that the stability of the ExoN(-) motif I genotype in MHV (ExoN-
AA) is a consequence of the limitations and opportunities of the genetic landscape it explores 
during replication (Figure 33). Our results support a model in which the viable adaptive 
pathways leading to direct reversion of motif I from AA-to-DE are relatively flat on a fitness 
landscapes, as intermediate revertants remain phenotypically ExoN(-) and confer no fitness 
advantage over ExoN-AA. In contrast, at least one alternative adaptive pathway is readily 
accessible and imparts immediate fitness gains over ExoN-AA. We propose that even minimal 
alternative pathway adaptive fitness gains reduce the likelihood and benefits of motif I reversion, 
until eventually the changing genetic background renders reversion detrimental. These data and 
this model suggest that selection during replication favors immediate, incremental fitness gains 
along the most accessible pathway rather than dramatic fitness increases across a larger genetic 
barrier. 
 
Our results also extend existing studies of CoV ExoN motif I. Motif I AAàDE mutations in the 
SARS-CoV nsp14-ExoN dramatically reduce nuclease activity in biochemical assays, but no 
study has examined the contributions of each residue independently (Bouvet et al., 2012; Ma et 
al., 2015). Intermediate revertants of ExoN-AA did not display consistent or statistical 
differences in replication, 5-FU sensitivity, or competitive fitness relative to ExoN-AA, 
suggesting that they remain phenotypically ExoN(-) during infection and supporting previous 
studies that motif I DE is essential for WT ExoN function. Given these results, we were surprised 
to observe repeated reversion of the ExoN-AE but not the other two 2nt variants, ExoN-DA and 
ExoN-ED. One potential explanation is that the specific mutational bias of ExoN-AE makes the  
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Figure 33. Model for the in vitro evolution of MHV-ExoN-AA. 
 
 
 
 
 
 
 
 
 
 
Figure 33. Model for the in vitro evolution of MHV-ExoN-AA. MHV-ExoN-AA(black dot) is a 
low-fitness variant. Reversion to WT-ExoN-DE would dramatically increase fitness but can only be 
achieved by traversing a flat landscape and climbing a steep fitness cliff (dotted white arrows). 
However, secondary mutations that incrementally increase fitness are more accessible (solid white 
arrow). Eventually, the genetic background changes enough that reversion becomes detrimental 
(dotted yellow line). 
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revertant mutations more accessible than in ExoN-DA or ExoN-ED. Alternatively, if ExoN-AE 
has profound replication or fitness defects, selection could drive primary reversion more quickly 
away from this genotype. Consistent with this hypothesis, ExoN-AE reverted more quickly at a 
higher MOI, where natural selection acts more efficiently on a larger population size (Table 1) 
(Dolan et al., 2018b).  Biochemical studies would be valuable to understand how nsp14-ExoN-
AE differs from the other intermediate revertants, with an eye towards understanding the 
catalytic constraints and functional interactions with nascent CoV RNA.  
 
CoV replication proceeds through the concerted action of multiple proteins proposed to resemble 
DNA replication holoenzymes (Smith et al., 2014). Due to the extensive interactions between 
CoV proteins, they must coevolve in a highly cooperative manner to maintain their essential 
functions. Consistent with this hypothesis, the fitness effects of mutations in nsp12-P250 and 
nsp14-P250 differ based on the motif I genotype; they are beneficial in ExoN-AA but 
detrimental in the WT-ExoN-DE background. In previous studies, it has been difficult to 
determine whether the fitness defects in ExoN(-) CoVs are directly linked to low-fidelity 
replication or through some other mechanism. Our data suggest that the proofreading function of 
nsp14-ExoN can be uncoupled from its more general role in replication (Figure 32), providing an 
opportunity to examine additional roles for this essential protein. Nsp12-P250 also will be an 
important tool for understanding the relationship between RdRp fidelity and ExoN proofreading 
during CoV replication and for studying replication complex assembly and interactions. Our 
studies suggest that compensatory mutations identified through long-term passage could stabilize 
the ExoN-AA genotype. In particular, the high-fidelity nsp12-P250 could reduce the probability 
of reversion by reducing mutational sampling within motif I (Arnold et al., 2005), and both 
nsp12-P250 and nsp14-P250 render the MHV genome inhospitable to a WT-ExoN-DE. 
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Together, these studies argue that experimental evolution can generate reagents to define critical 
interactions involved in CoV replication and can identify new strategies for stabilizing attenuated 
CoVs. 
 
In this chapter, I provide the first glimpse of a coronavirus genotype-fitness landscape and 
establish the genetic basis of ExoN(-) motif I stability in MHV. I also demonstrate that 
compensatory mutations derived from experimental evolution are highly dependent upon the 
genetic background, suggesting that they may be useful for stabilizing live-attenuated 
coronavirus vaccines. The high conservation of nsp14-ExoN across diverse coronaviruses 
suggests that they may be subject to similar genetic barriers, supporting the proposed strategy of 
ExoN-inactivation as a broadly applicable platform for attenuation of emerging coronaviruses.  
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CHAPTER 5: NEW METHODS FOR MEASURING MURINE HEPATITIS VIRUS 
FIDELITY AND FITNESS 
 
Introduction 
Mutation rates and viral fitness are two key parameters that influence viral evolutionary 
dynamics. Recent technological advances have greatly enhanced our ability to measure mutation 
rates and viral fitness with high sensitivity and accuracy (Dolan et al., 2018a). Most of the new 
tools are developed for model viruses like poliovirus and influenza due to the ease of genome 
manipulation and the sheer number of investigators working on these pathogens. By comparison, 
the tools available for studying coronavirus evolution are limited in scope and sensitivity. In this 
chapter, I discuss the development of two new tools for murine hepatitis virus: a next-generation 
sequencing pipeline for highly accurate measurement of mutation rates and a competitive fitness 
assay for MHV variants.  
 
Coauthor contributions 
I designed all primer sets for PrimerID and performed all analysis. Tia Hughes optimized library 
preparation and generated all libraries reported in this dissertation. I received bioinformatic 
software and guidance from Shuntai Zhou (University of North Carolina Chapel Hill), Adam 
Lauring and Matthew Pauly (University of Michigan), Jennifer Gribble (Vanderbilt University, 
Denison lab), and Ben Reisman (Vanderbilt University, Bachmann lab). Jim Chappell helped me 
to design the competition experiments. I performed all benchwork and analysis for competitive 
fitness assays. 
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Highly accurate measurement of coronaviral mutation frequencies and rates by deep 
sequencing 
The notorious adaptability of RNA viruses is driven by their capacity to generate enormous 
genetic diversity through mutation and recombination. Accurate measurements of mutation rates 
and biases in RNA viruses is essential for understanding and anticipating their evolutionary 
dynamics. The primary viral determinant of mutation rates, replication fidelity, can be measured 
in a variety of ways. Biochemical experiments with expressed proteins are the gold standard for 
quantifying polymerase fidelity and have been instrumental in identifying the molecular 
mechanisms of nucleotide (mis)incorporation (Arnold and Cameron, 2004; Arnold et al., 2005; 
Ferron et al., 2018; Moustafa et al., 2014). Biochemical data for coronavirus replication is, to 
date, relatively limited. The SARS-CoV RNA-dependent RNA polymerase is unstable when 
expressed alone and requires, at minimum, nsp7 and nsp8 for stable and processive 
polymerization (Subissi et al., 2014; Velthuis et al., 2010). Recent biochemical data 
demonstrates that the SARS-CoV RdRp (in complex with nsp7 and nsp8) has lower intrinsic 
fidelity than the dengue virus RdRp (isolated protein), probably indicating that the coronavirus 
proofreading ExoN relieves the RdRp of constraints on fidelity (Ferron et al., 2018). Consistent 
with this hypothesis, MHV RdRp fidelity effects are masked by intact proofreading, so 
biochemical studies should ideally incorporate all components of the purported coronavirus 
replicase-transcriptase complex (Chapter 1, Figure 10) (Sexton et al., 2016; Smith et al., 2014). 
To date, no such biochemical system exists. Still, biochemical systems, by design, exclude the 
complex milieu of viral and cellular factors that may influence fidelity during infections, 
potentially obscuring details about replication in living cells.  
 
Nucleoside analogues (artificial compounds structurally similar to natural nucleosides) can also 
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be used to measure replication fidelity. Resistance to one or more nucleoside analogues typically 
correlates with higher overall fidelity (for example, (Arribas et al., 2011; Graepel et al., 2017; 
Pfeiffer and Kirkegaard, 2003; Sexton et al., 2016; Stapleford et al., 2015). However, mutations 
conferring nucleoside analogue resistance can decrease fidelity in the absence of drug, 
suggesting that mechanisms for excluding unnatural nucleosides are not identical to those 
preventing misincorporation of natural nucleosides (Arias et al., 2008; Sexton et al., 2016; Sierra 
et al., 2007). Further, the results of nucleoside analogue sensitivity experiments are, at best, 
semi-quantitative (e.g. virus A is 5-fold less sensitive than virus B to drug X at concentration Y), 
making it difficult to extrapolate to conclusions about replication errors in the absence of drug. 
Still, nucleoside analogue experiments have been massively informative for understanding 
fidelity regulation in coronaviruses and have contributed key findings to the body of work 
supporting the proofreading function of nsp14-ExoN (Graepel et al., 2017; Sexton et al., 2016; 
Smith et al., 2013; 2015).  
 
Whereas biochemical studies and nucleoside analogue sensitivities examine fidelity under “non-
normal” conditions, fidelity can also be investigated during “normal” infection cycles, in the 
presence of all viral and cellular factors that contribute to replication errors. Results from such 
studies are typically reported as either mutation rates or mutation frequencies (Bradwell et al., 
2013; Peris et al., 2010). The difference between rates and frequencies is subtle but important. 
Mutation rates describe the number of errors incorporated during a discrete unit of time (e.g. 
mutations per infection cycle); that is, the rate at which the replicase makes mistakes. By 
contrast, a mutation frequency is the number of mutations identified per nucleotide sequenced. 
Frequency measurements, therefore, reflect both the rate at which a mutation is generated and its 
ability to persist in the population. Thus, mutation frequencies can be skewed by individual 
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fitness effects and genetic drift. Still, mutation rates and frequencies are both valid measurements 
of replication fidelity in experimental settings. 
 
A common strategy for measuring mutation rates is to use a Luria-Delbrück fluctuation test 
(Luria and Delbrück, 1943). In this method, parallel cultures are assessed for a scorable 
phenotype after a defined period of growth. Scorable phenotypes include, for example, escape 
from neutralizing antibodies or sensitivity to guanidine-hydrochloride (Furió et al., 2005; Pfeiffer 
and Kirkegaard, 2003), and should be accessible by just a single nucleotide change. The ratio of 
resistant-to-sensitive variants corresponds to the mutation rate. However, these typically sample 
just a few sites or mutational classes (e.g. AàG, GàC, etc) and may not reflect the rate of all 
possible mutation types. Recently, Pauly et al. reported a fluctuation test for influenza based on 
reversion to fluorescence of virally-encoded green fluorescent protein (GFP) mutants that can 
interrogate all 12 mutation classes (Pauly et al., 2017b). This type of assay is potentially feasible 
in coronaviruses but would require significant genetic engineering. The stability of the required 
viruses would be difficult to predict given high rates of recombination in coronaviruses that 
rapidly delete non-essential genes (Chinese SARS Molecular Epidemiology Consortium, 2004; 
Graepel et al., 2017; Makino et al., 1986). 
 
Genome sequencing studies can also be used to measure viral mutation rates and frequencies. 
One strategy is to clone and dideoxy sequence large numbers of individual genomes to determine 
changes in mutation accumulation (Gnädig et al., 2012; Rozen-Gagnon et al., 2014). However, 
this method has a small dynamic range unless thousands of clones are analyzed, which quickly 
becomes labor-prohibitive (Sexton, 2017). Next-generation sequencing (“deep sequencing”) 
strategies are less labor-intensive and more sensitive for measuring mutation frequencies. 
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However, artifacts incorporated and propagated during all steps of sample preparation and 
sequencing occur at a rate of ~1-2%, confounding data interpretation (Dohm et al., 2008). New 
techniques for sample preparation, including circular resequencing (cir-seq) and duplex 
sequencing, have been developed to computationally identify and remove erroneous bases 
(Acevedo et al., 2014; Lou et al., 2013; Schmitt et al., 2012). However, cir-seq and duplex 
sequencing do not enrich for virus-specific sequence and require large quantities of RNA, which 
may be limiting for some viral variants. For instance, ExoN-inactivation greatly reduces genomic 
RNA production (Eckerle et al., 2007; Graepel et al., 2017; Smith et al., 2013). A separate 
strategy, termed PrimerID, offers similar error correction but requires vastly less total RNA 
(Figure 34). In this strategy, individual RNA genomes are tagged with a unique barcode 
(PrimerID) during reverse transcription, allowing reconstruction of consensus sequences derived 
from the same initial template during analysis. Genome-specific primers allow selective 
amplification and sequencing of viral RNA even from contaminated mixtures, and robust data 
can be obtained with as few as 370 initial templates (Zhou et al., 2015). For these reasons, I 
chose to develop a PrimerID-based sequencing assay for MHV. 
 
Amplicon selection and primer design. Mutation rates can be measured as the frequency of 
“nonsense mutational targets” (NSMT) in sequencing data (Acevedo et al., 2014; Cuevas et al., 
2015; 2009; Pauly et al., 2017b). NSMT are specific mutations that are lethal for viral replication 
and therefore should be eliminated by negative selection. Put another way, lethal mutations 
should enter the population according to the mutation rate and should be removed immediately. 
Thus, the frequency of NSMTs in a population approximates the mutation rate. NSMT include, 
but are not limited to, mutations that introduce premature stop codons into RNA virus open-
reading frames (Peris et al., 2010; Sanjuán et al., 2004a; Visher et al., 2016). Eighteen of the 61  
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Figure 34. High-resolution measurement of mutation frequencies using PrimerID. 
 
Figure 34. High-resolution measurement of mutation frequencies using PrimerID. Genomic RNA 
templates are tagged with unique barcodes (PrimerIDs) during reverse transcription (1). Errors are 
introduced during library preparation and sequencing (2-3), but PrimerIDs allow construction of read 
families derived from the same original template (4). Mutations present in all reads are likely true 
variants, and those present in few templates are discarded (5). 
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sense codons are just a single mutation away from becoming a stop codon (Table 6). With 
sufficient coverage, deep sequencing experiments can use NSMT to measure mutation rates for 8 
mutational classes (Acevedo et al., 2014; Cuevas et al., 2009; 2015; Pauly et al., 2017b). I used a 
custom R script, generously provided by Adam Lauring (https://github.com/lauringlab/NGS_mut 
ation_rate_assay), to identify a 423 base region in ORF1ab of MHV-A59 (nts 20814-21265, 
covering portions of nsp15 and nsp16) with a balanced concentration of 63 total NSMT 
(MHV20814; Table 6). I used the IDT Oligoanalyzer (www.idtdna.com/calc/analyzer) to design 
gene-specific primers with little predicted secondary structure or cross-reactivity. Ten degenerate 
nucleotides (N10) in the reverse transcription primer serve as the primerID, allowing specific 
labeling of up to 1,048,576 (410) unique templates (Figure 35). The forward primer for the first 
round of PCR is virus-specific and contains Illumina adaptor sequences and four degenerate 
nucleotides to increase sequencing diversity; the reverse primer adds an Illumina adaptor. A 
second round of PCR appends index barcodes for multiplex sequencing. See Appendix B.1. for 
the library preparation protocol, including primer sequences. 
 
Example PrimerID experiment. We performed PrimerID on 100,000 copies of virion RNA 
from WT-MHV and ExoN(-) P3. The libraries were sequenced on the Illumina MiSeq with 
2x250 paired-end chemistry along with 50% bacterial DNA. Sequencing was performed by the 
Vanderbilt Technologies for Advanced Genomics (VANTAGE). Consensus sequences based on 
PrimerIDs were obtained using the web portal operated by the Swanstrom lab at UNC Chapel 
Hill, who developed this method (https://tcs-dr-dept-tcs.cloudapps.unc.edu/TCS/) (Zhou et al., 
2015). Jennifer Gribble assisted with data analysis, and additional code was provided by Adam 
Lauring (https://github.com/lauringlab/NGS_mutation_rate_assay) (Pauly et al., 2017b). We 
obtained >2 million reads per sample that condensed to >40,000 consensus sequences,  
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Table 6. Nonsense mutational targets. 
 
 
 
 
 
 
 
 
 
Table 6. Nonsense mutational targets. Eighteen of the 61 sense codons are one mutation away from 
becoming premature stop codons, representing eight mutational classes. Four mutational classes (N-to-
C and A-to-G) cannot reach premature stop codons. The MHV20814 amplicon contains 63 total 
NSMT. 
 
NSMT type NSMT Codons
Abundance in 
MHV20814 amplicon
U-to-A and U-to-G UUA, UAU 8
U-to-A UUG, UGU 10
C-to-A, C-to-G UCA, UAC 10
C-to-A UGC, UCG 5
C-to-U CAA, CAG, CGA 6
G-to-A UGG 7
A-to-U AAA, AAG, AGA 6
G-to-U GAA, GAG, GGA 11
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Figure 35. Library preparation for PrimerID sequencing. 
 
 
 
 
 
 
 
Figure 35. Library preparation for PrimerID sequencing. Genomic RNA is reverse transcribed 
with a gene-specific primer containing a 10-nucleotide PrimerID. A second gene-specific primer is 
used to amplify the region of interest, and then Illumina sequencing adaptors are added during a 
second round of PCR. 
Reverse transcription
1st Round PCR
2nd Round PCR
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N4 N10
N4
Virus-specific primers
5’ 3’
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representing 40.8% and 43.1% template recovery for WT-MHV and ExoN(-) P3 (Table 7). The 
mutation frequency of ExoN(-) P3 was 9.6-fold higher than that of WT, consistent with 
published results (Table 7 and Figure 36A) (Eckerle et al., 2007; 2010; Sexton et al., 2016). I 
also calculated mutation frequencies for individual mutational classes (Figure 36A, right). G-to-
A mutations were not dramatically overrepresented in these samples, as was expected due to the 
known mutational biases of reverse transcriptases (Cuevas et al., 2015; Holtz and Mansky, 2013; 
Pauly et al., 2017b). Neither virus had any C-to-G mutations at this coverage depth, 
recapitulating results from (Sexton et al., 2016). All other mutation types except for G-to-U were 
detected at greater frequency in ExoN(-) P3 than WT-MHV, with the largest difference detected 
for U-to-A substitutions. I also used the NSMT method to estimate the overall mutation rate for 
each virus (Table 7 and Figure 36B). For the eight mutational classes represented, the overall 
mutation rates for ExoN(-) P3 and WT-MHV were 2.02 x 10-5 and 5.33 x 10-6, respectively, a 
difference of 3.8-fold and close to previous estimates (Eckerle et al., 2007). The mutation rates 
for WT-MHV and ExoN(-) P3 were lower than mutation frequencies by 6- and 16-fold, 
respectively. The accumulation of mutations to frequencies above those of the NSMT mutations 
indicates the action of selection on newly generated variants, which may confound frequency 
measurements. I also calculated the ratio of mutation rates and frequencies of ExoN(-) P3 to WT-
MHV for each class (Figure 36C). The general shape of the distribution was similar between 
mutation rates and frequencies, but in most mutational classes, the ratio of mutation frequencies 
was greater than the ratio of mutation rates, further suggesting the action of selection. Without 
multiple replicates, it is difficult to assess the reproducibility and significance of these findings. 
 
Challenges and considerations. The most important limitation of PrimerID the inability to 
correct for errors during reverse transcription. Mutation rates in reverse transcriptases are similar  
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Table 7. Summary statistics from PrimerID experiment. 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Summary statistics from PrimerID experiment. Consensus threshold refers to the number 
of reads containing a given PrimerID required to build a reliable read family and is empirically 
determined during analysis. Mutation frequencies and rates are reported as mutations per nucleotide 
sequenced and mutations per nucleotide per infectious cycle, respectively. 
 
 
Virus Number of raw reads
Consensus 
threshold
Total consensus 
sequences
Template 
recovery
Mutation 
frequency
Mutation 
rate
WT-MHV 2,129,516 7 40,837 40.8% 3.34 x 10-5 5.33 x 10-6
ExoN(-) P3 2,617,306 8 43,087 43.1% 3.24 x 10-4 2.02 x 10-5
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Figure 36. MHV mutation frequencies and rates by PrimerID sequencing. 
 
 
Figure 36. MHV mutation frequencies and rates by PrimerID sequencing. (A) Mutation 
frequencies were measured by comparing the total number of variants detected with the total number 
of nucleotides sequenced. (B) Mutation rates were calculated as the frequency of nonsense mutations, 
which should not propagate through multiple replication cycles. (C) The ratio of ExoN(-) P3 to WT-
MHV was calculated for individual mutational classes using both mutation rates and mutation 
frequencies. 
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to those of RNA-dependent RNA polymerases, representing a theoretical lower-limit to the 
detectable mutation rates (Sanjuán et al., 2010). However, the mutational spectrum of reverse 
transcriptases is well-described and biased towards G-to-A substitutions (Cuevas et al., 2015; 
Holtz and Mansky, 2013; Pauly et al., 2017b). In the above experiment, G-to-A substitutions 
were not over-represented relative to other mutation types (Figure 36), suggesting either that G-
to-A substitutions are relatively low in coronaviruses at baseline or that the sequencing depth 
was too shallow. In addition, the data above demonstrates that selection can confound estimates 
of mutation frequency (Figure 36C), particularly within mutational classes, so mutation rates are 
preferred for these comparisons. Limiting the number of replication cycles should reduce the 
influence of selection, and increasing coverage depth should improve estimates of mutation rates 
by detecting very low-frequency variants. Illumina sequencing chips have a finite capacity, so 
there is a trade-off between sample number and data obtained: the more samples in a given run, 
the less data obtained per sample. Importantly, each library must be diluted with fragmented 
bacterial DNA to ensure sufficient sequence diversity on the Illumina chip, which is essential for 
focusing the optical detector. We added 50% bacterial DNA to each sequencing run discussed in 
this dissertation. To ensure sufficient coverage, we have multiplexed no more than four samples. 
Subsequent experiments to determine the optimal number of samples and percentage of bacterial 
DNA would be warranted to minimize costs. During data interpretation, it is important to bear in 
mind that PrimerID examines only a small segment of a genome. Mutation rates of retro- and 
flaviviruses vary depending upon RNA secondary structures and local sequence contexts (Geller 
et al., 2015; 2016; Pathak and Temin, 1992), so PrimerID results using MHV20814 may not be 
generalizable to the whole genome. It would be worthwhile to sequence PrimerID-tagged 
libraries derived from multiple genome regions. However, the trade-off between sample number 
and coverage depth should be considered carefully in designing such an experiment. 
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Development of a quantitative-PCR-based competitive fitness assay for MHV 
Although mutation rates determine the genetic diversity of a viral population, mutational fitness 
effects define the peaks, ridges, and valleys of genotype-fitness landscapes. As with replication 
fidelity, viral fitness can be measured in numerous ways. The simplest method is to measure a 
particular phenotype (e.g. growth rate) for multiple viruses in isolation and convert them to 
relative fitness values (for example, (Peris et al., 2010)). While informative, these studies often 
mask subtle (and not-so-subtle) fitness differences between variants that, in a mixed population, 
would affect evolutionary outcomes. For instance, recombinant MHV chimeras containing 
HCoV proteases replicate identically to wild-type MHV in isolation. However, in a mixed 
culture with wild-type MHV, the chimeras rapidly disappear from the population (Stobart et al., 
2013). Similarly, altered fidelity variants often replicate identically to their wild-type 
counterparts but are rapidly outcompeted in mixed cultures (Coffey et al., 2011; Dapp et al., 
2013; Fitzsimmons et al., 2018). Thus, direct competition experiments are preferred for viral 
fitness measurements. 
 
The key challenge for competition assays is to discriminate between variants in a mixed 
infection. Without genetic modifications, dideoxy or deep sequencing methods can be used to 
detect the frequency of individual variants within a population (Acevedo et al., 2014; Agostini et 
al., 2018). However, chromatographic traces from Sanger sequencing experiments are imprecise 
and have a narrow dynamic range, and deep sequencing experiments are expensive and may 
require development of new library preparation methods. Other experimentalists distinguish 
variants based on genetic tags that can be identified without sequencing, including restriction 
sites or monoclonal antibody-resistance mutations (Furió et al., 2005; Stobart et al., 2013). More 
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recently, the field has started using real-time quantitative polymerase chain reaction (qPCR) to 
distinguish competitors (Bordería et al., 2015; Carrasco et al., 2007; Lauring et al., 2012; 
Moratorio et al., 2017). qPCR is a highly sensitive technique for monitoring the amplification of 
DNA molecules in real-time, rather than at the end, as in conventional PCR. qPCR assays have 
wider dynamic ranges than other methods because they allow sensitive and specific detection of 
variants at very low frequencies within a sample. Additionally, the high-throughput of qPCR-
based assays can reveal the topography of large landscapes (Moratorio et al., 2017). These 
advantages have made qPCR-based competition assays the field standard for several years. 
 
Quantitative PCR relies on fluorescent labels to monitor the amplification of double-stranded 
DNA over multiple cycles of PCR. Two common methods for detection of PCR products in real-
time are Taqman probes and intercalating dyes. Taqman probes are sequence-specific 
oligonucleotides dual-labeled with a fluorescent reporter and a quencher. At rest, the quencher 
prevents detection of fluorescence. During PCR, the polymerase digests probes bound to DNA 
templates, breaking the reporter-quencher proximity and allowing detection of fluorescence. 
Taqman probes are highly specific, so detecting distinct variants requires two specific probes 
(selective detection). The other method for DNA detection in qPCR is through intercalating dyes, 
which fluoresce only when bound to double-stranded DNA. The most commonly used dye is 
SYBR green. SYBR assays are simpler to design than Taqman assays because they require 
primers but no probe. SYBR green will interact with any double-stranded DNA present, so 
assays must only amplify their intended target (selective amplification). 
 
Quantitative PCR assays based on selective detection of competitors are prone to 
amplification bias. At the start of this dissertation research, Clint Smith and Nicole Sexton had 
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generated reference viruses containing 10 synonymous substitutions in a 22-nucleotide region of 
nsp2 (“tagged RNA”, Figure 37A). I designed a Taqman assay with a probe complementary to 
the tag, flanked by PCR primers (Figure 37B; “reference assay”). Importantly, this assay 
amplifies both tagged and untagged genomes but only emits fluorescence when bound to tagged 
RNA. I also designed a Taqman assay upstream that detects all genomes in the sample, serving 
as the denominator for calculating relative frequency (Figure 37B, “competitor assay”). Both 
assays were highly efficient and specific for their targets (Figure 37C). However, I worried that 
because the reference assay amplifies all genomes, regardless of tag, it might susceptible to 
amplification bias. Amplification bias can occur when two targets are present in starkly different 
abundance. The more abundant target can continue to amplify and consume reagents, thereby 
hindering amplification of the scarce target (Figure 38). Using mixtures of tagged and untagged 
RNA standards, I measured assay performance over a 10-log10 range of known input ratios 
(105:1 to 1:105 untagged:tagged). Beyond ratios of 100:1 or 1:100, the experimentally-derived 
ratios diverge drastically from the expected results (Figure 39), indicating that assays based on 
selective detection can be dramatically skewed by amplification bias. 
 
qPCR assays based on selective amplification of competitors do not suffer from 
amplification bias. In single-plex assays (that is, one assay per tube), amplification bias can 
only occur when both targets are amplified by the same set of primers. To circumvent this 
limitation, I designed two assays that selectively amplify their targets. My reference virus 
contains seven consecutive synonymous substitutions within nsp2 (nucleotides 1301-1307; 
Figure 40A). The reverse primer (also the reverse transcription primer) is the same for both 
assays, and the forward primers discriminate the tagged and untagged RNA (Figure 40B). I 
chose to use SYBR chemistry to avoid potential interactions between primers and a Taqman 
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Figure 37. Taqman probes selectively detect marked reference genomes. 
 
 
 
 
Figure 37. Taqman probes selectively detect marked reference genomes. (A) The genome is 
tagged with 10 synonymous substitutions within nsp2. (B) Schematic of competitor and reference 
assays. The competitor assay detects all genomes in a sample, and the reference assay detects only the 
tagged RNA. (C) Both assays are highly specific and efficient. 
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Figure 38. Amplification bias can skew the results of qPCR. 
 
 
Figure 38. Amplification bias can skew the results of qPCR. (A) Competitors at equal proportions 
in the sample amplify at similar rates. (B) The more abundant competitor can be preferentially 
amplified and monopolize reagents. X indicates DNA copies not amplified in a given round of 
replication. 
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Figure 39. A qPCR assay based on selective detection is prone to amplification bias. 
 
 
Figure 39. A qPCR assay based on selective detection is prone to amplification bias. (A) 1 x 108 
copies of tagged RNA were added to serially-diluted samples of untagged RNA. RT-qPCR was 
performed with both competitor and reference assays, and copy numbers of each RNA were calculated 
and plotted. (B) Performed as in (A), except that 1 x 108 copies of untagged RNA were added to 
serially-diluted samples of tagged RNA. (C) Data from (A) and (B) were converted to ratios of tagged-
to-untagged RNA. 
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 probe. Both assays are specific for their intended target across a 5-log10 range of concentrations 
(Figure 40C) and show no evidence of amplification bias across an 8-log10 range of ratios 
(Figure 41). Thus, I chose to use these SYBR-based assays (and reference viruses) for my 
competitive fitness experiments. 
 
Experimental design. All experimental viruses are co-cultured with the genetically tagged 
reference virus at a known multiplicity of infection (MOI) and passaged four times (Figure 42). 
The ratio of competitor-to-reference is measured at each passage, and the change in relative 
frequency of competitor and references over time reflects their relative fitness. Note that this 
yields indirect comparisons of fitness between experimental viruses. That is, instead of direct 
competition between virus A and virus B, the immediate comparisons will be “fitness of virus A 
relative to reference” vs “fitness of virus B relative to reference.” 
 
Example competition assay. To determine whether the variant ExoN AD is more fit than 
ExoN(-) P3, I competed each virus against the ExoN(-) reference virus (Chapter 4, Figure 19). I 
passaged each lineage at a total MOI of 0.1 PFU/cell four times. The relative frequency of each 
competitor decreased over passage (Figure 43A), suggesting either that the genetic tag is not 
selectively neutral, or more likely, that the stock reference virus contains additional mutations. 
The results were consistent across all three individual lineages for each virus. I performed linear 
regressions of each lineage (Figure 43B) and converted the slopes to relative fitness (relative 
fitness = 10slope) (Figure 43C). To account for potential fitness-altering mutations in the ExoN(-) 
reference stock, I then normalized all values to the mean relative fitness of ExoN(-) P3 (Figure 
43D). This step reduces the influence of stock effects for the reference viruses and permits direct 
comparison of relative fitness values from different experiments. 
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Figure 40. SYBR green-based assays selectively amplify their intended targets with high efficiency. 
 
 
 
 
 
 
Figure 40. SYBR green-based assays selectively amplify their intended targets with high 
efficiency. (A) The genome is tagged with 7 consecutive synonymous substitutions within nsp2. (B) 
Schematic of competitor and reference assays. Both assays use the same reverse primer, and forward 
primers discriminate tagged and untagged RNA. (C) Both assays are highly specific and efficient. All 
data points in open triangles (assays against their nonspecific target) were within 1 Ct of the no-
template control. 
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Figure 41. A qPCR assay based on selective amplification does not suffer from amplification bias. 
 
 
 
Figure 41. A qPCR assay based on selective amplification does not suffer from amplification 
bias. (A) 0.05 nanograms of tagged RNA were added to serially-diluted samples of untagged RNA. 
RT-qPCR was performed with both competitor and reference assays. (B) Performed as in (A), except 
that 0.05 nanograms of untagged RNA were added to serially-diluted samples of tagged RNA. (C) 
Data from (A) and (B) were converted to ratios of tagged-to-untagged RNA. 
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Figure 42. Experimental schematic of competitive fitness assay. 
 
 
 
 
 
 
 
 
 
Figure 42. Experimental schematic of competitive fitness assay. 
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Figure 43. Example data from competitive fitness experiment 
 
 
 
 
 
 
Figure 43. Example data from competitive fitness experiment. ExoN(-) P3 and ExoN AD were 
competed against an ExoN(-) reference containing 7 synonymous substitutions and passaged four 
times. (A) Ratio of competitor-to-reference for individual lineages at each passage. (B) Linear 
regressions of each lineage. (C) Fitness of each competitor relative to the reference were plotted, and 
then (D) normalized to mean of ExoN(-) P3. Dotted lines in panels (A) and (B) represent 1:1 ratio. 
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Challenges and considerations. The outcomes of viral evolution depend on both viral fitness 
and the random stochastic effects of genetic drift. To minimize the effects of genetic drift,  
experiments should be performed with large population sizes (minimum total MOI of 0.1 PFU 
per cell; MOI = 0.05 PFU/cell each for competitor and reference). Synchronizing infections can 
also reduce genetic drift by ensuring that virions enter cells simultaneously (Voronin et al., 
2009). Additionally, because viral fitness varies with experimental conditions, technical 
consistency is essential for reproducibility. I take the following measures to ensure consistent 
conditions across passages and across experiments: (1) I count cells before seeding plates, 
delivering 1 x 105 cells per well; (2) I infect cells exactly 24 hours after plating; (3) I incubate 
virus and cells for 30 minutes on ice to synchronize infections; (4) I titer all samples after each 
passage to maintain the same input MOI. I also perform a control in every experiment to account 
for variability in stocks of reference viruses (e.g. compete ExoN(-) P3 versus the ExoN(-) 
reference). I then normalize all relative fitness values to the control. Finally, because this assay 
measures RNA content, viruses that generate large quantities of defective particles can yield 
artificially high fitness values, so this assay should be used only with viruses of similar specific 
infectivity.  
 
Discussion 
With their multi-subunit replicase complex and proofreading exoribonuclease, coronaviruses are 
a unique RNA viral system for studying the relationships between replication fidelity, fitness, 
and evolution. However, the techniques for studying coronavirus evolution are less extensive 
than those available for simpler RNA viruses. In this chapter, I extend the toolkit for coronavirus 
evolution with new methods to measure murine hepatitis virus replication fidelity and fitness. 
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PrimerID sequencing circumvents the interpretive challenges of nucleoside analogue sensitivities 
and reduces artifacts that confound conventional deep sequencing approaches, yielding sensitive 
and accurate measurements of mutation frequencies and rates. PrimerID will allow us to 
discriminate subtle fidelity phenotypes, as well as identify differences in mutational biases that 
could change the accessible sequence landscapes. The competitive fitness assay described in this 
chapter can reveal the contours of these sequence landscapes, allowing us to trace, and 
potentially predict, coronavirus evolutionary trajectories. By varying experimental conditions 
and selective pressures, we can examine evolutionary pathways leading to antiviral drug 
resistance or escape from immune responses. Further, fitness experiments can reveal interactive 
networks between coronaviral proteins, as discussed in Chapter 4. In combination, PrimerID and 
competitive fitness assays will allow dissection of the fundamental relationships between 
coronavirus replication fidelity and fitness, informing the design of countermeasures against 
emerging and endemic coronaviruses.  
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CHAPTER 6: MATERIALS AND METHODS 
 
Cell culture 
Delayed brain tumor (DBT-9) cells (Chen and Baric, 1996) and baby hamster kidney 21 cells 
expressing the MHV receptor (BHK-R) (Yount et al., 2002) were maintained at 37°C in 
Dulbecco’s modified Eagle Medium (DMEM, Gibco) supplemented with 10% serum (HyClone 
FetalClone II, GE Healthcare or Fetal Bovine Serum, Invitrogen), 100 U/mL penicillin and 
streptomycin (Gibco), and 0.25 µM amphotericin B (Corning). BHK-R cells were further 
supplemented with 0.8 mg/mL G418 selection antibiotic (Gibco). The infectious clone of the 
murine hepatitis virus strain A59 (MHV-A59; GenBank accession number AY910861) was used 
as the template for all recombinant viruses in this dissertation (Yount et al., 2002). 
 
Determination of viral titer by plaque assay 
Virus samples were serially diluted and inoculated on subconfluent DBT-9 cell monolayers in 
either 6- or 12-well format. Cells were overlaid with a 1% agar in DMEM and incubated 
overnight at 37°C. Plates were fixed with 4% formaldehyde and agar plugs were removed. The 
number of plaques per well was counted by hand and used to calculate titer. For plaque assays of 
viruses containing the spike protein from MHV-ExoN(-) P250, which does not form syncytia, 
plaques were visualized with neutral red (Sigma #N6264, diluted 1:10 in PBS containing calcium 
and magnesium). Neutral red was added 24 hours after plating and incubated for an additional 3-
8 hours before formaldehyde fixation. 
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Recombinant virus recovery 
The MHV-A59 reverse genetics system divides the genome into 7 fragments, A through G, 
maintained on separate plasmids. Plasmids are digested using pairs of restriction enzymes 
yielding unique termini, and digested fragments are purified by gel extraction. Cut fragments are 
pooled in equimolar amounts (total DNA content 1.5 µg) and ligated using T4 DNA ligase 
(NEB) to generate a linear, double-stranded product containing a T7 promoter. Full-length RNA 
genomes are in vitro transcribed using mMessage mMachine T7 Transcription kit (Invitrogen) 
and electroporated into BHK-R cells. Cells are monitored for signs of cytopathic effect, and 
recombinants are harvested by freeze-thaw, aliquoted, and sequenced as described below.  
 
Molecular cloning 
With few exceptions noted below, site-directed mutatgenesis in MHV genome fragments was 
performed using “round the horn” PCR (originally described in (Ho et al., 1989)). Briefly, 
adjacent primers containing the mutation of interest were 5¢-phosphorylated using T4 
polynucleotide kinase (NEB, M0201S) using the buffer from the T4 DNA ligase, which contains 
ATP (M0202S). PCR was performed on a plasmid template using the Q5 High-fidelity 2x 
Master Mix (NEB, M0492L), with primers at final concentration of 500nM. The linear 
amplification product was purified using the Promega Wizard SV Gel and PCR Clean-up System 
(Promega Corporation, A9282), and 4 µL was ligated at 16°C overnight with the T4 DNA ligase 
(NEB M0202S). After transformation into chemically-competent Top10 E. coli (lab-derived) and 
expansion in liquid culture, the MHV segment of each plasmid was sequenced. For larger 
regions (e.g. nsp12 and nsp14 swapped viruses, Chapter 2), the region of interest was amplified 
by RT-PCR from viral RNA and ligated into the desired vector by Gibson Assembly (Gibson et 
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al., 2009) using the InFusion HD Cloning kit (Takara Bio USA, Inc, Mountain View, CA). 
Several fragments intended for the ExoN(-) P160 infectious clone were synthesized 
commercially by GenScript, Inc. 
 
Generation of experimental stocks 
Experimental stocks were generated by infecting a subconfluent 150 cm2 flask of DBT-9 cells at 
MOI of 0.01 PFU/cell. Flasks were frozen at -80°C when monolayers were fully involved, 
approximately 20-28 hours post-infection depending on the variant. After thawing, the 
supernatant was clarified by centrifugation at 4,000 x g (Sorvall RC 3B Plus; HA-6000A rotor) 
for 10 min at 4°C. For intermediate revertants, stocks were generated in serum-free DMEM and 
processed as above before being concentrated roughly 10-fold by centrifugation at 4,000 x g 
using Amicon Ultra-15 Centrifugal Filter Units, 100kDa (EMD Millipore, UFC910008). The 
virus titer of each stock was determined by plaque assay using DBT-9 cells as described above. 
 
Plaque purification of viral populations 
DBT-9 cells were infected with serial dilutions of virus and overlaid with 1% agar in DMEM. 
Single plaques were isolated with glass Pasteur pipettes, resuspended in PBS containing calcium 
and magnesium, and inoculated onto fresh DBT-9s. This process was completed 3 times before 
experimental stocks were generated, as above. 
 
Sequencing of virus stocks 
RNA was purified from the harvested TRIzol samples according to the manufacturer’s protocol 
and reverse transcribed (RT) using SuperScript III (Invitrogen) as described previously (Eckerle 
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et al., 2007). Full-genome di-deoxy sequencing was performed for both WT-MHV P250 and 
MHV-ExoN(-) P250 using 12 overlapping amplicons approximately three kilobases in length. 
Two microliters of RT product were used for each PCR reaction (Smith et al., 2013). Di-deoxy 
sequencing was performed by Genhunter Corporation (Nashville, TN) and GENEWIZ (South 
Plainfield, NJ). Sequence analysis was performed using MacVector version 14 (MacVector, Inc.; 
Apex, North Carolina) using the MHV-A59 infectious clone reference genome (GenBank 
accession no. AY910861). 
 
Experimental evolution of viruses 
The infectious cDNA clone for MHV-A59 and the recovery of MHV-ExoN(-) are described 
previously (Eckerle et al., 2007; Yount et al., 2002). Long-term passage (P250; Chapter 2) was 
initiated by infecting subconfluent monolayers of DBT-9 cells in 25 cm2 flasks with either wild-
type MHV-A59 or MHV-ExoN(-) at a MOI of approximately 0.1 PFU/cell. One lineage of each 
virus was passaged for a total of 250 passages (P250). Supernatant was harvested at each passage 
and stored at -80°C. Total RNA was harvested for most passages using 1 ml of TRIzol Reagent 
(Ambion) per 25 cm2 flask and stored at -80°C. Intermediate revertants of MHV-ExoN(-) 
(Chapter 5) were passaged 10 times on subconfluent DBT-9 cell monolayers in 24-well plates at 
an estimated MOI of either 0.01 or 0.5 PFU/cell. Supernatants were harvested at 24 and 20 hours 
post-infection for MOI = 0.01 and 0.5 PFU/cell, respectively. 
Replication kinetics 
Viral replication kinetics in DBT-9 cells were determined at indicated MOIs as described 
previously (Smith et al., 2015). Experiments in Chapter 5 were synchronized by adding virus to 
cells on ice and incubating for 30 minutes before transferring to the 37°C incubator. Supernatant 
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(300 μL) was harvested at the indicated time points, and the virus titer was determined by plaque 
assay. 
 
Genomic RNA accumulation kinetics 
The accumulation of genomic RNA at MOI = 1 PFU/cell was measured by two-step real-time 
quantitative RT-PCR (RT-qPCR). RNA was harvested from infected monolayers at the indicated 
times using TRIzol (Invitrogen). RNA was reverse-transcribed using SuperScript III and random 
hexamers (Invitrogen), and cDNA derived from intracellular viral RNA was measured using 
primers directed to nsp10. Values were normalized to levels of the endogenous control 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). No mutations within the primer binding 
sites emerged in either P250 population. The primers and amplification conditions are the same 
as reported previously (Smith et al., 2013), except that the RT product was diluted 1:10 prior to 
use. Samples were plated in technical duplicate to minimize well-to-well variation. Data are 
presented as 2-ΔCt, where ΔCT denotes Ctnsp10 – CtGAPDH.  
 
Determination of specific infectivity 
Subconfluent monolayers of DBT-9 cells in 24-well plates were infected with the indicated virus 
at MOI = 1 PFU/cell, and supernatant was harvested at 12 hours post-infection. The levels of 
genomic RNA in supernatant were measured using one-step real-time quantitative RT-PCR (RT-
qPCR) on TRIzol-extracted RNA as described previously (Sexton et al., 2016). Briefly, genomic 
RNA was detected with a 5’ 6-carboxyfluorescein (FAM) and 3’ black hole quencher 1 (BHQ-1) 
labeled probe targeting nsp2 (Biosearch Technologies, Petaluma, CA), and RNA copy number 
was calculated by reference to an RNA standard derived from the MHV A fragment. Samples 
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were plated in technical duplicate to minimize well-to-well variation. Titers were determined by 
plaque assay in DBT-9 cells, and specific infectivity was calculated as PFU per supernatant 
genomic RNA copy. 
 
Nucleoside and base analogue sensitivity assays 
Nucleoside and base analogue sensitivity assays were performed as described (Graepel et al., 
2017; Smith et al., 2013) 5-azacytidine (AZC), 5-fluorouracil (5-FU), and ribavirin (RBV) were 
purchased from Sigma (product numbers A2385, F6627, and R9644, respectively), and stock 
solutions were prepared in dimethyl sulfoxide (DMSO). 2’-C-methyladenosine (CMeA) was 
received from Gilead Sciences, Inc (Foster City, CA). Sensitivity assays were performed in 24-
well plates at MOI = 0.01 PFU/cell. Cells were incubated with drug for 30 minutes prior to 
infection. Supernatants were harvested at 24 hours post-infection, and titers were determined by 
plaque assay. 
 
Measurement of mutation frequency using PrimerID 
A custom R script, generously provided by Adam Lauring (https://github.com/lauringlab/NGS_ 
mutation_rate_assay) was used to identify a 452-base region in ORF1ab of MHV-A59 (nts 
20814-21265, covering portions of nsp15 and nsp16) with the highest concentration of nonsense 
mutational targets. Supernatant RNA genomes were isolated from DBT-9 monolayers infected 
with wild-type, ExoN(-), or ExoN(-) nsp12-250 (MOI of 0.01 PFU/cell) using QIAamp viral 
RNA mini kit. Supernatant genomes were quantified by one-step RT-qPCR by reference to an 
RNA standard derived from the MHV A fragment, as described previously (Sexton et al., 2016). 
PrimerID libraries were prepared from 5 x 104 genome copies using SuperScript III (Invitrogen) 
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and reverse transcription primer MHV20184-cDNA (5¢-GTGACTGGAGTTCAGACGTGTGC-
TCTTCCGATCTNNNNNNNNNNCCAATGTTCTTAGTAAGAGGGTCGTACATA-3¢), 
which contains N10 degenerate barcode sequences. Reaction mixtures containing only RNA 
template, cDNA primer, and dNTPs were incubated 65°C for 5 minutes, followed by addition of 
remaining reagents on ice. Reverse transcription proceeded at 50°C and 55°C for one hour each, 
followed by 15 minute incubation at 70°C to inactivate enzyme. Reactions were treated with 
RNaseH for 20 minutes at 37°C and cleaned up with Agencourt RNAClean XP beads (1.2:1 
bead:cDNA ratio). The resulting PrimerID-tagged cDNAs were amplified by PCR using 
KAPA2G Robust Hotstart (Kapa Biosystems, Woburn, MA) and forward primer MHV20184-
PCR1 (5¢-ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAGAAGGTCATGACT-
TTCTATCCTCGTTTGC-3¢) and reverse primer PID-PCR1-R (5¢-GTGACTGGAGTTCAGAC-
GTGTGCTC-3¢). The PCR cycling protocol was initial denaturation at 95°C for 1 minute 
followed by 25 cycles of 95°C for 15 seconds, 58°C for 1 minute, and 72°C for 30 seconds, with 
a final extension at 72°C for 3 minutes. PCR1 products were purified using Agencourt AMPure 
XP beads (1.2:1 bead:PCR1 ratio). A second round of PCR was performed to add indexed 
Illumina adaptors. The forward primer was 5¢-AATGATACGGCGACCACCGAGATCTACAC-
[index]ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3¢ and the reverse primer was 5¢-
CAAGCAGAAGACGGCATACGAGAT[index]GTGACTGGAGTTCAGACGTGTGCTCTTC
CGATC-3¢. PCR was performed using Kapa HiFi PCR Hotstart (Kapa Biosystems, Woburn, 
MA) with an initial denaturation of 95°C for 2 minutes followed by 25 cycles of 98°C for 20 
seconds, 63°C for 15 seconds, and 72°C for 30 seconds, with a final extension at 72°C for 3 
minutes. PCR2 products were gel-extracted using the MinElute Gel Extraction Kit (Qiagen). 
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Libraries were quantified by Qubit and pooled at 5nM each. We used 250-bp paired-end 
multiplex Illumina MiSeq (San Diego, CA) to sequence the constructed libraries. The pooled 
libraries made up half of the DNA input for the sequencing run, with the remaining DNA 
composed of bacterial genome library. Sequencing was performed by the Vanderbilt 
Technologies for Advanced Genomics core facility (VANTAGE). 
 
Phyre2-modeling of MHV-nsp14 
The MHV nsp14 structure was modeled with the Phyre2 online program (Kelley et al., 2015) 
using nsp14 residues 3-519, corresponding to residues 6056-6573 of the ORF1ab polyprotein. 
The model was analyzed using the Pymol Molecular Graphics System, Version (Schrödinger, 
LLC). 
 
Taqman-based competitive fitness assays 
Experimental viruses were competed with an MHV-ExoN(-) virus harboring 10 silent mutations 
in the probe-binding region within nsp2. Subconfluent DBT-9 monolayers in 24-well plates were 
coinfected at a total MOI of 0.01 PFU/cell with competitor and reference viruses at a 1:1 ratio 
and passaged 4 times. For each passage, supernatants were harvested at 24 hours. RNA was 
extracted from 100μL of supernatant using 900μL of TRIzol reagent and PureLink RNA Mini 
Kit columns (Thermo Scientific, Waltham, MA), and 150μL was used to infect fresh cells in a 
24-well plate (total MOI estimated at 1 PFU/cell). The proportion of each virus was determined 
by real-time RT-qPCR from the infection supernatant using two Taqman probes with different 
fluorescent dyes in separate reactions. Competitor viruses were detected with the same probe 
used in specific infectivity analyses (Eckerle et al., 2007). Reference viruses were detected by a 
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probe targeting the same region but with 10 silent mutations (5’-TCCGAACTACTGCAACCC-
CAAGTG-3’) and labeled with 5’ Quasar 670 and 3’ black hole quencher 2 (BHQ-2) (Biosearch 
Technologies, Petaluma, CA). RNA copy number was calculated by reference to an RNA 
standard generated by in vitro transcription of the corresponding MHV A fragment, and relative 
RNA abundance was calculated as the ratio of competitor genomes to reference genomes. 
 
SYBR-based competitive fitness assays 
ExoN(-) and ExoN(+) reference viruses were marked with 7 consecutive silent mutations within 
nsp2 (wild-type: 1301-TTCGTCC-1307; silent: 1301-CAGCAGC-1307) by round the horn PCR, 
as described above. Competitions were performed in triplicate on DBT-9 cells in 12-well plates, 
plated at a density of 1 x 105 cells per well 24 hours prior to infection. Cells were infected at a 
total MOI of 0.1 PFU/cell (MOI = 0.05 PFU/cell each for competitor and reference virus). 
Supernatants were harvested 15 and 16 hours post-infection for experiments with ExoN(+) 
reference and ExoN(-) reference, respectively, and passaged 4 times. Samples were titered 
between all passages to maintain total MOI of 0.1 PFU/cell. RNA was extracted from 70μL of 
supernatant using QIAamp 96 virus QIAcube HT kit on the QIAcube HT System (Qiagen). Each 
RNA sample was analyzed by one-step RT-qPCR with two SYBR Green assays. Reference 
viruses were detected with forward primer SS-qPCR-Sil-F (5¢-CTATGCTGTATACGGACAGC 
AGT-3¢; 200nM final) and reverse primer SS-qPCR-R2 (5¢-GGTGTCACCACAACAATCCAC-
3¢, 200nM final). Competitors were detected with forward primer SS-qPCR-WT-F (5¢-CTATG-
CTGTATACGGATTCGTCC-3¢, 450nM final) and reverse primer SS-qPCR-R2 (5¢-GGTGTC-
ACCACAACAATCCAC-3¢, 450nM final). RNA samples were diluted 1:100 prior to RT-qPCR 
with Power SYBR Green RNA-to-Ct 1-step kit (Applied Biosystems) according to the 
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manufacturer’s protocol. Duplicate wells were averaged, and values were excluded from 
subsequent analysis if the duplicate wells differed by > 0.5 Ct. The relative abundance of 
competitor and reference were determined by subtracting Ct thresholds (DCtcompetitor = Ctcompetitor 
– Ctreference) and converted to reflect the fold-change in ratio (Dratio = 2-DCt competitor). The log-
10Dratio was plotted against passage number, and the change in log10Dratio (i.e. slope of linear 
regression) is the relative fitness. Note that regressions were fit only through P1-P4, as slight 
deviations in 1:1 ratio in the input (P0) can skew the slope. 
 
Statistical analysis 
GraphPad Prism 6 (La Jolla, CA) was used to perform statistical tests. Only the comparisons 
shown [e.g. ns or asterisk(s)] within the figure or legend were performed. In many cases the data 
were normalized to untreated controls. This was performed using GraphPad Prism 6. The 
number of replicate samples is denoted within each figure legend.  
Accession numbers 
Full-length genome sequences for WT-MHV P250, MHV-ExoN(-) P250 can be downloaded 
from the GenBank (accession numbers MF618252, and MF618253, respectively). 
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CHAPTER 7: SUMMARY AND FUTURE DIRECTIONS 
 
Introduction 
Coronaviruses cause human illnesses ranging from the common cold to severe and lethal disease, 
and they are potent drivers of economic losses in commercial animals (Annamalai et al., 2015; 
Cavanagh, 2007; de Wit et al., 2016; Saif, 2010). Since 2002, two coronaviruses (SARS-CoV 
and MERS-CoV) have emerged as zoonoses with pandemic potential, and close relatives of 
SARS- and MERS-CoV circulate in animal populations around the globe (Drosten et al., 2003; 
Ksiazek et al., 2003; Li et al., 2005; Menachery et al., 2015; 2016; Zaki et al., 2012). With no 
approved coronavirus vaccines or antivirals available, our ability to respond rapidly to the next 
highly pathogenic coronavirus depends upon intensive study of conserved coronavirus genetic 
elements and proteins. Coronaviruses have considerably larger genomes than other RNA viruses, 
encoding a correspondingly intricate replication machine distinguished by an exoribonuclease 
(ExoN) (Smith et al., 2014) (Figure 10). At the start of this dissertation research, the coronavirus 
ExoN had been revealed as the first proofreading ExoN encoded by an RNA virus, establishing a 
new paradigm for RNA virus replication fidelity. ExoN is highly conserved across all known 
coronaviruses and is critical for efficient viral replication, genome maintenance, and innate 
immune evasion (Case et al., 2017; Eckerle et al., 2007; Gorbalenya et al., 2006). Accordingly, 
disruption of ExoN activity yields mutator viruses with diminished fitness and virulence, 
suggesting that ExoN could be a viable target for coronavirus countermeasures (Graham et al., 
2012; Menachery et al., 2018). In this dissertation, I have used experimental evolution and 
reverse genetics to examine the complex protein interactions involved in coronavirus replication 
and to understand how the unique proofreading function of coronaviruses affects their evolution. 
In this chapter, I summarize the key findings and implications of my dissertation research.  
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High-fidelity replication is important for coronavirus fitness 
High RNA virus mutation rates are proposed to constrain genome size and complexity (Bradwell 
et al., 2013; Bull et al., 2007). According to this model, maintenance of large coronavirus 
genomes requires a commensurate reduction in mutation rates to prevent error catastrophe, 
suggesting that high-fidelity replication is an essential component of coronaviral fitness. 
Consistent with this hypothesis, coronaviruses are the first known RNA viruses to encode a 
proofreading ExoN, and disruption of proofreading activity impairs both replication fidelity and 
fitness (Eckerle et al., 2007; 2010; Graepel et al., 2017; Graham et al., 2012; Minskaia et al., 
2006; Sexton et al., 2016). Despite this correlation, it has not been clear whether fitness defects 
in ExoN(-) coronaviruses derive specifically from altered fidelity or from some other function of 
nsp14-ExoN. Support for the proposed link between fidelity and fitness came during the course 
of this dissertation, when Nicole Sexton discovered that a high-fidelity RdRp variant (nsp12-
V553I), engineered through homology modeling with picornaviral RdRps, increases the fitness 
of MHV-ExoN(-) (Sexton et al., 2016). The research in this dissertation extends her observations 
by demonstrating that MHV-ExoN(-) is under selective pressure for increased fidelity during 
experimental evolution (Chapter 2). Passaged MHV-ExoN(-) P250 displays near wild-type 
fidelity, as measured by nucleoside analogue sensitivities, and surpasses wild-type fitness 
(Figure 11, Figure 15, Figure 18). The high-fidelity phenotype of MHV-ExoN(-) P250 is 
partially mediated by nsp12-250, which reduces mutation frequencies of MHV-ExoN(-) by 1.7-
fold, similar to known high-fidelity RdRps (Figure 18) (Smith et al., 2014). Further, nsp12-250 
independently increased the competitive fitness of MHV-ExoN(-), directly correlating 
polymerase selectivity and viral fitness. I have not yet determined whether or how individual 
mutations in nsp12-250 (7 total nonsynonymous substitutions) increase replication fidelity, and I 
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cannot exclude the possibility that one or more were fixed by genetic drift. However, I favor the 
hypothesis that the nsp12-250 mutations form an interdependent network. Fidelity regulation in 
RdRps is a dynamic process driven by coordinated movements across the whole enzyme 
(Korboukh et al., 2014; Korneeva and Cameron, 2007; Moustafa et al., 2014). This delicate 
process is easily disrupted, so it is unlikely that individual nonsynonymous substitutions were 
fixed by chance. Indeed, MERS-CoV nsp12-RdRp is subject to strong purifying selection, 
suggesting that coronavirus RdRps are relatively intolerant to mutations (Forni et al., 2016b). 
Instead, I propose that at least a subset of the seven mutations in nsp12-250 cooperate to drive 
high-fidelity replication. In MHV-ExoN(-), nsp12-RdRp is clearly undergoing rapid adaptive 
evolution, which tends to enrich for epistatically interacting substitutions (Gong and Bloom, 
2014). Similar networks of epistatic interactions affecting replication fidelity have been 
identified in the RdRps of influenza virus and the oral poliovirus vaccine strain (Liu et al., 2015; 
Pauly et al., 2017a). With mutations distributed across the fingers, palm, and thumb domains 
(Figure 17), biochemical or next-generation sequencing studies of nsp12-250 would reveal 
important insights into the long-range dynamics of fidelity regulation by RdRps.  
 
Coronavirus replicase proteins are tightly co-evolved and cooperate to optimize replication 
kinetics and fidelity 
The predicted coronavirus replicase-transcriptase complex (RTC) contains, at minimum, 7 
nonstructural proteins that interact extensively to maintain efficient and accurate RNA synthesis 
(Figure 10) (Smith et al., 2014). Mutations in nsps7-14 are likely under strong purifying 
selection to preserve both their individual and collective functions, ensuring that RTC proteins 
evolve cooperatively (Forni et al., 2016b). In this dissertation, we observed very little evidence 
of adaptive evolution between wild-type replicase proteins (Figure 13, Appendix A.1). In 
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contrast, the selective pressures provoked by altered proofreading drove extensive evolution 
within the RTC (Figure 13, Appendix A.2). Recombinant viruses containing subsets of 
P160/P250 replicase proteins revealed complex evolutionary interactions between these 
mutations. For instance, nsp12-250 and nsp14-250 both independently increased fitness in 
MHV-ExoN(-), but their fitness effects were not additive (Figure 19). Instead, ExoN(-) 
nsp12/14-250 was less fit than ExoN(-) nsp12-250, suggesting that other replicase mutations 
support the interactions between the RdRp and ExoN. In addition, passage-associated 
phenotypes were lost when placed in a different genetic background. For example, inserting the 
high-fidelity nsp12-250 polymerase into a proofreading-capable virus did not result in an 
additive increase in fidelity (Figure 32). Instead, nsp12-250 interfered with normal proofreading, 
as measured by sensitivity to 5-fluorouracil, and was detrimental to overall replication and 
competitive fitness (Figure 32). This observation is consistent with Nicole Sexton’s work on the 
likely high-fidelity mutant, nsp12-V553I (Sexton et al., 2016). In that case, nsp12-V553I did not 
modify proofreading in the wild-type background, but it did delay replication, suggesting that it 
still interfered with RTC assembly or function. These data suggest that nsp12 and nsp14-ExoN 
coevolve to optimize distinct properties of viral replication. I favor the hypothesis that the 
proofreading activity nsp14-ExoN, through interaction with nsp10, relaxes the selective pressure 
on polymerase nucleotide selectivity, allowing nsp12-RdRp to optimize other parameters, such 
as replication speed or processivity. Consistent with this hypothesis, the SARS-CoV nsp12-
RdRp is lower fidelity than the dengue virus RdRp, a virus with a genome one-third of its size 
(Ferron et al., 2018). Under this model, there is a trade-off between replication speed and 
fidelity—the slower the polymerase proceeds, the more time it has to discriminate incoming 
nucleotides (Elena and Sanjuán, 2005; Fitzsimmons et al., 2018; Pandey et al., 1996; Regoes et 
al., 2013). Thus, increasing polymerase fidelity would disrupt the kinetic balance between 
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extension and excision during replication. In line with this expectation, both nsp12-V553I and 
nsp12-250 delay replication by the wild-type RTC (Figure 32) (Sexton et al., 2016). 
Additionally, one or more mutations in nsp12-250 could dysregulate physical interactions with 
wild-type nsp14. For example, if nsp14-ExoN(-) disrupts replication by binding to, but not 
excising, nucleotide mismatches, then mutations that disrupt the nsp12-nsp14 interaction could 
have been advantageous. Whether and how passage-associated mutations in nsp8, nsp9, and 
nsp13 fit into this model is an open question, but it is clear that they do not modify fidelity 
directly (Chapter 3). However, the recombinant viruses described in Chapter 3 will be useful 
tools for investigating replication complex assembly and function. The ability to test these 
hypotheses in replicating viruses or in vitro reconstituted biochemical systems provides a unique 
opportunity to map the coronavirus replication machinery. 
 
nsp14-ExoN is more than just the first proofreading enzyme in an RNA virus 
The experiments in this dissertation have focused on the proofreading activity of nsp14-ExoN, 
and appropriately so, given the novelty of this enzymatic activity in the RNA world and its 
implications for coronavirus evolution and emergence. Proofreading allows coronaviruses to 
encode numerous innate immune antagonists, to replicate faithfully despite changes to nucleotide 
pools, and to resist antiviral nucleoside analogues (Graepel et al., 2017; Lauber et al., 2013; 
Sexton et al., 2016; Smith et al., 2013). However, I have not intended to imply that nsp14-
ExoN’s role in coronavirus biology is limited to preventing error catastrophe. Indeed, the close 
association of nsp14 with other components of the replicase complex suggests that this protein 
may be intimately involved in regulating replication at multiple levels. This hypothesis is 
supported by abundant evidence from this dissertation and other studies. For instance, although 
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catalytic mutants of MHV-nsp14-ExoN can be recovered, full deletions of nsp14 prevent virus 
recovery (unpublished observations, Denison lab), indicating that the presence of the ExoN 
domain itself is important for viability. The ExoN domain is linked by a flexible hinge region to 
an N7-methyltransferase domain (N7-MT) involved in capping RNA molecules (Ferron et al., 
2018). The catalytic sites of nsp14-ExoN and nsp14-N7-MT are functionally distinct and 
physically independent, but ExoN and N7-MT activities require the presence of both domains 
(Bouvet et al., 2010; Case et al., 2016; Chen et al., 2009; Ferron et al., 2018). The two domains 
interact through an extensive hydrophobic surface proximal to the hinge, which may act as a 
molecular switch to spatially and temporally regulate capping of nascent viral RNAs (Ferron et 
al., 2018; Ma et al., 2015). Coronavirus ExoN activity has been implicated in evasion of innate 
immune responses independently of viral capping. In the Alphacoronavirus transmissible 
gastroenteritis virus (TGEV), an ExoN zinc finger mutant triggered a reduced antiviral response 
relative to wild-type TGEV by generating lower levels of double-stranded RNA during infection 
(Becares et al., 2016). ExoN catalytic mutants of TGEV were not viable, so their effects on 
innate immunity could not be measured. However, catalytic mutants in MHV are highly sensitive 
to interferon treatment, through an undefined mechanism (Case, 2018; Case et al., 2017). These 
studies have clearly demonstrated that nsp14-ExoN has important roles in replication beyond 
fidelity regulation. The data presented in this dissertation extends this understanding by 
identifying mutations in nsp14 that modify replication and fitness without affecting proofreading 
(Figure 18, Figure 19, Figure 32). The stark difference in fitness effects of nsp14-250 mutations 
between the ExoN(-) and ExoN(+) backgrounds provides an exciting opportunity to examine 
how proofreading is linked to other properties of the coronavirus RTC, including speed, 
processivity, and assembly. Together, my work and existing studies suggest a model for a 
multifunctional nsp14, in which the ExoN domain interacts with numerous viral, and potentially 
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host, proteins to regulate multiple steps of the coronavirus life cycle. Indeed, the high structural 
flexibility of nsp14 has been compared to intrinsically disordered proteins (IDPs) (Ferron et al., 
2018). IDPs function as hubs in protein interaction networks, coordinating signaling cascades by 
interacting with numerous partners in multiple combinations (Dyson, 2016). Like IDPs, nsp14 
appears to be a critical nucleus of the coronavirus replication machinery (Imbert et al., 2008; 
Smith et al., 2014; Subissi et al., 2014; V'kovski et al., 2019). Understanding the various roles of 
nsp14 in MHV will allow us to understand and overcome the obstacles to recovery of ExoN(-) 
mutants in other coronaviruses and may reveal new strategies for therapeutic targeting of nsp14. 
 
MHV-ExoN(-) P250 is a sandbox for studying coronavirus biology 
In this dissertation, I show that MHV-ExoN(-) is capable of adapting for high-level fitness 
without primary reversion, displaying dramatic increases in replication, RNA synthesis, and 
replication fidelity. I traced small contributions to these phenotypes to individual, adapted 
proteins, but I could never recapitulate the full-genome phenotype using recombinant viruses 
(Chapters 2,3). These data suggested that multiple proteins contribute additively and/or 
collaboratively to various adaptive phenotypes, and in many cases, may involve long-range 
interactions across the entire genome. Some mutations, including those in nsp12-RdRp, directly 
compensated for ExoN(-) activities and may represent generalizable strategies for overcoming 
ExoN(-) defects in other cell types and in other coronaviruses (Figure 18, Figure 19). 
Understanding the mechanisms by which MHV-ExoN(-) P250 compensated for ExoN activity 
could allow recovery of ExoN(-) variants of other CoVs, such as transmissible gastroenteritis 
virus, HCoV-229E, and MERS-CoV, which to date have been nonviable as ExoN(-) 
recombinants (Becares et al., 2016; Minskaia et al., 2006). More broadly, I envision MHV-
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ExoN(-) P250 at the center of a wheel, with spokes representing different avenues of potential 
research. I have focused primarily on the adaptive changes related to replication fidelity, but 
mutations in MHV-ExoN(-) P250 could conceivably affect any step in the replication cycle. For 
example, do spike mutations influence entry, assembly, egress, or environmental stability of 
MHV? Could the nsp2 mutations reveal the function(s) of this conserved but dispensable 
protein? Do mutations in nsp4 and nsp6 affect the formation of double membrane vesicles, and 
do mutations in nsp3 modify proteolytic cleavage? Could the lone mutation in the nsp12-NiRAN 
domain of MHV-ExoN(-) P250 peel back the curtain on this essential but enigmatic enzyme? 
The questions are limitless, and we have only begun to scratch the surface. 
 
Experimental evolution reveals important insights for coronavirus vaccine development 
Early strategies for vaccine development were based on a fundamental observation: pathogenic 
viruses tend to lose their virulence when passaged experimentally in foreign hosts, such as 
cultured cells or embryonated eggs. Several life-saving vaccines still in use today were derived 
from prolonged passage experiments, including the oral poliovirus vaccine and the yellow fever 
virus vaccine. However, long-term passage has lost favor in the vaccine development world for 
two related reasons. First, because live-attenuated vaccines are able to replicate, they always 
carry a risk for reversion to virulence. The oral poliovirus vaccine, for instance, can evolve 
virulence with just two mutations, and these vaccine-derived polioviruses are the Achilles heel of 
poliovirus eradication efforts (Kew, 2012). Second, it can be difficult to define the mechanism of 
attenuation in passaged viruses, raising safety concerns and hampering efforts to predict or 
prevent reversion (Bull, 2015). With the emergence of new technologies, vaccine development 
efforts have shifted focus to rational attenuation using genetic engineering. However, the 
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research in this dissertation argues that experimental evolution can still contribute key insights 
for vaccine development. Using the toolkit of evolutionary biology, I defined genetic 
impediments to ExoN(-) reversion that strongly support the potential genetic stability of an 
ExoN(-) coronavirus vaccine. I also characterized a more accessible evolutionary pathway and 
demonstrated that passage-adapted protein sequences can constrain the reversibility of 
attenuating mutations. In their own right, these insights will almost certainly inform strategies to 
prevent and treat coronavirus infections, while simultaneously developing new reagents for 
characterizing the critical interactions involved in coronavirus replication.  Unfortunately, the 
experiments described in this dissertation may not be feasible for all viruses, especially those 
subject to gain-of-function or dual-use-of-concern restrictions. However, the lessons learned 
from experiments in MHV should be applicable to closely-related viruses like SARS-CoV and 
MERS-CoV. Thus, long-term passage studies should complement rational genetic engineering in 
the pursuit of safe and effective vaccine candidates.  
 
Concluding remarks 
I remember the fear surrounding the SARS epidemic—the images of healthcare workers in 
masks on the front of newspapers, the suspicious glances at anyone who coughed, the stories of 
heroes and victims from across the world. In the preceding pages, I have described my humble 
contributions to the body of knowledge about coronavirus biology and evolution. I hope that this 
work has opened doors to illuminate the intricate mechanisms underlying coronavirus 
replication, evolution, and emergence, and I hope that these insights will aid in developing 
broadly effective countermeasures for coronavirus disease. With focused study and a little bit of 
luck, I hope that the next time a coronavirus emerges, we will be able to tell a different story.  
  150 
 
Post-script 
The story of coronaviruses, at its core, is one of evolution. The incessant swirl of mutation and 
recombination in coronavirus ecology has, on at least six occasions, and without any foresight or 
intention, allowed coronaviruses to jump from animals to humans. It seems fitting, then, that the 
foundational experiment igniting this entire dissertation was undertaken without any agenda or 
expectations. It started with just a simple question: what will the virus do? This dissertation 
serves as a reminder, for me at least, of the importance of humility and of curiosity. When 
Xiaotao and Brett began passaging MHV-ExoN(-), they had no idea that it would reveal so much 
about coronavirus replication or inform vaccine development efforts for emerging coronaviruses. 
They just wanted to see what would happen. So, if I may leave one final message, it would be 
this: nature will tell you what is important, but only if you let it.  
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APPENDIX A. Mutations in passaged viruses 
A.1 Mutations in WT-MHV P250. 
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A.2 Mutations in MHV-ExoN(-) P250 
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A.3 Mutations in MHV-ExoN(-) P160 
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APPENDIX B. New protocols 
B1. PrimerID for measuring mutation frequencies in murine hepatitis virus 
Reagents and kits: 
1. QIAamp viral RNA mini kit (Qiagen #52904) 
2. Nuclease-free H2O 
3. Mixed dNTPs at 10mM each (any supplier) 
4. Superscript III First-Strand Synthesis System (Invitrogen #18080051) or your preferred 
reverse transcriptase 
5. RNaseOUT Recombinant Ribonuclease Inhibitor (Invitrogen #10777019) 
6. Ribonuclease H (Invitrogen #18021071) 
7. Agencourt RNAclean XP beads (Beckman Coulter #A63987) 
8. Agencourt AMPure beads (Beckman Coulter #A63881) 
9. Dynamag-2 Magnetic Bead Rack (Invitrogen #12321D) 
10. 100% ethanol 
11. Kapa2G Robust PCR Kit (Kapa Biosystems #07960867001) 
12. Kapa HiFi PCR Kit (Kapa Biosystems #07958846001) 
13. MinElute Gel Extraction Kit (Qiagen # 28604) 
14. Qubit dsDNA BR Assay Kit (Invitrogen #Q32850) 
 
Primer ID primers. 
PrimerID is in bold; indices for multiplex barcoding are underlined. 
Primer Name Purpose Sequence 
MHV20814-cDNA Reverse transcription 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNN
NNNNNNCCAATGTTCTTAGTAAGAGGGTCGTACATA 
MHV20814-PCR1 PCR1, forward ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAGAAGGTCATGACTTTCTATCCTCGTTTGC 
PID-PCR-1 PCR1 reverse GTGACTGGAGTTCAGACGTGTGCTC 
D501-TATAGCCT Index, forward AATGATACGGCGACCACCGAGATCTACACTATAGCCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
D502-ATAGAGGC Index, forward AATGATACGGCGACCACCGAGATCTACACATAGAGGCACACTCTTTCCCTACACGACGCTCTTCCGATCT 
D503-CCTATCCT Index, forward AATGATACGGCGACCACCGAGATCTACACCCTATCCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
D504-GGCTCTGA Index, forward AATGATACGGCGACCACCGAGATCTACACGGCTCTGAACACTCTTTCCCTACACGACGCTCTTCCGATCT 
D505-AGGCGAAG Index, forward AATGATACGGCGACCACCGAGATCTACACAGGCGAAGACACTCTTTCCCTACACGACGCTCTTCCGATCT 
D506-TAATCTTA Index, forward AATGATACGGCGACCACCGAGATCTACACTAATCTTAACACTCTTTCCCTACACGACGCTCTTCCGATCT 
D507-CAGGACGT Index, forward AATGATACGGCGACCACCGAGATCTACACCAGGACGTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
D508-GTACTGAC Index, forward AATGATACGGCGACCACCGAGATCTACACGTACTGACACACTCTTTCCCTACACGACGCTCTTCCGATCT 
D701-ATTACTCG_R Index, reverse CAAGCAGAAGACGGCATACGAGATCGAGTAATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC 
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Library Preparation and Sequencing. 
The starting material for library preparation should be RNA genomes purified from supernatant 
RNA. I like to use the Qiagen QIAamp viral RNA mini kit because it can be used at the 
benchtop, unlike TRIzol which requires the fume hood. Quantify genomic RNA copies using the 
qPCR method of your choice. 
 
Reverse transcription. 
This step creates PrimerID-tagged cDNA. 
 
1. Make initial RNA mixture 
Reagent [stock] Volume (µL) 
RNA template Variable 100,000 genome copies 
dNTP mix 10 mL each 3 
MHV20814-cDNA 10 µM 1.5 
Nuclease free H2O N/A to 39 µL 
 
2. Incubate at 65ºC for 5 minutes to denature RNA template, then transfer to ice for at least 
1 minute to anneal cDNA primer. 
3. Add the remaining reverse transcription reagents. I typically make a master mix to 
streamline the process. 
Reagent [stock] Volume (µL) 
5x Buffer 5x 12 
DTT 100mL 3 
RNaseOUT 40 u/µL 3 
SuperScript III 200 u/µL 3 
Volume per tube N/A 21 
 
4. Incubate in the thermocycler: 
a. 50ºC 1 hour 
b. 55ºC 1 hour 
c. 70ºC 15 minutes (to inactivate SSIII) 
5. Add 1 µL of RNase H to each tube and incubate at 37ºC for 20 minutes. 
6. Purify cDNA with Agencourt RNAClean XP beads 
a. Resuspend beads, remove an aliquot, and let them equilibrate to room 
temperature. Vortex immediately before use. 
b. Transfer cDNA reactions to 1.5mL Eppendorf tubes and add beads at a ratio of 
1.2:1 (72 µL beads per 60 µL sample). 
c. Mix thoroughly without vortexing and incubate at room temperature for 20 
minutes. 
d. Place tube on magnetic rack and allow to separate for 5 minutes. 
e. Leaving the tube on the rack, remove supernatant and discard. 
f. Rinse beads three times with 300µL of 80% ethanol. 
g. After third wash, spin tubes briefly with benchtop microfuge and place back on 
the rack; remove any remaining liquid. 
h. Allow beads to dry until they just turn matte, 5-10 minutes. Over-drying reduces 
yields. 
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i. When beads are dry, remove tubes from rack and add 24 µL of nuclease-free 
H2O. Resuspend beads by pipetting up and down and incubate 5 minutes. 
j. Move tubes back to rack and remove cDNA solution. Use directly in next step. 
 
First-round PCR. 
This step amplifies the region of interest. 
1. Set up PCR. 
Reagent [stock] Volume (µL) 
Template cDNA  23.5 
5x Buffer A 5x 10 
5x Enhancer 1 5x 10 
dNTP mix 10 mM each 1 
MHV20814-PCR1 10 µM 2.5 
PID-PCR1-R 10 µM 2.5 
Kapa2G Robust 
polymerase 5 U/mL 0.5 
 
2. Incubate in thermocycler: 
a. 95ºC 1 min 
b. 95ºC 15 sec 
c. 58ºC 1 min 
d. 72ºC 30 sec 
e. Repeat (b) – (d) for 25 cycles. 
f. 72ºC 3 min 
g. 4ºC hold 
3. Purify PCR1 products with Agencourt AMPureXP beads. 
a. Resuspend beads, remove an aliquot, and let them equilibrate to room 
temperature. Vortex immediately before use. 
b. Transfer PCR1 solution to 1.5mL Eppendorf tubes and add beads at a ratio of 
1.2:1 (60 µL beads per 50 µL sample). 
c. Mix thoroughly without vortexing and incubate at room temperature for 20 
minutes. 
d. Place tube on magnetic rack and allow to separate for 5 minutes. 
e. Leaving the tube on the rack, remove supernatant and discard. 
f. Rinse beads three times with 300µL of 80% ethanol. 
g. After third wash, spin tubes briefly with benchtop microfuge and place back on 
the rack; remove any remaining liquid. 
h. Allow beads to dry until they just turn matte, 5-10 minutes. Over-drying reduces 
yields. 
i. When beads are dry, remove tubes from rack and add 50 µL of nuclease-free 
H2O. Resuspend beads by pipetting up and down and incubate 5 minutes. 
j. Move tubes back to rack and remove cDNA solution. 
 
Second-round PCR. 
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This step adds Illumina adaptors and indexed barcodes for multiplex sequencing. 
1. Set up PCR. 
Reagent [stock] Volume (µL) 
PCR1 product  2 
5x Kapa HiFi Buffer 5x 5 
dNTP mix 10 mM each 1 
D50(x) primer 10 µM 1 
D701-ATTACTCG_R 10 µM 1 
Kapa HiFi polymerase 1 U/mL 0.5 
Nuclease-free H20  14.5 
 
2. Incubate in thermocycler: 
a. 95ºC 2 min 
b. 98ºC 20 sec 
c. 63ºC 15 sec 
d. 72ºC 30 sec 
e. Repeat (b) – (d) for 25 cycles. 
f. 72ºC 3 min 
g. 4ºC hold 
3. Run PCR2 products on a 1.2% agarose gel and extract with the Qiagen MinElute gel 
extraction kit. 
a. Excise DNA fragment and weigh the gel. 
b. Add 3 volumes of buffer QG to 1 volume of gel and incubate at 50ºC, vortexing 
intermittently, until fully dissolved. If the solution is not yellow, add 10 µL of 3M 
sodium acetate. 
c. Apply sample to MinElute column, and centrifuge at top speed 1 minute at room 
temperature. Discard flowthrough. 
d. Add 500 µL buffer QG, and centrifuge at top speed 1 minute at room temperature. 
Discard flowthrough. 
e. Add 750 µL buffer PE, incubate at room temperature for 5 minutes, then 
centrifuge at top speed 1 minute at room temperature. 
f. Discard flowthrough and centrifuge at top speed an additional 3 minutes to dry 
the membrane. 
g. Transfer MinElute column to a fresh 1.5mL Eppendorf tube and add 10 µL buffer 
EB. Incubate at room temperature for 5 minutes, then centrifuge at top speed for 2 
minutes to elute DNA products.  
4. Quantify library using the Invitrogen Qubit dsDNA BR assay kit. 
a. Follow manufacturer’s instructions. 
b. Do not use Nanodrop to quantify; it is not precise enough. 
5. Dilute libraries to 5 nM and pool in equal volumes for sequencing. 
6. Quality control should include: 
a. qPCR to establish the presence of adaptor sequences 
b. BioAnalyzer to find primer dimers that can interfere with sequencing. 
 
Sequencing.  
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1. Libraries should be sequenced on the Illumina MiSeq with 2x250 paired-end chemistry. 
2. The pooled libraries should make up 50% of the chip, with bacterially-derived DNA 
(“PhiX”) making up the remainder. 
 
Analysis. 
Sequencing results should arrive as zipped drives containing fastq files (XX.fastq.gz). Shuntai 
Zhou (UNC Chapel Hill) wrote the ruby code for creating PrimerID-derived consensus 
sequences and for combining forward and reverse reads into single reads. The subsequent 
analysis and code were provided by Matthew Pauly (University of Michigan, Lauring lab; 
https://github.com/lauringlab/NGS_mutation_rate_assay) (Pauly et al., 2017b). 
 
1. Generate PrimerID consensus sequences. Follow either (a) or (b) below. 
a. The Swanstrom lab developed a web portal that will automatically generate 
consensus scripts from raw data. https://tcs-dr-dept-tcs.cloudapps.unc.edu/TCS/ 
i. Upload sequencing files (name.fastq.gz) to a Dropbox folder. 
ii. Submit link to Dropbox folder along with primer sequences: 
1. MHV20814-cDNA 
2. MHV20814-PCR1 
iii. You will get an email with a link to download the results. This sometimes 
lands in a spam folder, so if you don’t receive them in 24 hours, follow up 
with Michael Clark (clarkmu@email.unc.edu). 
 
b. Run the ruby script on your own data. 
i. Unzip the fastq files: 
 
gunzip file.gz  
 
ii. Run ruby script: 
 
ruby TCS_MHV20814.rb {input_directory} {length of primerID} 
 
c. Regardless of whether you use 1a or 1b, the output will be a new directory within 
the input directory that contains: 
i. Consensus files (r1.txt and r2.txt, corresponding to r1 and r2 reads from 
Illumina sequencing) 
ii. Log file (look here for the number of consensus sequences and the 
consensus threshold) 
iii. PrimerID statistics (identity and usage) 
 
2. Combine the read1 and read2 consensus into a single consensus sequence. 
a. It’s easiest to make a new directory for this, organized as follows: 
i. Name_of_directory 
1. Sample1 
a. r1.txt 
b. r2.txt 
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2. Sample2 
a. r1.txt 
b. r2.txt 
3. …etc 
b. The script will combine overlapped regions so that they are not counted twice in 
downstream analysis. The size of the overlap has to be set in the script; for 
MHV20814, the overlap is 33. 
 
ruby pid_join_two_ends.rb “/name_of_directory” 
 
c. Output will be single .txt files for each sample 
 
3. Convert .txt files from (2c) to .fasta 
 
cp combined.txt combined.fasta 
 
4. Align the combined consensus sequences using bowtie2. 
a. Bowtie2 needs an indexed genome file to use as its reference during alignment. If 
you don’t have one, you’ll need to make it. Generate a fasta file containing the 
region of interest (e.g. nts 20600-21400 of MHV genome for “MHV20814”).  
 
bowtie2 build -f MHV20814ref.fasta MHV20814ref 
 
b. Align reads to your new indexed reference. 
i. -f designates that input is in fasta format rather than fastq 
ii. -x marks the reference file 
iii. -U marked the sequences as unpaired 
iv. -S names the output file 
 
bowtie2 -f -x MHV20814ref -U “combined.fasta” -S “aligned.sam” 
 
5. Use samtools to convert .sam files to .bam files (necessary for subsequent steps). 
 
samtools view -Sb “aligned.sam” > “aligned.bam” 
 
6. Use samtools to create a pileup that lists all consensus sequences in the alignment by base 
position. (-d 100000 designates depth. Default is 8000, which will be too low oo low) 
 
samtools mpileup -d 100000 “aligned.bam” > “aligned.pileup” 
 
7. Use Lauring lab python script to count the number of each base type at each position in 
the alignment. This gives the number of A, T, C, G, and N at each position in the 
sequence. 
 
python counts.py “aligned.pileup” “output.csv” 
 
8. I determine nonsense mutation frequencies manually after opening the output.csv in Excel. 
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9. Lauring lab script “Mutcount_analysis.R” can be used to determine the frequencies of all 
mutations in R. The input will be your unmodified output.csv files. 
 
B2. Bioinformatic code for PrimerID analysis 
Identifying nonsense mutational targets within an open reading frame 
File name: stop_codon_script.R (necessary modifications bolded below). Script prepared by 
Matthew Pauly (Pauly et al., 2017b) 
 
Note: the script scans along until it finds the first ATG, so make sure the earliest ATG in your 
genome file is actually your ORF’s start codon. Also, it will not recognize the ATG if it is at the 
start of the sequence, so add at least 10 nucleotides before it.  
 
#This script is designed to determine the number of codons in a gene that can 
mutate into a premature stop codon. 
 
#function inputs are: 
# genomefile - the ".fas" file that you want to analyze 
# bases - the number of bases that you want in each window that is analyzed 
for codons that can mutate to stop codons 
# sortcol - the column in the output that you want to sort by   
 # 2- sum of all codons that can mutate to stop codon 
 # 3-  codons assessing U2A and U2G 
 # 4- codons assessing U2A 
 # 5- codons assessing C2A and C2G 
 # 6- codons assessing C2A 
 # 7- codons assessing C2U 
 # 8- codons assessing G2A 
 # 9- codons assessing A2U 
 # 10- codons assessing G2U 
 
StopCodon<-function(genomefile, bases, sortcol){ 
 
genefile<-read.csv(“your_genome_file”,sep=";")   #reads the 
unzipped file 
 
genefile2<-genefile[,]     #Makes the read-in file 
usable for the following manipulation  
 
gene<-toupper(paste(genefile2, collapse=""))   #pastes the read-
in file into a list of the entire genome 
 
start<-(regexpr("ATG", gene)[1])              #Finds the FIRST start 
codon in the seqience that is given 
 
genesplit<-strsplit(gene,split='')        #This and next 2 split string into 
list of individual bases 
 
same<-function(x){x} 
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singlebase<-sapply(genesplit, same) 
 
len<-length(singlebase) 
 
geneORF<-paste(singlebase[(start:len),], collapse="")    #makes string 
starting with the forst ATG 
 
geneORF 
 
######## 
 
    #The following for loop will break the gene into 
codons 
 
 
for (q in 1:length(geneORF)){ 
  codons<-substring(geneORF[q], seq(1,nchar(geneORF[q])-
1,3),seq(3,nchar(geneORF[q]),3)) 
} 
 
  #The following replaces all codons that can mutate to a stop 
codon with  "1". All other codons replaced with a "0" 
   
 
lethcodonmut<-function(x){ 
 y<-gsub("TTA|TAT","1",x) 
 y<-gsub("TTG|TGT","1",y) 
 y<-gsub("TCA|TAC","1",y) 
 y<-gsub("TGC|TCG","1",y) 
 y<-gsub("CAA|CAG|CGA","1",y) 
 y<-gsub("TGG","1",y) 
 y<-gsub("AAA|AAG|AGA","1",y) 
 y<-gsub("GAA|GAG|GGA","1",y) 
 y<-gsub("...","0",y) 
 y 
 } 
 
lethcodonmutations<-lethcodonmut(codons)   #changes codons to 
character numerals 
 
le<-as.numeric(lethcodonmutations)    #makes numeric   
 
###### 
 
lethcodonmuta<-function(x){ 
 y<-gsub("TTA|TAT","1",x) 
 y<-gsub("TTG|TGT","2",y) 
 y<-gsub("TCA|TAC","3",y) 
 y<-gsub("TGC|TCG","4",y) 
 y<-gsub("CAA|CAG|CGA","5",y) 
 y<-gsub("TGG","6",y) 
 y<-gsub("AAA|AAG|AGA","7",y) 
 y<-gsub("GAA|GAG|GGA","8",y) 
 y<-gsub("...","0",y) 
 y 
 } 
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lethcodonmutationsa<-lethcodonmuta(codons)   #changes codons 
to character numerals 
 
lea<-as.numeric(lethcodonmutationsa)    #makes numeric 
  
 
####### 
 
 
 
cod<-round(“bases”/3)      #converts the bases 
input into number of codons; set “bases” to the amplicon size you want. Make 
sure it is evenly divisible by 3. 
 
 
 
 
windows<-matrix(rep(0),nrow=(length(le)-cod), ncol=10)  #makes 
vector to populate with scores for windows of codons 
 
 
        #the following will divide 
into windows of 100 codons (300 bases) and sum 
 
colnames(windows)<-c("start base","number of lethal codons","U2A and 
U2G","U2A","C2A and C2G","C2A","C2U","G2A","A2U","G2U") 
 
for (q in 1:(length(le)-cod)){ 
 windows[q,2]<-sum(le[(0+q):(cod-1+q)])  
 windows[q,1]<-((3*q)-2) 
 windows[q,3]<-sum(lea[(0+q):(cod-1+q)]==1) 
 windows[q,4]<-sum(lea[(0+q):(cod-1+q)]==2) 
 windows[q,5]<-sum(lea[(0+q):(cod-1+q)]==3) 
 windows[q,6]<-sum(lea[(0+q):(cod-1+q)]==4) 
 windows[q,7]<-sum(lea[(0+q):(cod-1+q)]==5) 
 windows[q,8]<-sum(lea[(0+q):(cod-1+q)]==6) 
 windows[q,9]<-sum(lea[(0+q):(cod-1+q)]==7) 
 windows[q,10]<-sum(lea[(0+q):(cod-1+q)]==8) 
 
} 
 
windowsort<-windows[order(windows[,sortcol], decreasing=TRUE),] 
 
   #The following will allow the script to return two things 
(The ORF sequence and the output table) 
 
ret<-(head(windowsort, 100)) 
 
retu<-list(geneORF,ret) 
 
return(retu) 
 
} 
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Generating consensus reads using the PrimerID 
 
File name: TCS_MHV20814.rb (no modifications should be necessary). Script was written by 
Shuntai Zhou (Zhou et al., 2015). 
 
=begin 
TCS Pipeline Version 1.38-07AUG2018 
Create Primer ID template consensus sequences from raw MiSeq FASTq file 
Input = directory of raw sequences of two ends (R1 and R2 fasta files, 
unzipped) 
Require parameters: 
  list of Primer Sequence of cDNA primer and 1st round PCR forward Primer, 
including a tag for the pair name 
  ignore the first nucleotide of Primer ID: Yes/No 
=end 
ver = "1.38-07AUG2018" 
#############Patch Note############# 
=begin 
  1. Improved performace. 
=end 
 
 
 
#############cDNA gene-specific region and forward primer region needs to be 
defined####### 
 
#mutilple cDNA primers, remove the # before use 
primers = {} 
 
#change set_name, forward primer sequence and cDNA primer sequence. both 
forward primer sequence and cDNA primer sequence should include the entire 
sequence, not just biological sequence 
#primers["set_name"] = ["forward primer sequence", "cDNA primer sequence"] 
#example of primer 
 
primers["MHV20814"] = 
["ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAGAAGGTCATGACTTTCTATCCTCGTTTGC","GTGAC
TGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNCCAATGTTCTTAGTAAGAGGGTCGTACATA"] 
 
#ignore the first nucleotide of the PID, default value true, remove the # 
before use 
 
$ignore_first_nt = true unless defined? $ignore_first_nt 
 
#input file is the directory containing sequences from both ends of one 
library 
indir = ARGV[0] 
 
#####################General Methods 
 
#convert array to hash in a memory-saving way 
def array_to_hash(array) 
  count = 0 
  hash = Hash.new 
  (array.length / 2).times do 
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    hash[array[count]] = array[count+1] 
    count += 2 
  end 
  return hash 
end 
 
#count frequencies of elements in a array. 
def count(array) 
  hash = Hash.new(0) 
  array.each do |element| 
    hash[element] +=1 
  end 
  return hash 
end 
 
#calculate consensus cutoff 
#error = 0.02 
def calculate_cut_off(m) 
  n = 0 
  if m <= 10 
    n = 2 
  elsif m <= 8500 
    n = -1.24*10**-21*m**6 + 3.53*10**-17*m**5 - 3.90*10**-13*m**4 + 
2.12*10**-9*m**3 - 6.06*10**-6*m**2 + 1.80*10**-2*m + 3.15 
  else 
    n = 0.0079 * m + 9.4869 
  end 
  n = n.round 
  n = 2 if n < 3 
  return n 
end 
 
=begin 
#error rate = 0.01 
def calculate_cut_off(m) 
  n = 0 
  if m <= 10 
    n = 2 
  else 
    n = 1.09*10**-26*m**6 + 7.82*10**-22*m**5 - 1.93*10**-16*m**4 + 
1.01*10**-11*m**3 - 2.31*10**-7*m**2 + 0.00645*m + 2.872 
  end 
  n = n.round 
  n = 2 if n < 3 
  return n 
end 
=end 
 
=begin 
#error rate = 0.005 
def calculate_cut_off(m) 
  n = 0 
  if m <= 10 
    n = 2 
  else 
    n = -9.59*10**-27*m**6 + 3.27*10**-21*m**5 - 3.05*10**-16*m**4 + 
1.2*10**-11*m**3 - 2.19*10**-7*m**2 + 0.004044*m + 2.273 
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  end 
  n = n.round 
  n = 2 if n < 3 
  return n 
end 
=end 
 
#obtain a consensus sequences 
def consensus_without_alignment(seq_array,gap_treatment = 1) 
  all_length = [] 
  seq_array.each {|seq| all_length << seq.size} 
  length = all_length.mean.round(0) 
  consensus_bases = [] 
  (0..(length-1)).each do |n| 
    bases = [] 
    seq_array.each do |seq| 
      bases << seq[n] 
    end 
    if gap_treatment == 1 
      consensus_bases << creat_consensus_base_non_gap(bases) 
    else 
      consensus_bases << creat_consensus_base_gap(bases) 
    end 
  end 
  consensus_seq = consensus_bases.join('') 
end 
 
#create a consensus base call at a position.  
def creat_consensus_base_non_gap(base_array_input) 
  base_array = Array.new(base_array_input) 
  consensus_base = '-' 
  number_of_bases = base_array.size 
  h = Hash.new(0) 
  if base_array.size >0 
    base_array.each do |base| 
      h[base] += 1 
    end 
    max_number = h.values.max 
    max_list = [] 
    h.each do |k,v| 
      if v == max_number 
        max_list << k 
      end 
    end 
    maxi_list_size = max_list.size 
    if maxi_list_size == 1 
      consensus_base = max_list.shift 
    elsif maxi_list_size >= 3 
      consensus_base = "N" 
    elsif maxi_list_size == 2 
      if max_list.include?("A") and max_list.include?("T") 
        consensus_base = "W" 
      elsif max_list.include?("A") and max_list.include?("C") 
        consensus_base = "M" 
      elsif max_list.include?("A") and max_list.include?("G") 
        consensus_base = "R" 
      elsif max_list.include?("T") and max_list.include?("C") 
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        consensus_base = "Y" 
      elsif max_list.include?("G") and max_list.include?("C") 
        consensus_base = "S" 
      elsif max_list.include?("T") and max_list.include?("G") 
        consensus_base = "K" 
      elsif max_list.include?('-') 
        max_list.delete('-') 
        consensus_base = max_list.shift 
      end 
    end 
  end 
  return consensus_base.chr if consensus_base 
end 
 
 
#primer with ambiguities to match 
def primer_match (primer = "") 
  match = "" 
  primer.each_char.each do |base| 
    base_array = to_list(base) 
    if base_array.size == 1 
      match += base_array[0] 
    else 
      pattern = "[" + base_array.join("|") + "]" 
      match += pattern 
    end 
  end 
  return match 
end 
 
def to_list(base = "") 
  list = [] 
  case base 
  when /[A|T|C|G]/ 
    list << base 
  when "W" 
    list = ['A','T'] 
  when "S" 
    list = ['C','G'] 
  when "M" 
    list = ['A','C'] 
  when 'K' 
    list = ['G','C'] 
  when 'R' 
    list = ['A','G'] 
  when 'Y' 
    list = ['C','T'] 
  when 'B' 
    list = ['C','G','T'] 
  when 'D' 
    list = ['A','G','T'] 
  when 'H' 
    list = ['A','C','T'] 
  when 'V' 
    list = ['A','C','G'] 
  when 'N' 
    list = ['A','T','C','G'] 
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  end 
  return list 
end 
 
module Enumerable 
  def median      
    len = self.length 
    sorted = self.sort 
    median = len % 2 == 1 ? sorted[len/2] : (sorted[len/2 - 1] + 
sorted[len/2]).to_f / 2 
  end  
   
  def sum 
     self.inject(0){|accum, i| accum + i } 
  end 
   
  def mean 
    self.sum/self.length.to_f 
  end 
   
  def sample_variance 
    m = self.mean 
    sum = self.inject(0){|accum, i| accum + (i-m)**2 } 
    sum/(self.length - 1).to_f 
  end 
   
  def stdev 
    return Math.sqrt(self.sample_variance) 
  end 
 
end 
 
 
#compare PID with sequences which have identical sequences.  
#PIDs differ by 1 base will be recognized.  
#if PID1 is x time greater than PID2, PID2 will be disgarded 
 
def filter_similar_pid(sequence_hash = {}, cutoff = 10) 
  seq = sequence_hash 
  uni_seq = seq.values.uniq 
  uni_seq_pid = {} 
  uni_seq.each do |k| 
    seq.each do |name,s| 
      name = name[1..-1] 
      if k == s 
        if uni_seq_pid[k] 
          uni_seq_pid[k] << [name.split("_")[0],name.split("_")[1]] 
        else 
          uni_seq_pid[k] = [] 
          uni_seq_pid[k] << [name.split("_")[0],name.split("_")[1]] 
        end 
      end 
    end  
  end 
   
  dup_pid = [] 
  uni_seq_pid.values.each do |v| 
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    next if v.size == 1 
    pid_hash = Hash[v] 
    list = pid_hash.keys 
    list2 = Array.new(list) 
    pairs = [] 
   
    list.each do |k| 
      list2.delete(k) 
      list2.each do |k1| 
        pairs << [k,k1] 
      end 
    end 
     
    pairs.each do |p| 
      pid1 = p[0] 
      pid2 = p[1] 
      if two_pid_x_base_different(pid1,pid2,1) 
        n1 = pid_hash[pid1].to_i 
        n2 = pid_hash[pid2].to_i 
        if n1 >= cutoff * n2 
          dup_pid << pid2 
          #puts pid1 + "\t" + n1.to_s + "\t" + pid2 + "\t" + n2.to_s 
        elsif n2 >= cutoff * n1 
          dup_pid << pid1 
          #puts pid2 + "\t" + n2.to_s + "\t" + pid1 + "\t" + n1.to_s 
        end 
      end 
    end 
  end 
 
  new_seq = {} 
  seq.each do |name,s| 
    pid = name.split("_")[0][1..-1] 
    unless dup_pid.include?(pid) 
      new_seq[name] = s 
    end 
  end 
  return new_seq 
end 
 
#compare two primer ID sequences. If they differ in x base, return boolean 
value "TURE", else, return boolean value "FALSE" 
def two_pid_x_base_different(pid1="",pid2="", x=0) 
  l = pid1.size 
  m = l - x 
  n = 0 
  if pid1.size != pid2.size 
    return false 
  else 
    (0..(pid1.size - 1)).each do |k| 
      if pid1[k] == pid2[k] 
        n += 1 
      end 
    end 
    if n >= m 
      return true 
    else 
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      return false 
    end 
  end 
end 
 
def unzip_r(indir, f) 
  r_file = indir + "/" + f 
  if f =~ /.gz/ 
    `gzip -d #{r_file}` 
    new_f = f.sub ".gz", "" 
    r_file = indir + "/" + new_f 
  end 
  return r_file 
end 
 
#####################End of General Methods 
 
#obtain files for two ends for the input directory 
indir = ARGV[0] 
libname = File.basename(indir) 
 
files = [] 
Dir.chdir(indir) do 
  files = Dir.glob("*") 
end 
r1_f = "" 
r2_f = "" 
files.each do |f| 
  if f =~ /r1/i 
    r1_f = unzip_r(indir, f) 
  elsif f =~ /r2/i 
    r2_f = unzip_r(indir, f) 
  end 
end 
 
t = Time.now 
#outdir = indir + "/consensus_out" + "_" + t.year.to_s + "_" + t.month.to_s + 
"_" + t.day.to_s + "_" + t.hour.to_s + "_" + t.min.to_s 
outdir = indir + "/"# + File.basename(indir) 
Dir.mkdir(outdir) unless File.directory?(outdir) 
 
temp_out = indir + "/temp_seq" 
Dir.mkdir(temp_out) unless File.directory?(temp_out) 
 
primers.each do |setname,primer_pair| 
  puts "Processing " + setname 
  n_all_seq = 0 
  n_filter_r1 = 0 
  n_filter_r2 = 0 
  n_paired = 0 
  forward_primer = primer_pair[0] 
  reverse_primer = primer_pair[1] 
  if forward_primer.match(/(N+)(\w+)$/) 
    $forward_n = $1.size 
    $forward_bio_primer = $2 
  else 
    $forward_n = 0 
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    $forward_bio_primer = forward_primer 
  end 
  forward_bio_primer_size = $forward_bio_primer.size 
  forward_starting_number = $forward_n + forward_bio_primer_size 
  reverse_primer.match(/(N+)(\w+)$/) 
  reverse_n = $1.size 
  $reverse_bio_primer = $2 
  reverse_bio_primer_size = $reverse_bio_primer.size 
  $ignore_first_nt ? id_l = reverse_n - 1 : id_l = reverse_n 
  reverse_starting_number = reverse_n + reverse_bio_primer_size 
   
  def filter_r2(input_file,id_l=8) 
    ref = primer_match($reverse_bio_primer) 
    l = ref.size 
    count = 0 
    sequence_a = [] 
    sequence_h = {} 
     
    File.open(input_file,'r') do |file| 
      file.readlines.collect do |line| 
        count +=1 
        count_m = count % 4 
        if count_m == 1 
          line.tr!('@','>') 
          sequence_a << line.chomp 
        elsif count_m == 2 
          sequence_a << line.chomp 
        end 
      end 
    end 
     
    sequence_h = array_to_hash(sequence_a) 
    sequence_passed = {} 
    $ignore_first_nt ? id_l_for_primer = id_l + 1 : id_l_for_primer = id_l 
    sequence_h.each do |name,seq| 
      next if seq[1..-2] =~ /N/ 
      next if seq =~ /A{11}/ 
      next if seq =~ /T{11}/ 
      
      primer = seq[id_l_for_primer,l] 
      if primer =~ /#{ref}/ 
        sequence_passed[name] = seq 
      end 
    end 
    return sequence_passed 
  end 
   
  def filter_r1(input_file) 
    ref = primer_match($forward_bio_primer) 
    l = ref.size 
    count = 0 
    sequence_a = [] 
    sequence_h = {} 
     
    File.open(input_file,'r') do |file| 
      file.readlines.collect do |line| 
        count +=1 
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        count_m = count % 4 
        if count_m == 1 
          line.tr!('@','>') 
          sequence_a << line.chomp 
        elsif count_m == 2 
          sequence_a << line.chomp 
        end 
      end 
    end 
     
    sequence_h = array_to_hash(sequence_a) 
    n = sequence_h.size 
    sequence_passed = {} 
    sequence_h.each do |name,seq| 
      next if seq[1..-2] =~ /N/ 
      next if seq =~ /A{11}/ 
      next if seq =~ /T{11}/ 
       
      primer = seq[$forward_n,l] 
      if primer =~ /#{ref}/ 
        sequence_passed[name] = seq 
      end 
    end 
    return [sequence_passed,n] 
  end 
   
  puts "Filtering R1...." 
  r1_temp = filter_r1(r1_f) 
   
  filtered_r1_h = r1_temp[0] 
  n_all_seq = r1_temp[1] 
  print "The number of raw sequences is #{n_all_seq.to_s}\n" 
   
  n_filter_r1 = filtered_r1_h.size 
  puts "Filtering R2...." 
  filtered_r2_h = filter_r2(r2_f,id_l) 
  n_filter_r2 = filtered_r2_h.size 
   
  print "R1: #{n_filter_r1}\n" 
  print "R2: #{n_filter_r2}\n" 
   
  puts "Pairing...." 
  sequence_rtag1 = {} 
  sequence_rtag2 = {} 
   
  filtered_r1_h.each do |k,v| 
    k =~ /\s/ 
    k2 = $` 
    sequence_rtag1[k2]= v 
  end 
   
  filtered_r2_h.each do |k,v| 
    k =~ /\s/ 
    k2 = $` 
    sequence_rtag2[k2]= v 
  end 
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  keys = sequence_rtag1.keys & sequence_rtag2.keys 
   
  paired_r1 = {} 
  paired_r2 = {} 
   
  keys.each do |k| 
    paired_r1[k] = sequence_rtag1[k] 
    paired_r2[k] = sequence_rtag2[k] 
  end 
   
  n_paired = keys.size 
  puts "Paired raw sequences are : #{n_paired.to_s}" 
   
  #create a temp file. Temp file contains sequence names, primer ids, and 
sequences from two ends 
  puts "Create Temp File...." 
 
  temp_file = temp_out + "/temp_file_" + setname 
  temp_file_out = File.open(temp_file,'w') 
   
  #building hashes for Primer ID, and two end sequences 
  id = {} 
  bio_id = {} 
  bio_non_id = {} 
   
  $ignore_first_nt ? id_truncate = 1 : id_truncate = 0 
  paired_r2.each do |k,r2_seq| 
    r1 = paired_r1[k] 
    id[k] = r2_seq[id_truncate,id_l] 
    bio_id[k] = r2_seq[reverse_starting_number..-2] 
    bio_non_id[k] = r1[forward_starting_number..-2] 
    temp_file_out.print k+ "\n" + id[k] + "\n" + bio_id[k] + 
"\n"+bio_non_id[k] + "\n" 
  end 
  temp_file_out.close 
   
  #hashes of Primer ID list and Primer ID distribution  
  primer_id_list = {} 
  primer_id_dis = {}   
   
  puts "Calculate consensus cutoff...." 
  #count primer ID 
  primer_id_list = id.values 
  primer_id_count = count(primer_id_list) 
  #Primer ID distribution 
  primer_id_dis = count(primer_id_count.values) 
  primer_id_in_use = {} 
   
 #calculate distinct_to_raw 
  distinct_to_raw = (primer_id_count.size/primer_id_list.size.to_f).round(3) 
  #define consensus cutoff 
  #in case very little raw sequences, i.e. less than 5 unique PIDs. ignore 
this set and move to the next set. 
  if primer_id_dis.keys.size < 5 
    File.unlink(temp_file) 
    next 
  end 
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  max_id = primer_id_dis.keys.sort[-5..-1].mean  
  n = calculate_cut_off(max_id) 
  puts "Consensus cutoff is #{n}" 
  puts "Creating consensus..." 
   
  #Pick primer ID over threshold n 
  primer_id_count_over_n = [] 
  primer_id_count.each do |primer_id,count| 
    primer_id_count_over_n << primer_id if count > n 
  end 
  nn = primer_id_count_over_n.size 
  puts "Number of consensus to process: #{nn}" 
 
  #output part 1 
  out_dir_set = outdir + "/" + setname 
  Dir.mkdir(out_dir_set) unless File.directory?(out_dir_set) 
  out_dir_consensus = out_dir_set + "/consensus"  
  Dir.mkdir(out_dir_consensus) unless File.directory?(out_dir_consensus) 
   
  outfile_id = out_dir_consensus + "/r2.txt" 
  outfile_non_id = out_dir_consensus + "/r1.txt" 
   
  f1 = File.open(outfile_id,'w') 
  f2 = File.open(outfile_non_id,'w') 
   
  outdir_primer_id = out_dir_set + "/primer_id" 
  Dir.mkdir(outdir_primer_id) unless File.directory?(outdir_primer_id) 
   
  outfile_primer_id_count = outdir_primer_id + "/primer_id_count" 
  outfile_primer_id_dis = outdir_primer_id + "/primer_id_dis" 
  outfile_primer_id_in_use = outdir_primer_id + "/primer_id_in_use" 
   
  f3 = File.open(outfile_primer_id_count,'w') 
  f4 = File.open(outfile_primer_id_dis,'w') 
  f5 = File.open(outfile_primer_id_in_use,'w') 
   
  f3.print "Primer ID List and Counts\n\n" 
  f3.print "Primer ID\tCounts\n" 
   
  primer_id_count.each do |k,v| 
    f3.print k + "\t" + v.to_s + "\n" 
  end 
  f3.close 
   
  f4.print "Primer ID Frequence\n\n" 
  f4.print "Frequence\tCounts\n" 
  primer_id_dis.keys.sort.each do |c| 
    w = primer_id_dis[c] 
    f4.print c.to_s + "\t" + w.to_s + "\n" 
  end 
  f4.close 
  #output part 2 
 
  #List of sequences with same primer ID over n.Create consensus 
  id_hash2 = {} 
  id.each do |name,pid| 
    if id_hash2[pid] 
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      id_hash2[pid] << name 
    else 
      id_hash2[pid] = [] 
      id_hash2[pid] << name 
    end 
  end   
  consensus = {} 
  m = 0 
  primer_id_count_over_n.each do |primer_id| 
    m += 1 
    puts "Now processing number #{m}" if m%100 == 0 
    seq_with_same_primer_id = id_hash2[primer_id] 
     
    list_id_part = [] 
    list_non_id_part = [] 
    seq_with_same_primer_id.each do |seq_name| 
      id_part = bio_id[seq_name] 
      non_id_part = bio_non_id[seq_name] 
      list_id_part << id_part 
      list_non_id_part << non_id_part 
    end 
    #consensus name including the Primer ID and number of raw sequences of 
that Primer ID, library name and setname. 
    consensus_name = ">" + primer_id + "_" + 
seq_with_same_primer_id.size.to_s + "_" + libname + "_" + setname 
    consensus_id_part = consensus_without_alignment(list_id_part) 
    consensus_non_id_part = consensus_without_alignment(list_non_id_part) 
    #consensus name including the Primer ID and number of raw sequences of 
that Primer ID 
    next if consensus_id_part =~ /[^ATCG]/ 
    next if consensus_non_id_part =~ /[^ATCG]/ 
    #get reverse complement sequence of the R2 region 
    consensus_id_part.reverse!.tr!('ATCG','TAGC') 
    primer_id_in_use[primer_id] = seq_with_same_primer_id.size 
    consensus[consensus_name] = [consensus_id_part,consensus_non_id_part] 
  end 
   
  consensus_filtered = {} 
  r1_consensus = {} 
  r2_consensus = {} 
  consensus.each do |seq_name,seq| 
    r1_consensus[seq_name] = seq[1] 
    r2_consensus[seq_name] = seq[0] 
  end 
  consensus_number_temp = consensus.size 
   
  max_pid_comb = 4**id_l 
   
  if consensus_number_temp < 0.003*max_pid_comb 
    puts "Applying PID post consensus filter..." 
    r1_consensus_filtered = filter_similar_pid(r1_consensus,10) 
    r2_consensus_filtered = filter_similar_pid(r2_consensus,10) 
    common_pid = r1_consensus_filtered.keys & r2_consensus_filtered.keys 
    common_pid.each do |pid| 
      consensus_filtered[pid] = 
[r2_consensus_filtered[pid],r1_consensus_filtered[pid]] 
    end 
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  else 
    consensus_filtered = consensus 
  end 
   
  n_con = consensus_filtered.size 
  puts "Number of consensus sequences:\t" + n_con.to_s 
  #output part 2 
  consensus_filtered.each do |seq_name,seq| 
    f1.print seq_name + "_r2\n" + seq[0] + "\n" 
    f2.print seq_name + "_r1\n" + seq[1] + "\n" 
  end 
   
  f1.close 
  f2.close 
   
   
  f5.print "Primer ID used to create consensus\n\n" 
  f5.print "Primer ID\tCounts\n" 
  primer_id_in_use.each do |k,v| 
    f5.print k + "\t" + v.to_s + "\n" 
  end 
  f5.close 
   
  #output log file 
  log = out_dir_set + "/log.txt" 
   
  log_f = File.open(log,'w') 
   
  log_f.print "Primer ID pair-end consensus creator Version #{ver}\n\n" 
   
  log_f.print "Primer ID pair-end consensus creator\n\n" 
   
  log_f.print "Runtime: #{t}\n\n" 
   
  log_f.print "Primer set name:\n#{setname}\n\n" 
   
  log_f.puts "Forward primer sequence:\t" + forward_primer 
  log_f.puts "Reverse primer sequence:\t" + reverse_primer 
   
  log_f.print "\nNumber of Raw Sequences for each end is: #{n_all_seq}\n\n" 
   
  log_f.print "Number of R1 passed filtered is: #{n_filter_r1}\n\n" 
   
  log_f.print "Number of R2 passed filtered is: #{n_filter_r2}\n\n" 
   
  log_f.print "Number of sequences paired is: #{n_paired}\n\n" 
   
  log_f.print "The consensus threshold is #{n}.\n\n" 
   
  log_f.print "Length of Primer ID is #{id_l.to_s}.\n\n" 
   
  log_f.print "The number of consensus sequences process (including 
ambiguities) is #{nn}\n\n" 
   
  log_f.print "The number of consensus sequences is #{n_con}\n\n" 
   
  log_f.print "Distinct Primer ID to raw is #{distinct_to_raw}\n\n" 
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  log_f.print "Resampling Parameter is #{(n_con/nn.to_f).round(3)}\n\n" 
   
  if distinct_to_raw > 0.1 
    log_f.print "WARNING: NOT ENOUGH RAW SEQUENCES, SAMPLING DEPTH MAY NOT BE 
REVEALED!!!" 
    print "\t\t\t****************************\nWARNING: NOT ENOUGH RAW 
SEQUENCES, SAMPLING DEPTH MAY NOT BE 
REVEALED!!!\n\t\t\t****************************\n" 
  end 
   
  log_f.close 
end 
 
# outdir_tar = outdir + ".tar.gz" 
 
# if File.exists?(outdir_tar) 
#   File.unlink(outdir_tar) 
# end 
# Dir.chdir(indir) {print `tar -czf #{File.basename(outdir_tar)} 
#{File.basename(outdir)}`} 
 
# print `rm -rf #{outdir}` 
print `rm -rf #{r1_f}` 
print `rm -rf #{r2_f}` 
print `rm -rf #{temp_out}` 
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Assembling consensus r1 and r2 files into single reads 
File name: pid_join_two_ends_33.rb (does not need any modification if you’re using 
MHV20814. If you’re using a different amplicon, you will have to change the overlap. Script 
written by Shuntai Zhou (Zhou et al., 2015). 
 
# Script to join Primer ID R1 and R2 sequences 
# example: 
# ruby pid_join_two_ends.rb target_directory 
 
 
# target_directory contains library subdirectories, each has one r1 and one 
r2 file in it. 
# example: 
# target_directory 
# ├───lib1 
# │     lib1_r1.txt 
# │     lib1_r2.txt 
# ├───lib2 
# │     lib1_r2.txt 
# │     lib1_r2.txt 
# ... 
 
# The overlap number needs to be pre-determined. if overlap == 0, r1 and r2 
will be simply joined at the end. 
overlap = 33 
 
 
############# 
def fasta_to_hash(infile) 
  f=File.open(infile,"r") 
  return_hash = {} 
  name = "" 
  while line = f.gets do 
    if line =~ /^\>/ 
      name = line.chomp 
      return_hash[name] = "" 
    else 
      return_hash[name] += line.chomp.upcase 
    end 
  end 
  f.close 
  return return_hash 
end 
 
indir = ARGV[0] 
if indir =~ /\/$/ 
  indir = indir[0..-2] 
end 
 
outdir = indir + "_combined" 
Dir.mkdir(outdir) unless File.directory?(outdir) 
libs = Dir[indir + "/*"] 
 
libs.each do |lib| 
  outfile = outdir + "/" + File.basename(lib) 
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  out = File.open(outfile, "w") 
  files = Dir[lib + "/*"] 
  r1_file = "" 
  r2_file = "" 
  files.each do |f| 
    if File.basename(f) =~ /r1/ 
      r1_file = f 
      next 
    elsif File.basename(f) =~ /r2/ 
      r2_file = f 
      next 
    end 
  end 
  seq1 = fasta_to_hash(r1_file) 
  seq2 = fasta_to_hash(r2_file) 
  pid_seq1 = {} 
  seq1.each do |k,v| 
      pid = k.split("_")[0][1..-1] 
      pid_seq1[pid] = k 
  end 
  pid_seq2 = {} 
  seq2.each do |k,v| 
      pid = k.split("_")[0][1..-1] 
      pid_seq2[pid] = k 
  end 
 
  pid_seq1.each do |k,v| 
      fwd = seq1[v] 
      rev = seq2[pid_seq2[k]] 
      next unless (fwd and rev) 
      combined_seq = "" 
      if overlap == 0 
        combined_seq = fwd.tr("-","") + rev.tr("-","") 
      elsif fwd[-overlap..-1] == rev[0, overlap] 
        combined_seq = fwd + rev[overlap..-1] 
      else 
        next 
      end 
      out.puts v.gsub(/_r1/, "") 
      out.puts combined_seq 
  end 
  out.close 
end 
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Counting the number of each base at every site 
File name: counts.py (does not need any modification). Script written by Matthew Pauly (Pauly 
et al., 2017b). 
 
import sys 
from collections import Counter 
import re 
 
# Create the empty lists to count nucleotides 
pos=[] 
ref=[] 
cov=[] 
A=[] 
 
T=[] 
 
G=[] 
 
C=[] 
N=[] 
 
with open(sys.argv[1],'r') as pileup: 
    for line in pileup: 
        line = re.split(r'\t+', line) # split at tab 
        pos.append(str(line[1])) # position 
        ref.append(str(line[2])) # Reference base 
        cov.append(str(line[3])) # Coverage 
        counter=Counter(line[4]) # count the occurrence of each character in 
the bases string 
         
        A.append(str(counter['A'])) # how many A's 
       
        T.append(str(counter['T'])) # How many T's 
        
        G.append(str(counter['G'])) 
        
        C.append(str(counter['C'])) 
        N.append(str(counter['N'])) 
         
 
total_positions=len(pos)        #how many positions did we look at 
with open(sys.argv[2],'w') as out: 
    out.write("pos,ref,cov,A,T,G,C,N\n") # Write the header to the out file 
    for i in range(0,total_positions) : 
        
out.write(pos[i]+","+ref[i]+","+cov[i]+","+A[i]+","+T[i]+","+G[i]+","+C[i]+",
"+N[i]+"\n") # write each line to the outfile 
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Counting each type of mutation 
File name: Mutcount_analysis_MHV20814.R. Script written by Matthew Pauly (Pauly et al., 
2017b) and modified by Ben Reisman (Vanderbilt MSTP). Input is the .csv file derived from 
counts.py. 
 
mutcount <- function(A) { 
  n <- nrow(A) 
  con <- matrix(nrow = c(n), ncol = c(1)) 
   
  for (j in 1:n) 
  { 
    if (A[j, 4] > 1000) { 
      con[j, 1] <- c(1) 
    } 
     
    if (A[j, 5] > 1000) { 
      con[j, 1] <- c(2) 
    } 
    if (A[j, 6] > 1000) { 
      con[j, 1] <- c(3) 
    } 
    if (A[j, 7] > 1000) { 
      con[j, 1] <- c(4) 
    } 
  } 
   
  mut <- matrix(c(0), nrow = c(n), ncol = c(12)) 
   
  for (i in 1:n) { 
    if (con[i, 1] == 1) { 
      mut[i, 1] <- A[i, 7] 
      mut[i, 2] <- A[i, 6] 
      mut[i, 3] <- A[i, 5] 
    } 
    if (con[i, 1] == 2) { 
      mut[i, 10] <- A[i, 4] 
      mut[i, 11] <- A[i, 7] 
      mut[i, 12] <- A[i, 6] 
    } 
    if (con[i, 1] == 3) { 
      mut[i, 7] <- A[i, 4] 
      mut[i, 8] <- A[i, 7] 
      mut[i, 9] <- A[i, 5] 
    } 
    if (con[i, 1] == 4) { 
      mut[i, 4] <- A[i, 4] 
      mut[i, 5] <- A[i, 6] 
      mut[i, 6] <- A[i, 5] 
    } 
  } 
   
  mutnam <- 
    c("A2C", 
      "A2G", 
      "A2T", 
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      "C2A", 
      "C2G", 
      "C2T", 
      "G2A", 
      "G2C", 
      "G2T", 
      "T2A", 
      "T2C", 
      "T2G") 
   
  mutations <- matrix(c(0), nrow = c(1), ncol = c(12)) 
   
  colnames(mutations) <- mutnam 
   
  for (i in 1:12) { 
    mutations[1, i] <- sum(mut[, i]) 
  } 
  return(mutations) 
} 
 
 
 
raw_data <- read.csv("Your_file.csv") 
mutcount_output <- mutcount(raw_data) 
mutcount_output 
 
  185 
 
B3. Competitive fitness assay for murine hepatitis virus 
 
Purpose: 
This assay quantifies the competitive fitness of mutant viruses. All experimental viruses are co-
cultured with a reference genome tagged with synonymous mutations, allowing discrimination 
by qPCR. The change in the competitor-to-reference ratio over time reflects their relative fitness. 
Relevant references for this approach (but not necessarily the chemistry) include: 
1. Carrasco P, Daròs JA, Agudelo-Romero P, Elena SF. 2007. A real-time RT-PCR 
assay for quantifying the fitness of tobacco etch virus in competition experiments. 
Journal of Virological Methods 139:181–188. 
2. Visher E, Whitefield SE, McCrone JT, Fitzsimmons W, Lauring AS. 2016. The 
Mutational Robustness of Influenza A Virus. PLoS Pathog 12:e1005856–25. 
3. Fitzsimmons WJ, Woods RJ, McCrone JT, Woodman A, Arnold JJ, Yennawar M, 
Evans R, Cameron CE, Lauring AS. 2018. A speed–fidelity trade-off determines the 
mutation rate and virulence of an RNA virus. PLoS Biol 16:e2006459–20. 
4. Moratorio G, Henningsson R, Barbezange C, Carrau L, Bordería AV, Blanc H, 
Beaucourt S, Poirier EZ, Vallet T, Boussier J, Mounce BC, Fontes M, Vignuzzi M. 
2017. Attenuation of RNA viruses by redirecting their evolution in sequence space. Nat 
Microbiol 2:1–12. 
5. Bordería AV, Isakov O, Moratorio G, Henningsson R, Agüera-González S, 
Organtini L, Gnädig NF, Blanc H, Alcover A, Hafenstein S, Fontes M, Shomron N, 
Vignuzzi M. 2015. Group Selection and Contribution of Minority Variants during Virus 
Adaptation Determines Virus Fitness and Phenotype. PLoS Pathog 11:e1004838. 
 
Reagents and kits: 
1. Sample collection 
a. Complete DMEM 
b. PBS +/+ (containing calcium and magnesium) 
2. RNA extraction: 
a. QIAamp Virus 96 QIAcube HT kit (Qiagen # 57731) 
b. QIAcube HT plasticware (Qiagen # 950067) 
c. Buffer AVL (Qiagen #19073) 
d. cRNA, 1350ug (Qiagen #1017647) 
e. 100% ethanol 
3. RT-qPCR 
a. Nuclease-free water 
b. RNaseZap (Sigma #R2020) 
c. Power SYBR green RNA-to-Ct 1-step kit (ThermoFisher #4389986). 
 
Primer Design: 
The reference genome is tagged with a run of 7 consecutive synonymous substitutions within 
nsp2 (nt 1301-1307 for MHV) that permit selective amplification of the competitor (WT, below) 
and reference viruses. I have designed this for MHV such that the reverse primer (also the 
reverse transcription primer) is the same for both assays, with the forward primer discriminating 
each species. Validation data can be provided upon request. 
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MHV Primers: 
 
SS-WT Assay 
Direction Primer Name Primer Sequence Final [primer] 
Forward SS-qPCR-WT-F CTATGCTGTATACGGATTCGTCC 450 nM 
Reverse SS-qPCR-R2 GGTGTCACCACAACAATCCAC 450 nM 
 
SS-Sil Assay 
Direction Primer Name Primer Sequence Final [primer] 
Forward SS-qPCR-Sil-F CTATGCTGTATACGGACAGCAGT 200 nM 
Reverse SS-qPCR-R2 GGTGTCACCACAACAATCCAC 200 nM 
 
I optimized the concentrations by running a matrix for each assay and primer set, evaluating 
them according to (1) earliest Ct for the target and (2) latest Ct for the opposing target. Data 
available on request. 
 
I prepared and stored the primer sets as mixed aliquots (i.e. both forward and reverse) at 10x 
concentration. For SS-WT, each primer is at 4.5µM; for SS-Sil, each primer is at 2µM. Thus, use 
2µL of primer mix per 20µL reaction. 
 
Viruses: 
I engineered ExoN(+) (i.e. WT) and ExoN(-) viruses containing the synonymous tags that serve 
as the reference. The name “SS” refers to the substitutions at serines—the rest should be self-
explanatory. 
1. SS-XN(+) 
2. SS-XN(-) 
 
Experimental Considerations: 
1. Technical and biological consistency is essential for this assay. This includes all aspects 
of the design and execution, from timing, to pipetting (always with clean tips!), to 
harvesting, to qPCR. 
2. Choice of MOI and well size is important! You’ll be passaging mixtures of viruses – 
essentially, imposing a genetic bottleneck. If your population size is too small, then the 
experimental outcome can be altered by genetic drift. With larger populations, the 
outcome will depend more upon the fitness of individual variants. Thus, we want to 
maintain a “higher” MOI in larger plate. The below conditions have worked well for me: 
a. MOI = 0.1 PFU/cell total (MOI = 0.05 PFU/cell each of competitor and reference. 
b. 12-well plates 
c. Triplicate lineages for each experimental virus (i.e. competitor) 
d. I make sure that all competitors are present on each plate. If £4 viruses, I put them 
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all on one plate. If >4, I do one well per competitor per plate (i.e. 3 plates total). 
This reduces the chance of plate-specific bias. 
3. We could do this assay as a single-passage experiment, in line with some reports in the 
literature. However, in my opinion, performing multiple passages better reflects fitness 
differences over time, while a single-passage is prone to variability based on stock 
quality, input ratio, etc. 
4. Always include an apples-to-apples control. That is, if you’re competing against the SS-
XN(+), always include a wild-type control. For SS-XN(-), the control is MHV-ExoN(-). 
 
Protocol: 
 
Day -1: Prepare warm base for assay plates. 
1. Fill one T150 per experimental plate with dH2O and place in incubator. (Cover the 
mouth with cellophane before capping to block the paper filter). These take a long time to 
warm up. 
2. I usually keep my T150s in the incubator all the time so they’re always ready. 
 
Day 1: Plate cells for the assay  
1. Prepare cells as you normally would for splitting. 
2. Count cells using the Millipore Scepter 2.0 Handheld Automated Cell counter. 
a. Dilute resuspended cells 1:10 in PBS+/+ (100uL cells + 900uL PBS+/+) 
b. Mix well and measure twice, then average the measurements 
3. Dilute cells to 1 x 105 cells/mL in complete DMEM. 
4. Using a repeater pipette (I like the 10mL size for 12-well plates), add 1 mL cells. 
5. Carefully place each plate on its own pre-warmed T150 in the incubator. Note the time – 
you will inoculate with virus exactly 24 hours later. 
6. Prepare for day 2: 
a. Set out and label all sample collection tubes. 
b. Prep your calculations. Note: I inoculate 12-well plates with 400uL of virus. 
  
Day 2: Infection 
1. Several hours before you start, put 50mL conical tubes containing DMEM and PBS+/+ 
into the incubator to warm up. If you’re behind or forget, you can put them in the bead 
bath to get them started (but don’t overdo it, you don’t want them too hot). 
2. Complete these steps on ice: 
a. Place cells on ice 10 minutes before inoculation. 
b. Prepare virus dilutions. 
c. Aspirate medium and inoculate cells with virus. Do this one plate at a time. 
d. Transfer excess inoculum to a 1.5mL Eppendorf tube – this will be the “P0” or 
“input” in the analysis. 
e. Allow virus to adsorb for 30 min on ice. Do not go longer—D9s don’t like the 
cold very much. 
f. Rock once after 15 min. 
3. Transfer plates to their designated T150 in the 37C incubator.  
a. From this point on, do not remove the plates from their T150. 
b. If you want to be super super rigorous, add one plate at a time to the incubator at 
~3-minute intervals. This builds you some buffer time for sample collection later. 
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4. Incubate at 37C for 30 min, rocking once after 15min. 
5. Remove the plates from their incubator, keeping them on their T150s. 
6. Wash once with 1.5 mL warm PBS +/+. 
a. Aspirate supernatant. 
b. Add 1.5mL PBS+/+ 
c. If doing more than one plate, repeat steps a,b for each plate before continuing on. 
7. Aspirate PBS+/+ and add back total 1 mL warm DMEM. (One plate at a time.) 
8. Transfer back to incubator for the indicated time: 
a. SS-XN(+) reference (and WT-like competitors) – 15 hpi 
b. SS-XN(-) reference (and ExoN(-)-like competitiors) – 16 hpi 
9. Set out cells for plaque assay (1.5 x 12-well plate per competitor). 
 
Day 3: Harvest and titer: 
1. Turn on refrigerated centrifuge and cool to 4C. 
2. At harvest time, transfer all 1mL of supernatant to a 1.5mL Eppendorf tube. 
3. Spin samples at 10k x rcf for 5 min at 4C. 
4. Transfer clarified supernatant to your long-term storage tube, then remove 100uL into a 
separate tube. 
5. Freeze the long-term and 100uL aliquots. 
6. At your convenience, thaw 100uL aliquots and start plaque assay. 
a. For SS-XN(+) experiments, I plate dilutions 3-4-5. 
b. For SS-XN(-) experiments, I plate 2-3-4 for P1 and P2, then reduce to 1-2-3 of P3 
and P4. 
7. At your desired time, set out cells in 12-well plates to initiate P2, as described in “Day 1” 
above. 
 
Day 4: Initiate second passage 
1. Fixed plaques, pull plugs, and titer. 
2. For each sample, calculate the volume of inoculum needed to initiate MOI = 0.1 PFU/cell 
infection. Note that we are normalizing the total inoculum. We are not distinguishing the 
competitor and reference in any way during this step. 
3. Follow the steps above for Day 2, with the following modifications: 
a. Instead of doing virus dilutions as we did for passage 1, I aspirate off medium 
right after putting the D9s on ice. 
b. I add the amount of DMEM needed to make up 400uL total volume (volume 
DMEM = 400 -  volume virus). 
c. Note: if volume DMEM < 200, I wait until closer to the inoculation because I 
worry about drying the cells out. 
4. Set out cells for plaque assay (1.5 x 12-well plate per competitor). 
 
Repeat Days 3-4 until you’ve completed 4 passages. You do not need to titer the P4 samples, 
but I do typically set aside the 100uL aliquot just in case I feel I need to continue passage. 
 
 
Day X: RNA extraction 
Because consistency is key for this experiment, I use the QIAcube HT for automated, high-
throughput RNA extraction of all experimental samples simultaneously. I start with 70uL of 
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supernatant per sample, which yields plenty of RNA for qPCR. 
 
 
Steps: 
1. Transfer 70uL of each sample to the S-block in vertical orientation (e.g. A1àH1, 
A2àH2, etc) 
a. 13 total samples per competitor, including: 
i. Input/inoculum/P0 (however you refer to it) 
ii. 12 passaged samples (3 per passage) 
b. If you have empty wells in your last column, add 70uL H2O (the instrument can’t 
handle empty wells). You can leave whole columns unused! 
c. I store the sample tubes on ice while performing this, but I don’t put the S-block 
on ice or in the fridge because the purification chemistry is optimized for room-
temperature solutions. 
2. Turn on instrument and computer. 
3. Launch QIAcube HT Software 
4. Select the “ 
5. Click on the Wizard Hat: 
a. Designate the number of columns being run. 
b. Click Next to go through each of the protocol steps. 
i. Make sure the input volume is 70uL 
ii. Reagent volumes should not need to be changed. 
iii. Set elution volume to 75uL. 
6. Load adapters and plasticware:  
 
a. Riser Block (Right/Elution side of sink) 
b. Channeling block holder and adapter (Left/Waste side of sink.) 
c. Carriage (must be pushed all the way to the LEFT over the LEFT side of the 
sink.) 
d. QIAamp Virus 96 plate (taped off if applicable and pushed all the way to the 
LEFT.) Put film over any wells you’re not using! If you don’t, the vacuum will not 
elute your samples effectively. 
e. Elution plate (Place on the instrument with the lid and leave on until prompted 
during pre-run checklist to remove.  Plate must be pushed all the way to the LEFT 
to elute properly.) 
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f. Tips (with lids on until prompted during pre-run checklist to remove.)  
i. To reset number of tips: 
1. Right click over a tip position. 
2. Then select one of the options depending on what you are loading. 
 
7. Load all buffers  
a. AW1 
b. AW2 
c. AVE 
d. 100% Ethanol 
e. cRNA mix: 
i. Dissolve lyophilized pellet in Buffer AVE.  
1. Two sizes of cRNA: 310ug and 1350ug 
a. 310uL AVE to 310ug 
b. 1350uL AVE to 1350ug 
ii. Add cRNA+AVE to buffer AVL according to below: 
 
 
8. Gently Load the lysates into the B1 position. 
9. Press “Play.” 
10. At the end of the run: 
a. Remove elution plate and cover with lid. 
b. Remove and discard the QIAamp 96 plate (unused columns can be saved and 
used later) and any empty tip racks. 
c. Removing only the channeling block adapter (not the holder) from the waste sink 
and either swap for clean one or clean the one removed using DI water to rinse 
followed by 70% ethanol and allow to dry before next use.) 
d. Trough re-use instructions: 
i. Troughs without salts, AW2, AVE, cRNA mix, and 100% EtOH can have 
their residual volume used in place of the 20ml of water requested in the 
waste pail menu for flushing the sink.  Once empty, they can be placed 
upside down on a paper towel until needed again. 
ii. Troughs with salts or enzyme will need to have their residual volume 
disposed of via your Health and Safety regulations.  Once empty, they 
should be rinsed well, ~3 times, with diH2O and then placed upside down 
on a paper towel until needed again. 
11. When you close the software, it will automatically prompt a clean-up protocol. Follow 
the instructions, and add the UV step. 
12. Spin down elution tubes in their plate briefly to bring total volume to the bottom. 
13. Transfer eluted RNA to long-term storage tubes until ready for qPCR. 
 
Day X: RT-qPCR 
 
1. Dilute RNA: 
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a. Select your dilution according to the expected RNA content of reactions so that 
you stay within a linear range (for me, I shoot for Ct between 15-25). In my 
opinion, there’s no need to normalize the RNA content across all samples – the 
relevant output is the ratio between tagged and untagged templates in a given 
sample, which should not vary with RNA amount. 
b. For MHV samples, I use these calculations: 
i. SS-XN(+) and WT-like competitors: 
1. P0 RNA 1:10 (4uL RNA + 36uL H2O) 
2. P1-4 RNA 1:100 (2uL RNA + 198uL H2O 
ii. SS-XN(-) and ExoN(-)-like competitors: 
1. P0 RNA 1:10 (4uL RNA + 36uL H2O) 
2. P1-4 RNA 1:10 (4uL RNA + 36uL H2O) 
2. Prepare master mix (same calculations for both SS-WT and SS-Sil assays). Makes 
enough for one plate. 
Reagent 1x (µL) 32x (µL) 
Primer Mix (10x) 2 64 
RT (125x) 0.16 5.12 
2X Power SYBR 10 320 
Total 12.16 per rxn 
3. Add 12.16 uL master mix to wells first. 
4. Add 7.84uL diluted RNA per well.  
5. Cover plate with an optical film; make sure it’s well sealed so that liquid doesn’t escape 
and skew your results. 
6. Spin briefly with the plate centrifuge before loading into the StepOne Plus. 
 
Thermocycling conditions: 
1. 48C 30min 
2. 95C 10min 
3. 95C 15sec 
4. 60C 1min 
5. To (3) x 39 
6. Melt curve 
 
 
  192 
 
 
Data analysis workflow 
This assay assumes that fitness differences between variants are fixed. With fixed fitness 
differences, the proportion of each competitor should change by the same factor with every 
passage under identical conditions. (This is a big reason that consistency is so critical 
technically). Thus, the relative fitness describes the rate of change in the proportions of 
competitor and reference over time. 
 
The general workflow of the analysis is: 
1. Determine the ratio of competitor (SS-WT assay) relative to reference (SS-Sil assay) in 
each sample. This is performed exactly as though you were measuring MHV genome 
content relative to GAPDH. 
2. Plot those ratios over time. 
3. The rate in change of ratio (slope of a linear regression) is related to the relative fitness. 
4. Normalize all relative fitness values to the mean of the control (wild-type or MHV-
ExoN(-)). 
 
Note that this yields indirect comparisons of fitness between experimental viruses. That is, 
instead of direct competition between virus A and virus B, the comparisons will be “fitness of 
virus A relative to reference 1” vs “fitness of virus B relative to reference 1.” 
 
Detailed data analysis 
1. Average the Ct values for each assay in each sample. 
2. Calculate DCtcompetitor 
a. DCtcompetitor = Ctcompetitor - Ctreference. 
3. Calculate Dratiocompetitor  
a. PCR doubles DNA content in each cycle, so each Ct represents a 2-fold change. 
So if DCt = 2, Dratio = 22 = 4; DCt = 5, Dratio = 25 = 32) 
b. Dratiocompetitor = 2DCt-competitor 
 
4. Convert to the Dlog10ratiocompetitor 
a. Converting to the log10 allows use of linear regressions in the next step. 
b. Dlog10ratiocompetitor = log10(Dratiocompetitor) 
5. Plot Dlog10ratiocompetitor for each replicate against passage number 
a. Plot each lineage (i.e. replicate passage) separately for the purposes of your 
calculations. The below example shows a table with 2 viruses (AA and AD) with 
3 replicates each. 
b. I often leave out the P0 RNA from analysis because: 
i. It’s not necessary, and input ratio may not be exact depending on the 
quality of each stock. In subsequent passages, the samples will have been 
treated identically, so they are easier to compare. 
ii. Including it tends to skew the linear regressions. 
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c. You can also plot as mean ± SD (that is, a column for each virus with 3 
subcolumns representing individual replicates) to get a sense of how consistent 
your results are. However, if you try to take the relative fitness based on all the 
data at once, you won’t be able to perform useful statistical tests. Below example 
is the same data as above but formatted to plot as mean ± SD 
 
 
d. NOTE: The exact values of log10ratio are not important to interpretation. What 
matters is the slope of the linear regression! 
 
6. Perform linear regression on each individual lineage. 
a. You will not need to change analysis parameters in Prism. 
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b. The regression will automatically report whether the slope is statistically 
significant from zero. This sounds exciting but really doesn’t matter. All relative 
fitness values will be normalized to control, and the relevant comparison is 
between the normalized viral fitnesses. 
 
7. Using the calculated slope, convert to relative fitness and plot. 
a. Relative fitness = 10slope 
 
8.  Normalize the relative fitness values to the mean of control. 
a. Easiest way to do this is to first plot the raw relative fitness values in Prism: 
 
b. Then, take the mean of your control (in this case, AA) and use it to normalize all 
your data (including the control). 
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9. Statistics: 
a. If your experiment is n = 3, use nonparametric tests. 
i. 2 viruses: Mann-Whitney test 
ii. 3+ viruses: 
1. Kruskal-Wallis test 
2. Perform multiple comparisons (that is, compare each experimental 
virus to your control) 
b. If your experiment is n ³ 6, you can use parametric tests: 
i. 2 viruses: student’s t test 
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ii. 3+ viruses: 
1. One-way ANOVA 
2. Perform multiple comparisons (that is, compare each experimental 
virus to your control) 
 
10. Celebrate, then interpret data! 
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Proofreading-Deficient Coronaviruses
Adapt for Increased Fitness over Long-
Term Passage without Reversion of
Exoribonuclease-Inactivating Mutations
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ABSTRACT The coronavirus (CoV) RNA genome is the largest among the single-
stranded positive-sense RNA viruses. CoVs encode a proofreading 3=-to-5= exoribonu-
clease within nonstructural protein 14 (nsp14-ExoN) that is responsible for CoV high-
fidelity replication. Alanine substitution of ExoN catalytic residues [ExoN(-)] in severe
acute respiratory syndrome-associated coronavirus (SARS-CoV) and murine hepatitis
virus (MHV) disrupts ExoN activity, yielding viable mutant viruses with defective rep-
lication, up to 20-fold-decreased fidelity, and increased susceptibility to nucleoside
analogues. To test the stability of the ExoN(-) genotype and phenotype, we pas-
saged MHV-ExoN(-) 250 times in cultured cells (P250), in parallel with wild-type
MHV (WT-MHV). Compared to MHV-ExoN(-) P3, MHV-ExoN(-) P250 demonstrated
enhanced replication and increased competitive fitness without reversion at the
ExoN(-) active site. Furthermore, MHV-ExoN(-) P250 was less susceptible than
MHV-ExoN(-) P3 to multiple nucleoside analogues, suggesting that MHV-ExoN(-)
was under selection for increased replication fidelity. We subsequently identified
novel amino acid changes within the RNA-dependent RNA polymerase and
nsp14 of MHV-ExoN(-) P250 that partially accounted for the reduced susceptibil-
ity to nucleoside analogues. Our results suggest that increased replication fidelity
is selected in ExoN(-) CoVs and that there may be a significant barrier to ExoN(-)
reversion. These results also support the hypothesis that high-fidelity replication
is linked to CoV fitness and indicate that multiple replicase proteins could com-
pensate for ExoN functions during replication.
IMPORTANCE Uniquely among RNA viruses, CoVs encode a proofreading exoribo-
nuclease (ExoN) in nsp14 that mediates high-fidelity RNA genome replication.
Proofreading-deficient CoVs with disrupted ExoN activity [ExoN(-)] either are nonvia-
ble or have significant defects in replication, RNA synthesis, fidelity, fitness, and viru-
lence. In this study, we showed that ExoN(-) murine hepatitis virus can adapt during
long-term passage for increased replication and fitness without reverting the ExoN-
inactivating mutations. Passage-adapted ExoN(-) mutants also demonstrate increas-
ing resistance to nucleoside analogues that is explained only partially by secondary
mutations in nsp12 and nsp14. These data suggest that enhanced resistance to nu-
cleoside analogues is mediated by the interplay of multiple replicase proteins and
support the proposed link between CoV fidelity and fitness.
KEYWORDS RNA virus, adaptive evolution, competitive fitness, coronavirus,
exoribonuclease, plus-strand RNA virus, proofreading, replication fidelity
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A paradigm of RNA virus biology is error-prone genomic replication due to the lackof proofreading or postreplicative RNA repair mechanisms (1–3). Decreased repli-
cation fidelity may constrain RNA genome size and complexity and risks the accumu-
lation of deleterious mutations leading to population extinction (4–7). While genetic
diversity allows viral populations to adapt rapidly under selective pressure, many
mutations are neutral or detrimental to viral fitness (8–12). Research performed with
many RNA viruses supports the hypothesis that the mutation rate of RNA virus
replicases has evolved to balance multiple characteristics of the viral population such
as genetic diversity, genomic integrity, and virulence. High- or low-fidelity variants are
described for many RNA viruses infecting animals, including the coronaviruses (CoVs)
murine hepatitis virus (MHV-A59) and severe acute respiratory syndrome-associated
coronavirus (SARS-CoV) (13–17), as well as foot-and-mouth disease virus (18–22),
poliovirus (23–29), Chikungunya virus (30, 31), influenza virus (32), coxsackievirus B3
(33, 34), and human enterovirus 71 (35–37). Most altered-fidelity variants described to
date harbor mutations within the viral RNA-dependent RNA polymerase (RdRp), are
attenuated in vivo, and protect against reinfection, highlighting their potential utility as
live attenuated vaccines (24, 28, 29, 38, 39). Those studies underscored the importance
of understanding the molecular mechanisms by which RNA viruses regulate their
replication fidelity.
Viruses in the Coronavirinae subfamily have large single-stranded positive-sense
RNA genomes [(!)ssRNA] (40), ranging between 26 and 32 kb in length (41). CoVs
encode a 3=-to-5= exoribonuclease (ExoN) in the N-terminal half of nonstructural protein
14 (nsp14-ExoN) (42, 43). CoV ExoN activity depends on conserved magnesium-
coordinating acidic amino acids in three motifs (DE-E-D) that together constitute the
active site (Fig. 1) (44). The CoV ExoN is grouped with the DE-D-Dh superfamily of
exonucleases involved in proofreading during prokaryotic and eukaryotic DNA repli-
cation (42–46). Alanine substitution of CoV motif I DE residues (DE-to-AA) reduces
biochemical ExoN activity in SARS-CoV (44, 46) and human coronavirus 229E (42).
MHV-A59 and SARS-CoV lacking ExoN activity [ExoN(-)] have mutation frequencies
8-fold to 20-fold greater than are seen with WT viruses and are highly susceptible to the
activity of nucleoside analogues (13–17, 38). Thus, all available data to date support the
hypothesis that nsp14-ExoN is the first known proofreading enzyme encoded by an
RNA virus.
Despite the critical role of ExoN in virus replication, fidelity, fitness, and virulence,
reversion of the ExoN-inactiviting substitutions (Fig. 1) has not been detected following
20 passages in culture, 8 acute passages of SARS-CoV-ExoN(-) in aged BALB/c mice, and
60 days of persistent SARS-CoV-ExoN(-) infection in immunodeficient Rag"/" mice (13,
14, 16, 17, 38). In this study, we sought to determine whether long-term passage of
MHV-A59-ExoN(-) (250 passages over 1 year [P250])—here MHV-ExoN(-)—would result
in virus extinction, ExoN(-) reversion, or compensation for the loss of proofreading. We
demonstrate that MHV-ExoN(-) did not extinguish during passage and adapted for
increased replication. MHV-ExoN(-) concurrently evolved reduced susceptibility to mul-
tiple nucleoside and base analogues, consistent with selection for increased replication
fidelity. Importantly, the ExoN-inactivating substitutions did not revert. The evolved
mutations in MHV-ExoN(-) nsp14 and nsp12, which encodes the RdRp, accounted for
only part of the increased nucleoside analogue resistance of MHV-ExoN(-) P250, impli-
cating multiple replicase proteins in adaptation for viral fitness. The results of this study
support the proposed link between CoV fidelity and fitness, demonstrate the surprising
stability of the ExoN-inactivating substitutions, and identify additional proteins outside
nsp12 and nsp14 that may contribute to CoV fidelity regulation.
RESULTS
Long-term passage of WT-MHV and MHV-ExoN(-). We serially passaged WT-MHV
and MHV-ExoN(-) in delayed brain tumor (DBT) cells 250 times (P250). Virus from each
passage was harvested once 50% to 100% of the monolayer was involved in syncytia,
which occurred between 8 and 24 hours postinfection (hpi). Passage conditions varied
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for WT-MHV and MHV-ExoN(-) due to differences in replication kinetics between the
two viruses. We stopped passage at P250 after observing reduced syncytium formation
in MHV-ExoN(-)-infected flasks, likely resulting from a mutation in the MHV-ExoN(-) P250
spike protein cleavage site (discussed below).
MHV-ExoN(-) and WT-MHV replicate with identical kinetics following 250 pas-
sages.MHV-ExoN(-) has a significant replication defect relative to WT-MHV (14). We first
tested whether replication of MHV-ExoN(-) P250 was affected by long-term passage by
examining replication at two different multiplicities of infection (MOI). At both MOI !
1 and MOI ! 0.01 PFU/cell, MHV-ExoN(-) P3 replication was delayed by ~2 h and the
peak titer was reduced by ~1 log10 relative to WT-MHV P3 (Fig. 2A and B), consistent
with our previous studies (14). By P250, the two viruses replicated with identical kinetics
(Fig. 2A and B, dotted lines). This represented an ~1 log10 increase in peak replication
for WT-MHV and an ~2 log10 increase for MHV-ExoN(-), compared with the respective
parental viruses. At MOI ! 0.01 PFU/cell, we also measured replication of MHV-ExoN(-)
at P10, P50, P100, and P160. Replication kinetics gradually increased during the
passages, reaching P250-like levels by P100 (Fig. 2B). To determine whether the
FIG 1 MHV genome organization and nsp14 exoribonuclease motifs. (Top) The MHV genome is a
31.4-kb, capped (dark circle), and polyadenylated positive-sense RNA molecule. The first two-thirds of the
genome encode 16 nonstructural proteins translated as a single polyprotein with a ribosomal frameshift.
The final one-third encodes the structural and accessory proteins. (Inset) Nsp14 encodes an exoribonu-
clease (solid blue) and an N7-methyltransferase (hatched blue) and has 3 zinc fingers (gray boxes)
predicted from the solved SARS nsp10/14 crystal structure (PDB 5C8U) (44). Catalytic residues for ExoN
are marked with white boxes, and the engineered mutations for MHV-ExoN(-) are shown below the
genome. The nsp12 RNA-dependent RNA polymerase is highlighted in red.
FIG 2 MHV-ExoN(-) evolved increased replicative capacity over long-term passage. Replication kinetics were examined for the indicated
viruses at MOI ! 1 PFU/cell (A) and MOI ! 0.01 PFU/cell (B). (C) Replication kinetics of plaque-purified WT-MHV P250 and MHV-ExoN(-)
P250 in parallel with the full population (MOI! 0.01 PFU/cell). Supernatants were collected at the indicated times postinfection, and titers
were determined by plaque assay. Data for panels A to C represent means and standard deviations of data from n ! 3.
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increased replication of MHV-ExoN(-) P250 was affected by the presence of potential
defective viral genomes or by some other population-based phenomenon, both WT-
MHV P250 and MHV-ExoN(-) P250 were plaque purified three times. The plaque-purified
viruses replicated indistinguishably from the parent populations (Fig. 2C). Together,
these data demonstrate that WT-MHV and MHV-ExoN(-) populations had adapted for
increased replication and that either individual genomes or those derived from a single
virus plaque encoded the adaptive changes required by the total population.
MHV-ExoN(-) accumulated 8-fold-more mutations than WT-MHV but did not
revert ExoN-inactivating substitutions. To determine whether the increased replica-
tion of MHV-ExoN(-) P250 resulted from primary reversion of ExoN(-) motif I, we
sequenced nsp14 from infected-cell total RNA. MHV-ExoN(-) P250 retained the motif I
DE-to-AA substitutions, demonstrating that primary reversion of ExoN(-) motif I did not
occur. To identify potentially adaptive consensus mutations, we performed full-genome
di-deoxy sequencing of MHV-ExoN(-) P250 and WT-MHV P250. Within WT-MHV P250,
we identified 23 mutations, of which 17 were nonsynonymous (NS) (Fig. 3A). In contrast,
MHV-ExoN(-) P250 had 171 total mutations (74 NS) (Fig. 3B). The full-genome sequences
have been deposited in GenBank, and the mutations for both viruses are listed in
Tables S1 and S2 in the supplemental material. We identified only one mutation shared
by both viruses (nsp1 A146T), though it was present in approximately 50% of the
FIG 3 Mutations within P250 viruses. The mutations shown were present at !50% by di-deoxy sequencing at passage 250 in WT-MHV
(A) and MHV-ExoN(-) (B). Nonsynonymous mutations (red), noncoding mutations (cyan), and deletions (green boxes) are plotted above
the schematic, and synonymous mutations (purple) are plotted below the schematic.
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WT-MHV P250 population by di-deoxy sequencing. Both viruses deleted most of the
hemagglutinin esterase (HE). In MHV-A59, HE mRNA is not transcribed in vitro (47–49),
and HE protein expression is detrimental to MHV-A59 fitness in cell culture (50).
WT-MHV P250 also deleted open reading frame 4a (ORF4a), which is dispensable for
MHV replication in cell culture (51). The C-terminal region of ns2 within MHV-ExoN(-)
P250 was truncated and fused to HE with a !1 frameshift. Ns2 is a phosphodiesterase
(PDE) that protects viral RNA by degrading 2=-to-5= oligoadenylate, the activating factor
for cellular RNase L (52–54). The portion of ns2 deleted in MHV-ExoN(-) P250 lies outside
the PDE catalytic domain, in a region of unknown function. C-terminally truncated ns2
retains enzymatic activity (55), but whether these specific deletions and fusions disrupt
PDE activity remains to be tested. Nevertheless, ns2 is dispensable for MHV replication
in immortalized cells (56, 57). Details about the deletion sites are provided in Fig. S1 in
the supplemental material. Within proteins predicted to be part of the replicase-
transcriptase complex (nsp7-16 and nucleocapsid) (39), WT-MHV P250 had only one NS
change, located in the nsp13-helicase (Fig. 3A and Table S1). In contrast, MHV-ExoN(-)
P250 had 17 NS changes within this region (Fig. 3B and Table S2).
MHV-ExoN(-) P250 displays increased genomic RNA accumulation and in-
creased resistance to 5-fluorouracil. Coronaviruses lacking ExoN consistently display
defects in RNA synthesis relative to WT strains (14, 16, 42). To determine whether the
increased replication of MHV-ExoN(-) P250 was associated with restored genomic RNA
(gRNA) production, we measured gRNA accumulation over time using two-step real-
time quantitative PCR (15, 16). MHV-ExoN(-) P250 accumulated levels of gRNA similar to
those accumulated by WT-MHV P3 and WT-MHV P250 at early time points, while gRNA
levels for MHV-ExoN(-) P3 were ~1 log10 lower (Fig. 4A). MHV-ExoN(-) P250 gRNA levels
fell below those of WT-MHV and WT-MHV P250 after 8 h and were similar to those of
MHV-ExoN(-) P3 at 10 hpi. Normalizing to the gRNA abundance at 4 h for each virus
demonstrated that the rates of gRNA accumulation were similar for all four viruses
(Fig. 4B). These data suggest that the increased replication of P250 viruses relative to
WT-MHV is not fully accounted for by increased RNA synthesis. In addition to RNA
synthesis defects, ExoN(-) CoVs have up to 20-fold-increased mutation frequencies and
profoundly increased sensitivity to nucleoside and base analogues relative to WT CoVs
(13, 14, 16, 17, 38). To determine whether the nucleoside analogue sensitivity of
MHV-ExoN(-) was altered by long-term passage, we treated cells infected with parental
and passaged viruses with the base analog, 5-fluorouracil (5-FU). 5-FU is converted
intracellularly into a nucleoside analogue that incorporates into growing RNA strands
and causes A:G and U:C mutations. For simplicity, we will hereafter refer to 5-FU as a
nucleoside analogue. Incorporation of 5-FU is increased in the absence of ExoN activity
(16). All viruses displayed a concentration-dependent decrease in viral titer but differed
greatly in their levels of susceptibility to 5-FU (Fig. 4C). At 120 !M, WT-MHV P3 titers
were reduced by ~1 log10, while MHV-ExoN(-) P3 titers were undetectable ("5 log10-
fold reduction). WT-MHV 5-FU sensitivity was not altered by passage. MHV-ExoN(-) P250
was less susceptible than MHV-ExoN(-) P3 to 5-FU treatment, with a decrease in titer of
only ~1.5 log10 at 120 !M. MHV-ExoN(-) P250 remained more sensitive to 5-FU than
WT-MHV, suggesting that WT-like resistance requires an intact ExoN. These data
demonstrate that MHV-ExoN(-) P3 evolved resistance to 5-FU through mutations
outside ExoN(-) motif I.
Spike mutations in MHV-ExoN(-) P250 do not increase resistance to 5-FU.
Bacteriophage "X174 acquired resistance to 5-FU by delaying cell lysis, thereby reduc-
ing the number of replication cycles in which 5-FU can be incorporated (58). MHV-
ExoN(-) P250 had multiple mutations in the spike glycoprotein, including one in the
spike furin cleavage site that reduced syncytium formation. To test whether the spike
mutations manifested in resistance to 5-FU, we cloned the spike gene from MHV-
ExoN(-) P250 into the isogenic MHV-ExoN(-) background. The recombinant virus dem-
onstrated intermediate replication kinetics between MHV-ExoN(-) P3 and MHV-ExoN(-)
P250 (Fig. 5A) and did not form syncytia. Spike-P250 also increased the specific
infectivity of viral particles (Fig. 5B). However, the MHV-ExoN(-) P250 spike did not affect
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the sensitivity of the recombinant virus to 5-FU (Fig. 5C). Thus, any adaptive increase in
5-FU resistance must be located elsewhere in the genome.
MHV-ExoN(-) passage resulted in unique mutations in nsp12 and nsp14. To
date, three proteins have been shown to alter CoV sensitivity to 5-FU: nsp12-RdRp,
nsp14-ExoN, and nsp10 (which stimulates ExoN activity) (15, 17, 39). Neither WT-MHV
nor MHV-ExoN(-) P250 contained an NS mutation in nsp10, and WT-MHV P250 had no
mutations within either nsp12 or nsp14. In contrast, MHV-ExoN(-) P250 had 7 NS
mutations in nsp12 and 6 NS mutations in nsp14 (Fig. 3 and 6), none of which have
been described previously in vitro or in viable viruses. Within nsp12, six mutations were
in the predicted RdRp finger, palm, and thumb domains (Fig. 6A) (59). Four residues
(H709, F766, S776, and M814) can be visualized on a Phyre2-modeled structure of the
MHV-nsp12 RdRp, while the remaining residues lie outside the modeled core RdRp
(Fig. 6A) (17). One mutation, M288T, lies in the CoV-specific domain, which is conserved
among nidoviruses. This domain has been implicated in membrane targeting in
MHV-A59 (60) and performs an essential nucleotidylation activity in the Arterivirus
equine arteritis virus (61). However, M288T is not predicted to catalyze nucleotidylation.
Within nsp14, 4 NS mutations were identified in the ExoN domain, and 2 NS mutations
were in the C-terminal N7-methyltransferase domain (Fig. 6B). We next modeled the
structure of MHV nsp14 using Phyre2 software (62), resulting in highest-probability
similarity to the SARS-CoV nsp14-nsp10 complex (PDB 5C8S) (44) with high confidence
(i.e., the calculated probability of true homology between the structures) of 100% for
FIG 4 MHV-ExoN(-) evolved WT-like genomic RNA accumulation and increased resistance to multiple nucleoside analogues
over the passage. (A) Cells were infected with the indicated viruses at MOI ! 1 PFU/cell, and intracellular RNA was harvested
using TRIzol at the indicated times postinfection. MHV genomic RNA was detected using SYBR green and primers directed to
nsp10, and values were normalized to intracellular GAPDH. (B) Same data as in panel A normalized to the RNA level for each
virus at 4 hpi. Data represent means and standard errors of results for n ! 9 (3 triplicate experiments). (C to F) Sensitivity of
passaged viruses to nucleoside analogues at MOI! 0.01 PFU/cell. Cells were treated with the indicated concentrations of 5-FU
(C), RBV (D), AZC (E), or CMeA (F) for 30 min prior to infection, supernatants were harvested at 24 hpi, and titers were
determined by plaque assay. Data represent changes in titer relative to untreated control results and are plotted as means and
standard errors of results from n ! 6 (two triplicate experiments). For panels C to F, the statistical significance of changes in
the titer of MHV-ExoN(-) P3 relative to MHV-ExoN(-) P250 was determined using the Mann-Whitney test (*, P " 0.05; **, P "
0.01; ***, P " 0.001).
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residues 3 to 519 of MHV-nsp14. The model predicts that five mutations are located
close to surface of the protein (Fig. 6B). All three modeled zinc finger domains contain
one NS mutation (F216Y, Y248H, and L473I). Two mutations, D128E and F216Y, are
located near the interface between nsp10 and nsp14, though neither site has previ-
ously been implicated in nsp10-nsp14 interactions (15, 63, 64). One NS mutation
resulted in a D272E substitution in ExoN motif III, a metal-coordinating active site
residue. We previously reported that alanine substitution of D272 results in an ExoN(-)
phenotype (14), but the viability or phenotype of a D272E substitution was not tested
in that study. These data suggest that a network of residues evolved to regulate nsp12
and nsp14 activity or stability in the ExoN(-) background.
Fixed mutations in nsp12 and nsp14 in MHV-ExoN(-) P250 directly correlate
with increased resistance to multiple nucleoside analogues. To determine approx-
imately when the mutations in nsp12 and nsp14 arose, we performed di-deoxy
sequencing across these protein-coding regions roughly every 20 passages (P10, P31,
P50, P72, P90, P100, P120, P140, P160, P180, P200, P220, and 240). By this method, we
detected consensus NS mutations at P10, P50, and P160 for nsp12 and at P50 and P160
for nsp14 (Fig. 6). Both nsp12 and nsp14 carried their full complement of P250
consensus mutations by P160, except for a minority variant (D913E) in nsp12 that was
maintained at !50% of the population between P200 and P250. These passage levels
correlated with increased replication of MHV-ExoN(-) (Fig. 2B) and with decreasing
sensitivity to 5-FU (Fig. 4C). Neither replication nor 5-FU sensitivity of MHV-ExoN(-)
changed substantially between P160 and P250. To determine whether MHV-ExoN(-)
FIG 5 Mutations in the spike envelope protein from MHV-ExoN(-) P250 increase replicative capacity but
do not affect sensitivity to 5-fluorouracil. (A) Replication kinetics of indicated viruses (MOI " 0.01 PFU/
cell) plotted as means and standard deviations of results determined with n " 3. (B) Specific infectivity
of indicated viruses 12 hpi (MOI " 1 PFU/cell). Data represent means and standard errors of results from
n " 6 (two triplicate experiments). (C) Sensitivity of indicated viruses to 5-fluorouracil at MOI "
0.01 PFU/cell, determined as described for Fig. 4. Data represent means and standard errors of results
from n " 6 (two triplicate experiments). For panel B, the statistical significance was determined using
one-way analysis of variance (ANOVA). For panel C, the statistical significance of changes in the titer of
MHV-ExoN(-) spike-P250 relative to MHV-ExoN(-) P3 was determined using the Mann-Whitney test (*,
P ! 0.05; **, P ! 0.01; ***, P ! 0.001; ns, not significant).
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evolved increased resistance to multiple nucleoside analogues, we treated virus-
infected cells with three additional analogues that are substrates for viral RdRps:
ribavirin (RBV), a guanine analogue that inhibits viral replication through multiple
mechanisms, including mutagenesis and inhibition of purine biosynthesis (65);
5-azacytidine (AZC), an RNA mutagen (66); and 2=-C-methyladenosine (CMeA), which is
proposed to incorporate in viral RNA and terminate nascent transcripts (67). As with
5-FU, we observed dose-dependent sensitivity to RBV, AZC, and CMeA in all MHV-
ExoN(-) viruses that decreased with increasing passage number (Fig. 4D to F). Except for
AZC, MHV-ExoN(-) sensitivity did not change between P160 and P250. Together, these
data demonstrate that MHV-ExoN(-) evolved increased resistance to multiple nucleo-
side analogues that correlated with the length of passage and the acquisition of
mutations in nsp12 and nsp14. Importantly, this occurred in the absence of specific
mutagenic selection and without reversion of ExoN motif I. This increased general
selectivity toward all four classes of nucleotide strongly supports the idea of an overall
increase in fidelity in MHV-ExoN(-) P250.
Mutations in nsp12 partially account for increased resistance of MHV-ExoN(-)
P250 to multiple nucleoside analogues. We hypothesized that mutations in MHV-
ExoN(-) P250 nsp12 and nsp14 were most likely to impact replication and nucleoside
analogue sensitivity based on their enzymatic activities and temporal association with
phenotypic changes. To test this hypothesis, we engineered recombinant MHV-ExoN(-)
to encode the P250 nsp12 and nsp14 sequences, alone and together. Expression of
nsp12-P250 and nsp14-P250, alone or in combination, altered replication kinetics of
MHV-ExoN(-) without affecting peak titers (Fig. 7A) and increased gRNA levels above
those of MHV-ExoN(-) P3 (Fig. 7B). Nsp12-P250 had a greater effect than nsp14-P250 on
FIG 6 The timing of fixation of mutations in nsp12-RdRp and nsp14-ExoN within MHV-ExoN(-). (A) A schematic of nsp12-RdRp
with the CoV-specific region and the canonical finger, palm, and thumb domains of RdRps is shown. The nsp12-RdRp coding
region was sequenced at the indicated passage, and the nonsynonymous changes are plotted; gray boxes indicate consensus
changes, and hatched boxes indicate variants shown to be present in !50% of the population by di-deoxy sequencing. At
right, mutations are marked in orange on a Phyre2-modeled structure of MHV-nsp12, with the active site residues marked in
yellow (17). RdRp domains are colored according to the linear schematic. M288T, L376P, and D913E lie outside the modeled
region and thus are not marked. (B) A schematic of nsp14 with the ExoN and N7-methyltransferase domains is shown, with
mutation plotting depicted as described for panel A. The black box denotes a mutation to ExoN motif III. At right, mutations
are marked in orange on a Phyre2-modeled structure of MHV-nsp14. Domains are colored according to the linear schematic.
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the sensitivity of MHV-ExoN(-) to all analogues tested, and the combination of nsp12-
and nsp14-P250 did not increase resistance above that seen with nsp12-P250 alone
(Fig. 7C to E). None of the recombinant viruses recapitulated the resistance phenotypes
of the MHV-ExoN(-) P250 population. Together, these data demonstrate that nsp12-
P250 mutations account only partially for the nucleoside analogue resistance of MHV-
ExoN(-) P250 and that adaptations in nsp12-P250 mask those in nsp14-P250. We also
can conclude that the nsp14-P250 D272E active site mutation does not correct the
defect caused by the motif I DE-to-AA substitutions.
Resistance to nucleoside analogues correlates with MHV-ExoN(-) fitness. We
hypothesized that mutations in nsp12 and nsp14 provided a fitness advantage to
MHV-ExoN(-) P250. We competed the recombinant viruses with a reference MHV-
ExoN(-) virus (P1 stock) containing 10 silent mutations in the nsp2 coding region.
Mutant and reference viruses were detected in the mixed infection by real-time
quantitative PCR using dually labeled probes specific for each virus. MHV-ExoN(-) P3
showed a modest fitness advantage over the reference P1 MHV-ExoN(-) silent strain
(Fig. 7F, solid green). MHV-ExoN(-) P250 profoundly outcompeted MHV-ExoN(-) silent,
with !1,000-fold more MHV-ExoN(-) P250 genomes present at the end of passage 1
(Fig. 7F, dotted green line). MHV-ExoN(-) nsp12-P250 had greater relative fitness than
MHV-ExoN(-) nsp14-P250, and MHV-ExoN(-) nsp12/14-P250 was intermediate between
the single recombinants, implicating a complex evolutionary interaction between these
two proteins. The measured fitness correlated with the patterns of nucleoside analogue
FIG 7 Mutations in nsp12-RdRp and nsp14-ExoN from MHV-ExoN(-) P250 incompletely increase resistance to nucleoside analogues and increase fitness of
MHV-ExoN(-). (A) Replication kinetics of recombinant P250 viruses (MOI " 0.01 PFU/cell) plotted as means and standard deviations of results determined with
n " 3. (B) Genomic RNA accumulation relative to intracellular GAPDH determined as described for Fig. 4. Data represent means and standard errors of results
for n " 6 to 9 (2 to 3 triplicate experiments). (C to E) Sensitivity of recombinant MHV-ExoN(-) viruses to 5-FU (C), ribavirin (D), and 5-azacytidine (E) at MOI "
0.01 PFU/cell determined as described for Fig. 4. Data represent means and standard errors of results from n " 6. (F) Recombinant viruses were competed
against a reference MHV-ExoN(-) containing 10 silent mutations within nsp2. The ratio of competitor to reference genomes is plotted. Data represent means
and standard errors of results from n " 6. The MHV-ExoN(-) P250 data set contained 4 replicates at passage 3 and a single replicate at passage 4 due to
undetectable levels of MHV-ExoN(-) (silent). For panels C to E, the statistical significance of changes in the titer of swapped viruses relative to MHV-ExoN(-) P3
at the highest drug concentration tolerated was determined using the Mann-Whitney test (*, P # 0.05; **, P # 0.01; ***, P # 0.001; ns, not significant). For panel
F, the statistical significance for the indicated comparisons was determined using the Mann-Whitney test. Boxed points have the same P value.
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resistance and RNA synthesis associated with mutations in nsp12 and nsp14, suggest-
ing a link between the evolutions of these phenotypes. The result also confirms that
nsp12 and nsp14 are important but not sufficient to account for the significantly
increased fitness of MHV-ExoN(-) P250 relative to MHV-ExoN(-) P3.
DISCUSSION
In this report, we describe experimental adaptive evolution of WT-MHV and MHV-
ExoN(-) during long-term passage in cell culture. WT-MHV evolved increased replication
kinetics over 250 passages, with few consensus mutations arising in the WT-MHV P250
genome. In contrast, MHV-ExoN(-) accumulated 8-fold-more mutations than WT-MHV,
none of which occurred at the ExoN-inactivating substitutions. Nevertheless, MHV-
ExoN(-) P250 demonstrated increased replication kinetics and fitness compared to
MHV-ExoN(-) P3 (Fig. 2 and 7). Our previous studies demonstrated that ExoN-mediated
proofreading is required for CoV fitness (16, 17, 38). Thus, MHV-ExoN(-) was likely under
selective pressure for restoration of high-fidelity replication or for tolerance of the
increased mutational load. Consistent with this hypothesis, MHV-ExoN(-) P250 exhibited
increased resistance to multiple nucleoside analogues, a phenotype strongly associated
with high-fidelity viruses (15, 18, 19, 22). Our results raise several important questions.
In the face of selection for increased fidelity, why did MHV-ExoN(-) not revert? Can MHV
replicase proteins mediate high-fidelity replication without ExoN proofreading? Which
mechanisms other than increased fidelity can compensate for the loss of proofreading?
In the face of selective pressure for increased fidelity, why did MHV-ExoN(-) not
revert? Although our data suggest that MHV-ExoN(-) was under selective pressure for
increased fidelity, we detected no primary reversion at the DE-to-AA substitutions in
MHV-ExoN(-) at any passage tested. These data are consistent with and significantly
extend previous studies reporting genotypic stability of ExoN(-) motif I in MHV and
SARS-CoV (13, 14, 16, 17, 38). Complete reversion to DE within ExoN(-) motif I would
require four nucleotide changes. This likely represents a high genetic barrier to rever-
sion, especially given that fitness can be increased by mutations outside nsp14-ExoN
(Fig. 7F) (13). Single and double nucleotide changes within motif I could restore an
acidic charge to individual residues (e.g., motif I EA, AD, ED, etc.). However, the active
site compositions of DEDDh exonucleases, such as the Klenow fragment, are so
stringent that even conservative mutations (D to E or E to D) reduce ExoN activity by
!96% (68). Thus, intermediate amino acid changes may not have a selective advantage
compared to motif I AA, limiting the evolutionary pathways to reversion. However,
nsp14-P250 had detectable effects on RBV and AZC resistance as well as on the
competitive fitness of MHV-ExoN(-) (Fig. 7F), demonstrating a modest capacity for
fitness adaptation in nsp14 outside the catalytic residues. Whether these mutations
resulted from genetic drift or positive selection remains unclear. Nevertheless, our data
show that MHV-ExoN(-) can adapt for increased fitness without fully restoring exoribo-
nuclease activity. While some mutations in MHV-ExoN(-) P250 likely confer DBT cell-
specific selective advantages, others may represent generalizable strategies for over-
coming ExoN(-) defects in other cell types and in other coronaviruses. Thus,
understanding the mechanisms by which MHV-ExoN(-) P250 compensated for ExoN
activity could allow recovery of ExoN(-) variants of other CoVs, such as transmissible
gastroenteritis virus and human CoV 229E, which to date have been nonviable as
ExoN(-) recombinants (42, 69).
Can MHV replicase proteins mediate high-fidelity replication without ExoN
proofreading? MHV-ExoN(-) P250 exhibits increased resistance to four nucleoside
analogues after passage (Fig. 4). Although resistance to a single nucleoside analogue
can evolve without increasing overall fidelity, resistance to multiple nucleoside ana-
logues strongly suggests a broadly increased capacity to discriminate nucleotides (15,
18, 19, 22). Increased-fidelity variants in RNA viruses have most frequently been
mapped to RdRps (24, 25, 30, 70). Thus, if increased fidelity contributes to nucleoside
analogue resistance in MHV-ExoN(-) P250, the most likely protein involved would be
nsp12-P250. Three findings are consistent with the hypothesis that mutations within
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nsp12-P250 increase RdRp fidelity. First, nonsynonymous mutations to nsp12 arose in
the low-fidelity MHV-ExoN(-) strain but not in the presence of proofreading (WT-MHV).
Second, five of the mutations lie in or near structural motifs important for fidelity
regulation in other RdRps. Amino acid substitutions in the finger and palm domains
have been repeatedly shown to affect viral RdRp fidelity (25, 34), and we have recently
reported a finger mutation (nsp12-V553I) that likely increases the fidelity of the MHV
RdRp (17). Our modeled structure predicts that nsp12-P250 contains three mutations in
the palm domain and one in the finger domain, with the M814K thumb domain
mutation lying near the palm (Fig. 6A). Third, exchange of nsp12-P250 alone into the
background of MHV-ExoN(-) reduced the susceptibility of MHV-ExoN(-) to three differ-
ent nucleoside analogues (Fig. 7). Thus, all data support the hypothesis that nsp12-P250
is a high-fidelity RdRp. We are actively developing biochemical, phenotypic, and deep
sequencing assays to quantify the fidelity of nsp12-P250.
Importantly, nsp12-P250 accounts only partially for the MHV-ExoN(-) P250 nucleo-
side analogue resistance phenotype (Fig. 7), suggesting a possible limit to the com-
pensation achievable by mutating the RdRp alone. Further, the effects of mutations in
nsp12-P250 and nsp14-P250 are not additive and may be antagonistic when they are
isolated from the whole passaged virus (Fig. 7), indicating that the relationships
between nsp12- and nsp14-P250 mutations are likely evolutionarily linked with those
in other MHV proteins. In fact, a substantial component of the evolved resistance to
nucleoside analogues cannot be explained by the presence of nsp12-P250 and nsp14-
P250, alone or together. In support of this hypothesis, we identified several nonsyn-
onymous mutations in other replicase proteins, such as nsp8, nsp9, nsp13, and nsp15.
SARS-CoV nsp8 and nsp13 have functional interactions with nsp12, acting as a primase/
processivity factor (71, 72) and a helicase/NTPase, respectively (73). Processivity factors
in herpes simplex virus and Mycobacterium tuberculosis regulate DNA polymerase
fidelity by balancing polymerase extension and exonuclease activity (74, 75), and
helicases in Chikungunya virus and foot-and-mouth disease virus can evolve to increase
fidelity (76) and alter the frequency of ribavirin-induced mutations (77), respectively.
SARS-CoV nsp9 has RNA-binding activities and is proposed to participate in the
multiprotein replicase complex (39, 78), and MHV nsp15 is a uridylate-specific endori-
bonuclease (79). Both could plausibly be involved in modulating polymerase activity.
Additionally, it remains possible that evolution for increased fidelity could involve
proteins outside the canonical replication complex (nsp7 to nsp16), including those in
the structural and accessory cassette. Thus, while the immediate studies will focus on
testing whether replicase proteins nsp8, nsp9, nsp13, and nsp15 regulate fidelity, it is
exciting to consider the possibility that this virus-directed discovery approach will
reveal novel interactions between multiple MHV proteins.
Which mechanisms other than increased fidelity might account for MHV-
ExoN(-) P250 nucleoside analog resistance? Genomic mutations in RNA viruses are
most commonly detrimental or lethal (8–12). One strategy to prevent extinction by
mutational load is to increase replication fidelity, as discussed above. An alternative
strategy is to increase mutational robustness. Mutational robustness describes the
capacity of a virus to buffer the fitness effects of mutations. In the setting of low-fidelity
replication, as in MHV-ExoN(-), increased mutational robustness could have provided a
selective advantage (80–82). Selection for increased robustness could explain the ~90
synonymous changes in MHV-ExoN(-) P250. Synonymous changes can alter codons to
reduce the probability of nonconservative amino acid changes (83). Alternatively, the
increased population size of MHV-ExoN(-) P250 could promote robustness by a “safety-
in-numbers” effect, allowing efficient purging of low-fitness mutants while maintaining
population fitness (84). Large populations also increase the likelihood of coinfection,
allowing complementation between viral genomes. Although increased replication
conferred by mutations in spike did not alter 5-FU resistance (Fig. 5), results of a recent
study performed with poliovirus suggest that mutagenized populations have elevated
coinfection frequencies (85). Thus, complementation may contribute to MHV-ExoN(-)
P250 nucleoside analogue resistance. Conflicting evidence exists regarding whether
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mutational robustness itself affects the sensitivity to RNA mutagens (83, 86, 87);
nevertheless, the robustness of MHV-ExoN(-) P250 merits further investigation.
Conclusions. The proofreading activity of the nsp14 exoribonuclease is a critical
determinant of CoV replication, fidelity, and fitness. We showed that CoVs have the
capacity to compensate for loss of ExoN activity through a network of mutations in
nsp12 and nsp14 and elsewhere in the genome. Thus, while nsp14-ExoN appears to
play a dominant role in CoV replication fidelity, its activity is likely closely tied to a
highly evolved network of proteins. The demonstrated coadaptation for replication,
competitive fitness, and likely increased fidelity within MHV-ExoN(-) supports the
hypothesis that these roles are linked functionally and evolutionarily. It will be inter-
esting to test whether evolution in other cell types derived from different species or
with different innate immune environments would result in similar adaptive strategies.
Genetic and biochemical testing of the rich mutational resource revealed in MHV-
ExoN(-) P250 will likely inform the design of countermeasures for endemic and emerg-
ing CoVs by defining novel common targets for stable virus attenuation or direct
inhibition.
MATERIALS AND METHODS
Cell culture. DBT-9 (delayed brain tumor, murine astrocytoma clone 9) cells were maintained as
described previously (88). Baby hamster kidney (BHK) cells stably expressing the MHV-A59 receptor
CEACAM1 (BHK-R; 15) were maintained under conditions of selection with 0.8 mg/ml of G418 (Mediat-
ech) as described previously (88).
Long-term passage of virus and stock generation. The infectious cDNA clone for MHV-A59 and the
recovery of MHV-ExoN(-) were described previously (14, 88). Long-term passage was initiated by infecting
subconfluent monolayers of DBT-9 cells in 25-cm2 flasks with either wild-type MHV-A59 or MHV-ExoN(-)
at an MOI of approximately 0.1 PFU/cell. One lineage of each virus was subjected to a total of 250
passages (P250). Supernatant was harvested at each passage and stored at !80°C. Total RNA was
harvested for most passages using 1 ml of TRIzol reagent (Ambion) per 25-cm2 flask and stored at!80°C.
Virus stocks of select intermediate passages were generated by infecting a subconfluent 150-cm2 flask
of DBT-9 cells at an MOI of 0.01 PFU/cell. At approximately 24 hpi, the flask was frozen at !80°C and the
supernatant was clarified by centrifugation at 4,000 " g (Sorvall RC-3B Plus; HA-6000A rotor) for 10 min
at 4°C. The virus titer of each stock was determined by plaque assay using DBT-9 cells as described
previously (14, 88). For plaque assays of viruses containing the spike protein from MHV-ExoN(-) P250,
which does not form syncytia, plaques were visualized with neutral red (Sigma catalog no. N6264)
(dilution at 1:10 in phosphate-buffered saline [PBS] containing calcium and magnesium). Neutral red was
added 24 h after plating, and the reaction mixture was incubated for an additional 3 to 8 h before
formaldehyde fixation. Plaque purification was performed by infecting DBT cells with serial dilutions of
virus and overlaying the cultures with agar. Single plaques were isolated, resuspended in PBS containing
calcium and magnesium, and inoculated onto fresh DBTs. This process was completed 3 times before
experimental stocks were generated as described above.
Sequencing of virus stocks. Following P250, RNA was purified from the harvested TRIzol samples
according to the manufacturer’s protocol and reverse transcribed (RT) using SuperScript III (Invitrogen)
as described previously (14). Full-genome di-deoxy sequencing was performed for both WT-MHV P250
and MHV-ExoN(-) P250 using 12 overlapping amplicons approximately 3 kb in length. All coding regions
were sequenced fully, and, of 31,409 nucleotides, #99% were sequenced for each virus [for WT-MHV
P250, 21 to 31,279; for MHV-ExoN(-) P250, 21 to 31,275]. Two microliters of RT product was used for each
PCR (16). Di-deoxy sequencing was performed by Genhunter Corporation (Nashville, TN) and Genewiz
(South Plainfield, NJ). Sequence analysis was performed using MacVector version 14 (MacVector, Inc.,
Apex, NC) and the MHV-A59 infectious clone reference genome (GenBank accession number AY910861).
The nucleotide sequences of the amplicon and sequencing primers are available upon request. Sequenc-
ing of nsp12 and nsp14 from intermediate passages was performed using TRIzol-purified RNA from
infected monolayers and the primers listed below. Primers 6M1F (5=-TTTTGGCGAGATGGTAGC-3=) and
7M2R (5=-GGTAAGACAGTTTTAGGTGAG-3=) were used to generate a 3,425 nucleotide amplicon contain-
ing all of nsp12. Primers 7M3F (5=-ATGCTTACCAACTATGAGC-3=) and 8M3R (5=-CCGATTTGAATGGCGTA
G-3=) were used to generate a 2,713 nucleotide amplicon containing all of nsp14. The PCR conditions for
these reactions were the same as those used to generate the amplicons used for full-genome sequencing
(16).
Replication and RNA synthesis kinetics. Viral replication kinetics in DBT-9 cells were determined at
an MOI of 1 PFU/cell or an MOI of 0.01 PFU/cell as described previously (15). Supernatant (300 !l) was
harvested at the indicated time points, and the virus titer was determined by plaque assay. The
accumulation of genomic RNA at an MOI of 1 PFU/cell was measured by two-step real-time quantitative
RT-PCR. Intracellular RNA was harvested using TRIzol and reverse transcribed using SuperScript III
(Invitrogen). The levels of cDNA derived from intracellular positive-sense viral RNA were measured using
primers directed to nsp10. Values were normalized to levels of the endogenous control glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). No mutations within the primer binding sites emerged in either
P250 population. The primers and amplification conditions were the same as reported previously (15),
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except that the RT product was diluted 1:10 prior to use. Samples were plated in technical duplicate to
minimize well-to-well variation. Data are presented as 2!∆CT, where ∆CT denotes the threshold cycle (CT)
value for the target (nsp10) minus the CT value for the reference (GAPDH).
Determination of specific infectivity. Subconfluent monolayers of DBT-9 cells in 24-well plates
were infected with the indicated virus at an MOI of 1 PFU/cell, and supernatant was harvested at 12 hpi.
The levels of genomic RNA in supernatant were measured using one-step real-time quantitative RT-PCR
(RT-qPCR) of TRIzol-extracted RNA as described previously (17). Briefly, genomic RNA was detected with
a 5= 6-carboxyfluorescein (FAM)-labeled and 3= black hole quencher 1 (BHQ-1)-labeled probe targeting
nsp2 (Biosearch Technologies, Petaluma, CA), and RNA copy numbers were calculated by reference to an
RNA standard derived from the MHV A fragment. Samples were plated in technical duplicate to minimize
well-to-well variation. Titers were determined by plaque assay in DBT-9 cells, and specific infectivity was
calculated as PFU per supernatant genomic RNA copy.
Nucleoside and base analogue sensitivity assays. 5-azacytidine (AZC), 5-fluorouracil (5-FU), and
ribavirin (RBV) were purchased from Sigma (product numbers A2385, F6627, and R9644, respectively),
and stock solutions were prepared in dimethyl sulfoxide (DMSO). CMeA (2=-C-methyladenosine) was
received from Gilead Sciences (Foster City, CA). Sensitivity assays were performed as described previously
(16), except that 24-well plates were used at an MOI of 0.01 PFU/cell. Supernatants were harvested at
24 hpi, and titers were determined by plaque assay.
Phyre2 modeling of MHV-nsp14. The MHV nsp14 structure was modeled with the Phyre2 online
program (62) using nsp14 residues 3 to 519, corresponding to residues 6,056 to 6,573 of the ORF1ab
polyprotein. The model was analyzed using the PyMOL Molecular Graphics System, Version 1.3
(Schrödinger, LLC).
Generation of nsp12 and nsp14 swaps. Viruses containing nsp12-P250 or nsp14-P250 or both were
generated using the MHV-A59 reverse genetics system (88). RNA from the MHV-ExoN(-) P250 virus was
reversed transcribed with SuperScript III (Invitrogen) and used to generate amplicons containing either
nsp12 or nsp14. Each amplicon was flanked by 15 bp that overlapped an amplicon generated from the
backbone plasmid. Amplicons were inserted into MHV-A59 fragments using an InFusion HD cloning kit
(TaKaRa Bio USA, Inc., Mountain View, CA). nsp12 is split across MHV E and F, while nsp14 is contained
within MHV F. Reaction mixtures contained 50 ng of vector, 200 ng of insertion, and 2 !l of enzyme and
were incubated for 15 min at 50°C. Errors were corrected by site-directed mutagenesis using Pfu Turbo
polymerase (Agilent, Santa Clara, CA). The nsp12/14-P250 swap was generated through restriction
digestion of the individual swaps using BsmBI and StuI followed by gel purification and assembly using
T4 DNA ligase (NEB, Ipswich, MA). Viable viruses were constructed and rescued as described previously
(88).
Competitive fitness assays. Competitor viruses were competed with an MHV-ExoN(-) virus harbor-
ing 10 silent mutations in the probe-binding region within nsp2. Subconfluent DBT-9 monolayers in
24-well plates were coinfected at a total MOI of 0.01 PFU/cell with competitor and reference viruses at
a 1:1 ratio and passaged 4 times. For each passage, supernatants were harvested at 24 h. RNA was
extracted from 100 !l of supernatant using 900 !l of TRIzol reagent and PureLink RNA minikit columns
(Thermo Scientific, Waltham, MA), and 150 !l of supernatant was used to infect fresh cells in a 24-well
plate (total MOI estimated at 1 PFU/cell). The proportion of each virus was determined by real-time
RT-qPCR from the infection supernatant using two TaqMan probes with different fluorescent dyes in
separate reactions. Competitor viruses were detected with the same probe used in specific infectivity
analyses (14). Reference viruses were detected by a probe targeting the same region but with 10 silent
mutations (5=-TCCGAACTACTGCAACCCCAAGTG-3=) and labeled with 5= quasar 670 and 3= black hole
quencher 2 (BHQ-2) (Biosearch Technologies, Petaluma, CA). RNA copy numbers were calculated by
reference to an RNA standard generated by in vitro transcription of the corresponding MHV A fragment,
and relative RNA abundances were calculated as ratios of competitor genomes to reference genomes.
Statistical analysis. GraphPad Prism 6 (La Jolla, CA) was used to perform statistical tests. Only the
comparisons shown (with statistical significance indicated as "ns" [nonsignificance] or asterisk[s]) within
each figure or described in each legend were performed. In many cases, the data were normalized to the
results obtained with untreated controls. This was performed using GraphPad Prism 6. The number of
replicate samples is denoted within each figure legend.
Accession numbers. Full-length genome sequences for WT-MHV P250 and MHV-ExoN(-) P250 have
been deposited in GenBank (accession numbers MF618252 and MF618253, respectively).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.01503-17.
FIG S1, TIF file, 1.7 MB.
TABLE S1, PDF file, 0.1 MB.
TABLE S2, PDF file, 0.1 MB.
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APPENDIX D. Nelson’s Textbook of Pediatrics, 21st edition, Chapter 264: Coronaviruses 
The below text will be published in the upcoming 21st edition of the Nelson Textbook of 
Pediatrics. 
 
Chapter 264 
Coronaviruses 
Kevin W. Graepel and Mark R. Denison 
Coronaviruses are increasingly recognized as important human pathogens. They cause up to 15% 
of common colds and have been implicated in more serious diseases, including croup, asthma 
exacerbations, bronchiolitis, and pneumonia. Evidence also suggests that coronaviruses may 
cause enteritis or colitis in neonates and infants and may be underappreciated as agents of 
meningitis or encephalitis. Four coronaviruses are endemic in humans: human coronaviruses 
(HCoVs) 229E, OC43, NL63, and HKU1. In addition, 2 epidemics of previously unknown 
coronaviruses caused significant respiratory distress and high mortality rates among infected 
individuals. The discoveries of SARS-associated coronavirus (SARS-CoV) in 2003, the cause 
of severe acute respiratory syndrome (SARS), and of Middle East respiratory syndrome 
coronavirus (MERS-CoV) in 2012, support the potential for coronaviruses to emerge from 
animal hosts such as bats and camels and become important human pathogens. 
 
 
 
Etiology 
Coronaviruses are enveloped viruses of medium to large size (80-220 nm) that possess the 
largest known single-stranded positive-sense RNA genomes. These viruses encode the protein 
nsp14-ExoN, which is the first known RNA proofreading enzyme and is likely responsible for 
the evolution of the large and complex coronavirus genome. Coronaviruses derive their name 
from the characteristic surface projections of the spike protein, which give a corona or crown-
like appearance on negative-stain electron microscopy. Coronaviruses are organized 
taxonomically by a lettering system based on genomic phylogenetic relationships. 
Alphacoronaviruses include HCoV-229E and HCoV-NL63. Betacoronaviruses include 4 human 
pathogens and are commonly divided into 4 lineages, without formal taxonomic recognition. 
HCoV-OC43 and the HCoV-HKU1 are in lineage A, while SARS-CoV falls in lineage B. 
Lineages C and D were exclusively comprised of bat coronaviruses until the discovery of 
MERS-CoV, which aligns with lineage C. Gammacoronaviruses and deltacoronaviruses 
presently include exclusively nonhuman pathogens. 
 
In 2002-2003, coronaviruses received international attention during the SARS outbreak, which 
was responsible for more than 800 deaths in 30 countries. SARS-CoV, a novel coronavirus at the 
time of the epidemic, was found to be the causative agent of SARS. The detection of SARS-like 
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coronaviruses in a live animal market in the Guangdong province in Southern China, along with 
serologic evidence of exposure in food handlers in the same market, suggest that these markets 
may have facilitated the spread of SARS-CoV to humans from an animal reservoir. Subsequent 
studies identified SARS-like coronaviruses in fecal specimens from asymptomatic Chinese 
horseshoe bats that are very closely related, but not direct precursors to, SARS-CoV and are 
capable of infecting human cells. Thus, although bats are a reservoir for SARS-CoV-like 
precursors, the precise antecedent to SARS-CoV remains to be identified. 
 
In June 2012, another novel coronavirus, MERS-CoV, was isolated from a man with acute 
pneumonia and renal failure in Saudi Arabia. As of March 1, 2017, the WHO has recorded 
nearly 2000 confirmed cases of MERS, with nearly 700 deaths worldwide (~35% mortality). 
Dromedary camels are the likely reservoir host for MERS-CoV. MERS-CoV differs from SARS 
in that it seems to be less communicable, although human-to-human transmission has been 
documented. MERS-CoV uses dipeptidyl peptidase 4 and carcinoembryonic antigen-like cell-
adhesion molecule 5 as its cellular and co-receptor, respectively; SARS-CoV utilizes ACE-2. 
With this receptor specificity, MERS-CoV can infect cells from several animal lineages, 
including human, pig, and bat, suggesting the possibility of movement between multiple species. 
 
Epidemiology 
Seroprevalence studies have demonstrated that antibodies against 229E and OC43 increase 
rapidly during early childhood, so that by adulthood 90-100% of persons are seropositive. 
Although less information is available for HKU1 and NL63, available studies demonstrate 
similar patterns of seroconversion to these viruses during early childhood. Although some degree 
of strain-specific protection may be afforded by recent infection, reinfections are common and 
occur despite the presence of strain-specific antibodies. Attack rates are similar in different age 
groups. Although infections occur throughout the year, there is a peak during the winter and 
early spring for each of these HCoVs. In the United States, outbreaks of OC43 and 229E have 
occurred in 2- to 3-year alternating cycles. Independent studies of viral etiologies of upper and 
lower respiratory infections during the same period, but from different countries, have confirmed 
that all known HCoVs have a worldwide distribution. Studies using both viral culture and 
polymerase chain reaction (PCR) multiplex assays demonstrate that coronaviruses often occur as 
coinfections with other respiratory viruses, including respiratory syncytial virus, adenovirus, 
rhinovirus, or human metapneumovirus. Volunteer studies demonstrated that OC43 and 229E are 
transmitted predominantly through the respiratory route. Droplet spread appears to be most 
important, although aerosol transmission may also occur. 
 
There have been no identified natural or laboratory-acquired cases of SARS-CoV since 2004, but 
the mechanisms of introduction, spread, and disease remain important for potential animal-to-
human transmission and disease. The primary mode of SARS-CoV transmission occurred 
through direct or indirect contact of mucous membranes with infectious droplets or fomites. 
Aerosol transmission was less common, occurring primarily in the setting of endotracheal 
intubation, bronchoscopy, or treatment with aerosolized medications. Fecal-oral transmission did 
not appear to be an efficient mode of transmission, but may have occurred because of the profuse 
diarrhea observed in some patients. The seasonality of SARS-CoV remains unknown. SARS-
CoV is not highly infectious, with generally only 2-4 secondary cases resulting from a single 
infected adult. During the SARS epidemic, a small number of infected individuals, 
“superspreaders,” transmitted infection to a much larger number of persons, but the mechanism 
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for this high degree of spread remains unknown. In contrast, persons with mild disease, such as 
children younger than 12 years of age, rarely transmitted the infection to others. Infectivity 
correlated with disease stage; transmission occurred almost exclusively during symptomatic 
disease. During the 2003 outbreak, most individuals with SARS-CoV infection were hospitalized 
within 3-4 days of symptom onset. Consequently, most subsequent infections occurred within 
hospitals and involved either healthcare workers or other hospitalized patients. 
 
As of March 1, 2017, the World Health organization has recorded 1905 laboratory-confirmed 
cases of MERS-CoV from 27 countries, all of which are linked to exposures in the Arabian 
peninsula (approximately 80% in Saudi Arabia). Though the route of transmission between 
animals and humans is not fully understood, MERS-CoV is proposed to have repeatedly entered 
the human population through contact with respiratory secretions of dromedary camels and 
possibly to raw camel products (e.g. unpasteurized milk). Antibodies to MERS-CoV are found in 
dromedaries throughout the Middle East, and strains identical to human MERS-CoV isolates 
have been found in camels in Egypt, Oman, Qatar, and Saudi Arabia. These strains do not appear 
to be highly pathogenic or virulent in camels and have likely circulated within dromedaries for 
>30 years. Despite well-documented zoonotic transmission, most reported cases are linked 
human-to-human transmission in healthcare settings, including outbreaks in Jordan, South 
Korea, and Saudi Arabia in 2015 and 2016. Risk factors for nosocomial MERS-CoV outbreaks 
include overcrowded emergency departments, delayed diagnosis or isolation, and poor infection 
control practices. Transmission most likely occurs through respiratory droplets and is thus a 
greater risk during aerosol-generating procedures. Outside of healthcare settings, human-to-
human transmission has been infrequently documented and is primarily associated with close 
contact within households. No sustained human-to-human transmission has yet been reported. 
Pathogenesis of SARS and MERS 
Severe disease in SARS and MERS likely results from both direct virologic damage and 
subsequent immunopathology. Studies with SARS-CoV in human airway epithelial cell cultures 
indicate that ciliated cells are principal targets for infection, while MERS-CoV preferentially 
infects bronchial epithelial cells, type I and II pneumocytes, and vascular endothelial cells. 
Substantial viral loads can be detected in the lower respiratory tract and in blood for both viruses. 
However, late progression to severe disease appears independent of the quantity and timing of 
viremia. Thus, excessive host immune responses likely play an important role in the progression 
to lower respiratory disease and acute respiratory distress syndrome. CoV infections are 
associated with massive elaboration of inflammatory cytokines and recruitment of inflammatory 
cells. The roles for inflammatory cells are controversial, with cytotoxic T cells and macrophages 
implicated variously in immune protection and immunopathology. Recapitulation of human 
clinical features in animal models of MERS-CoV infection remains challenging, but promising 
new models are in development. 
 
 
 
Clinical Manifestations 
Respiratory Infections 
Even though up to 50% of respiratory tract infections with OC43 and 229E are asymptomatic, 
coronaviruses are still responsible for up to 15% of common colds and can cause fatal disease. 
Cold symptoms caused by HCoVs are indistinguishable from those caused by rhinoviruses and 
other respiratory viruses. The average incubation period is 2-4 days, with symptoms typically 
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lasting 4-7 days. Rhinorrhea, cough, sore throat, malaise, and headache are the most common 
symptoms. Fever occurs in up to 60% of cases. Coronavirus NL63 is a cause of croup in children 
younger than 3 years of age. Coronavirus infections are linked to episodes of wheezing in 
asthmatic children, albeit at a lower frequency and severity than observed with rhinovirus and 
respiratory syncytial virus infections. Lower respiratory tract infections, including bronchiolitis 
and pneumonia, are also reported in immunocompetent and immunocompromised children and 
adults. As with respiratory syncytial virus or rhinovirus, coronavirus detection in upper 
respiratory infections is frequently associated with acute otitis media and can be isolated from 
middle ear fluid. 
Nonrespiratory Sequelae 
There is some evidence to support a role for coronaviruses in human gastrointestinal disease, 
particularly in young children. Coronavirus-like particles have been detected by electron 
microscopy in the stools of infants with nonbacterial gastroenteritis. In addition, several 
outbreaks in neonatal intensive care units of gastrointestinal disease characterized by diarrhea, 
bloody stools, abdominal distention, bilious gastric aspirates, and classic necrotizing enterocolitis 
have also been associated with the presence of coronavirus-like particles in stools. In older 
children and adults, coronavirus-like viruses have been observed with similar frequency in 
symptomatic and asymptomatic individuals, making it difficult to discern if they are pathogenic 
in the gastrointestinal tract. Coronaviruses are well-known causes of neurologic disease in 
animals, including demyelinating encephalitis, but their role in causing human neurologic 
disease remains unclear. They have been detected by culture, in situ hybridization, and reverse 
transcriptase PCR (RT-PCR) in brain tissue from a few patients with multiple sclerosis. HCoV-
OC43 has been detected by RT-PCR in the spinal fluid, nasopharynx, or brain biopsy specimens 
of two children with acute encephalomyelitis. However, coronavirus RNA has also been 
recovered from the spinal fluid and brain tissue of adults without neurologic disease.  
Severe Acute Respiratory Syndrome–Associated Coronavirus 
SARS-CoV infections in teenagers and adults included a viral replication phase and an 
immunologic phase. During the viral replication phase, there was a progressive increase in viral 
load that reached its peak during the 2nd week of illness. The appearance of specific antibodies 
coincided with peak viral replication. The clinical deterioration that typified the 2nd and 3rd 
week of illness was characterized by a decline in the viral load and evidence of tissue injury, 
likely from cytokine-mediated immunity. The explanation for milder clinical disease in children 
younger than 12 years of age has not been determined. Seroepidemiologic studies suggest that 
asymptomatic SARS-CoV infections were uncommon. The incubation period ranged from 1-14 
days, with a median of 4-6 days. The clinical manifestations were nonspecific, most commonly 
consisting of fever, cough, malaise, coryza, chills or rigors, headache, and myalgia. Coryza was 
more common in children younger than 12 years of age, whereas systemic symptoms were seen 
more often in teenagers. Some young children had no respiratory symptoms. Gastrointestinal 
symptoms, including diarrhea and nausea or vomiting, occurred in up to one third of cases. The 
clinical course of SARS-CoV infection varied with age. Adults were most severely affected, with 
initial onset of fever, cough, chills, myalgia, malaise, and headache. Following an initial 
improvement at the end of the 1st week, fever recurred and respiratory distress developed, with 
dyspnea, hypoxemia, and diarrhea. These symptoms progressed in 20% of patients to acute 
respiratory distress syndrome and respiratory failure. Acute renal failure with histologic acute 
tubular necrosis was present in 6.9% of patients, likely a result of hypoxic kidney damage. Of 
SARS patients, 28.8% had abnormal urinalysis, with viral genome detectable by quantitative RT-
PCR. In contrast, children younger than 12 years of age had a relatively mild nonspecific illness, 
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with only a minority experiencing significant lower respiratory tract disease and illness typically 
lasting less than 5 days. There were no deaths or acute respiratory distress syndrome in children 
younger than 12 years of age from SARS-CoV infection. Adolescents manifested increasing 
severity in direct correlation to increasing age; respiratory distress and hypoxemia were observed 
in 10-20% of patients, one-third of whom required ventilator support. The case fatality rate from 
SARS-CoV infection during the 2003 outbreak was 9.6%. No pediatric deaths were reported. 
The estimated case fatality rate according to age varied from <1% for those younger than 20 
years of age to >50% for those older than 65 years of age. 
Middle East Respiratory Syndrome Coronavirus 
The incubation period of MERS-CoV is between 2-14 days and typically presents with 
nonspecific clinical features typical of acute febrile respiratory illnesses, including low-grade 
fever, rhinorrhea, sore throat, and myalgia. In mildly symptomatic cases, radiographic findings 
are typically normal. Severe disease is characterized by the acute respiratory distress syndrome 
with multilobular airspace disease, ground-glass opacities, and occasional pleural effusions on 
radiography. The median time between hospitalization and ICU transfer for critical illness is 2 
days. Risk factors for severe disease include age >50 years and comorbidities like obesity, 
diabetes, COPD, end-stage renal disease, cancer, and immunosuppression. Specific host genetic 
risk factors have not been identified. Variation in clinical outcomes does not appear to be 
explained by viral strain-specific sequence variability. As with SARS, extrapulmonary 
manifestations are common in severe MERS disease. Gastrointestinal symptoms such as nausea, 
vomiting, and diarrhea occur in one-third of patients, and acute kidney injury has been 
documented in half of critically ill patients. Encephalitis-like neurological manifestations have 
been observed in three cases. Laboratory analyses typically detect leukopenia and lymphopenia 
with occasional thrombocytopenia, anemia, and aminotransferase elevations. The case fatality 
rate remains at 35%, though the true incidence of MERS-CoV infection is likely underestimated 
by existing data. Most patients have been adults, although children as young as 9 months of age 
have been infected. It is not known whether children are less susceptible to MERS-CoV or 
present with a different clinical picture. 
 
Diagnosis 
In the past, specific diagnostic tests for coronavirus infections were not available in most 
clinical settings. The use of conserved PCR primers for coronaviruses in multiplex RT-PCR viral 
diagnostic panels now allows widely available and sensitive detection of the viruses. Virus 
culture of primary clinical specimens remains a challenge for HCoVs HKU1, OC43, 229E, and 
NL63, even though both SARS-CoV and MERS-CoV can successfully be grown in culture from 
respiratory samples. Serodiagnosis with complement fixation, neutralization, hemagglutination 
inhibition, enzyme immunoassay, and Western blots have been used in the research setting. The 
diagnosis of SARS-CoV infection can be confirmed by serologic testing, detection of viral RNA 
using RT-PCR, or isolation of the virus in cell culture. Even though serology for SARS-CoV has 
sensitivity and specificity approaching 100%, antibodies are not detectable until 10 days after the 
onset of symptoms, and immunoglobulin G seroconversion may be delayed for up to 4 weeks. In 
addition, the SARS epidemic resulted in the inclusion of coronavirus-conserved primers in many 
diagnostic PCR multiplex assays such that coronaviruses may be more readily detected. 
Diagnosis of MERS-CoV should be guided by clinical features and an epidemiological link. The 
mainstay for laboratory confirmation of MERS-CoV infection is real-time RT-PCR. Screening 
should target the region upstream of the envelope gene (upE) followed by confirmation with an 
assay targeting open reading frame 1a. The best diagnostic sensitivity is achieved from lower 
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respiratory tract samples collected within the first week of infection, though MERS-CoV RNA 
can be detected in upper respiratory and blood samples. Alternatively, seroconversion can be 
documented by screening enzyme-linked immunosorbent assays followed by 
immunofluorescence microscopy. For all known endemic and emerging HCoVs, respiratory 
specimens (nasopharyngeal swabs or aspirates) are most likely to be positive, but in a setting of a 
possible novel coronavirus, serum or stool may be positive. 
 
 
Treatment and Prevention 
Coronavirus infections of humans are acute and self-limited, although persistent infection 
and shedding occurs in multiple animal models in the setting of minimal or no symptomology. 
There are no available antiviral agents for clinical use against coronaviruses, although strategies 
targeting conserved coronavirus proteases and coronavirus polymerases have been shown to 
block replication of the viruses in vitro and are in the drug development pipeline. Thus, treatment 
of SARS-CoV and MERS-CoV infections is primarily supportive. The role of antiviral and 
immune-modulating agents remains inconclusive, though several clinical trials are ongoing. 
Ribavirin was extensively used during the 2003 SARS-CoV outbreak, but is of questionable 
benefit given its poor in vitro activity against SARS-CoV at clinically relevant concentrations. 
The identification of the proofreading nsp14-exonuclease in multiple coronaviruses suggests that 
this activity may be important in resistance to antiviral nucleosides and RNA mutagens such as 
ribavirin. Systemic corticosteroid therapy may be associated with increased mortality in SARS-
CoV and MERS-CoV and is thus not recommended unless indicated for another clinical 
condition. Meta-analysis of observational studies suggests that human convalescent plasma may 
reduce SARS mortality; the use of blood products has not been well-studied in MERS. Several 
monoclonal antibody preparations have shown positive results against SARS- and MERS-CoV 
in animal studies. 
 
Challenges for development of effective vaccines targeted against OC43, 229E, HKU1, and 
NL63 include the fact that infections are rarely life-threatening and reinfection is the rule, even 
in the presence of natural immunity from previous infections. The durability of immunity to 
SARS-CoV and MERS-CoV is poorly understood. Nevertheless, effective vaccines for SARS-
CoV and MERS-CoV are highly desirable but not yet available. A potential vaccine target is the 
viral spike protein, which could be delivered as a recombinant protein or by viral or DNA 
vectors. This approach appears to be effective against closely related strains of SARS-CoV but 
not necessarily early animal or human variants. A SARS-CoV vaccine approach that recently has 
shown success in animal models used a live recombinant SARS-CoV mutant with inactivated 
ExoN, demonstrating attenuation and protection in aged, immunocompromised mice. 
Approaches for rapid development of stably attenuated live viruses or broadly immunogenic and 
cross-protective protein immunogens continues to be a key area for future research. Although 
SARS-CoV demonstrated characteristics of symptomatic transmission that made it controllable 
by public health measures like quarantine, these characteristics cannot be assumed for future 
novel HCoVs. The recent discovery of MERS-CoV serves as a reminder that coronavirus 
emergence is both likely and unpredictable, making it important to continue studies of the 
replication, emergence, and transmission of coronaviruses. Additionally, strategies for rapid 
recovery, testing, and development of vaccines and neutralizing human monoclonal antibodies 
may be essential to prevent the high morbidity and mortality associated with previous epidemics. 
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APPENDIX E. Fitness barriers limit reversion of a proofreading-deficient coronavirus 
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ABSTRACT 
The 3¢-to-5¢ exoribonuclease in coronavirus (CoV) nonstructural protein 14 (nsp14-ExoN) 
mediates RNA proofreading during genome replication. ExoN catalytic residues are arranged in 
three motifs: I (DE), II (E), III (D). Alanine substitution of the motif I residues (AA-E-D, four 
nucleotide substitutions) in murine hepatitis virus (MHV) and SARS-CoV yields viable mutants 
with impaired replication and fitness, increased mutation rates, and attenuated virulence in vivo. 
Despite these impairments, MHV- and SARS-CoV ExoN motif I AA mutants (ExoN-AA) have 
not reverted at motif I in diverse in vitro and in vivo environments, suggesting that profound 
fitness barriers prevent motif I reversion. To test this hypothesis, we engineered MHV-ExoN-AA 
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with 1, 2 or 3 nucleotide mutations along genetic pathways to AA-to-DE reversion. We show 
that engineered intermediate revertants were viable but had no increased replication or 
competitive fitness compared to MHV-ExoN-AA. In contrast, a low passage (P10) MHV-ExoN-
AA showed increased replication and competitive fitness without reversion of ExoN-AA. 
Finally, engineered reversion of ExoN-AA to ExoN-DE in the presence of ExoN-AA passage-
adaptive mutations resulted in significant fitness loss. These results demonstrate that while 
reversion is possible, at least one alternative adaptive pathway is more rapidly advantageous than 
intermediate revertants and may alter the genetic background to render reversion detrimental to 
fitness. Our results provide an evolutionary rationale for lack of ExoN-AA reversion, illuminate 
potential multi-protein replicase interactions and coevolution, and support future studies aimed at 
stabilizing attenuated CoV ExoN-AA mutants. 
 
IMPORTANCE 
Coronaviruses encode an exoribonuclease (ExoN) that is important for viral replication, fitness, 
and virulence, yet coronaviruses with a defective ExoN (ExoN-AA) have not reverted under 
diverse experimental conditions. In this study, we identify multiple impediments to MHV-ExoN-
AA reversion. We show that ExoN-AA reversion is possible but evolutionarily unfavorable. 
Instead, compensatory mutations outside of ExoN-AA motif I are more accessible and beneficial 
than partial reversion. We also show that coevolution between replicase proteins over long-term 
passage partially compensates for ExoN-AA motif I but renders the virus inhospitable to a 
reverted ExoN. Our results reveal the evolutionary basis for the genetic stability of ExoN-
inactivating mutations, illuminate complex functional and evolutionary relationships between 
coronavirus replicase proteins, and identify potential mechanisms for stabilization of ExoN-AA 
coronavirus mutants.  
 
INTRODUCTION 
The rapid evolution of RNA viruses represents a significant challenge for preventing, treating, 
and eradicating RNA viral diseases. High mutation rates in RNA viruses generate extensive 
opportunities to overcome evolutionary hurdles, such as antiviral drugs, host immunity, or 
engineered attenuating changes (1). The evolutionary pathways traversed by RNA viruses are 
shaped by natural selection, which will favor some evolutionary trajectories more than others 
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based on whether mutations are beneficial, deleterious, or neutral (2). Predicting the likely results 
of RNA virus evolution is an important step for anticipating viral emergence and for developing 
escape-resistant antiviral drugs and vaccines (3, 4).  
 
Coronaviruses (CoVs) are a family of positive-sense RNA viruses that cause human illnesses 
ranging from the common cold to severe and lethal respiratory disease (5). All CoVs encode a 
proofreading exoribonuclease within nonstructural protein 14 (nsp14-ExoN) that is critical for 
replication, fidelity, fitness, and virulence, and ExoN-inactivation has been proposed as a 
strategy for live-attenuated vaccine development (6-15). As members of the DEDDh superfamily 
of exonucleases, CoV ExoNs hydrolyze nucleotides using four metal-coordinating amino acids 
arranged in 3 motifs: I (DE), II (E), III (D) (16, 17). Alanine substitution of ExoN motif I (DE-
to-AA) disrupts ExoN biochemical activity in both SARS-CoV and human CoV 229E (hCoV-
229E) (16, 18, 19). The betacoronaviruses murine hepatitis virus (MHV) and SARS-CoV 
tolerate disruption of ExoN activity [ExoN(-)] but display mutator phenotypes accompanied by 
defects in replication, competitive fitness, and evasion of innate immune responses (10, 13, 14). 
ExoN active site mutants in alphacoronaviruses, including transmissible gastroenteritis virus and 
hCoV-229E, have yet to be recovered and are proposed to be lethal for replication (19, 20).  
 
Given the critical role of ExoN in CoV biology and the elevated mutation rate, we expected that 
natural selection would repeatedly drive reversion of the ExoN-inactivating substitutions. In line 
with this expectation, ExoN motif III mutants of SARS-CoV and MHV rapidly and repeatedly 
revert ((14) and unpublished observations). In contrast, we have never detected partial or 
complete reversion of ExoN motif I mutants (ExoN-AA) in SARS-CoV or MHV during 10 years 
of study and hundreds of experiments. More specifically, we have not detected consensus or 
minority variants of any kind at the motif I AA codons in either virus strain during acute 
infections and prolonged passage in tissue culture and following treatment with multiple 
nucleoside analogues (6-11, 13, 14). SARS-CoV-ExoN-AA also is stable during acute and 
persistent animal infections in immunocompetent and immune-compromised mice (12). The lack 
of primary reversion is not due simply to reduced adaptive capacity, as both SARS-CoV- and 
MHV-ExoN-AA can adapt for increased replication (7, 14). Most strikingly, long-term passage 
of MHV-ExoN-AA (250 passages, P250) yielded a highly fit population that had directly 
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compensated for defective proofreading through evolution of a likely high-fidelity RdRp (7). 
Yet, where primary reversion would have required just four total consensus mutations, MHV-
ExoN-AA-P250 contained more than 170.  
 
In this study, we sought to determine whether specific genetic or fitness barriers prevent primary 
reversion of ExoN motif I AA. To this end, we identified and engineered viable genetic 
pathways towards ExoN-AA motif I reversion in MHV (hereafter, ExoN-AA). Our results show 
that partial reversion did not confer a selective advantage compared to ExoN-AA. Further, 
ExoN-AA adapted within 10 passages for greater fitness than any of the intermediate revertants. 
Finally, restoration of WT-ExoN-DE in the setting of passage-selected mutations in the nsp12 
RNA-dependent RNA polymerase (RdRp) and nsp14-ExoN exacted profound fitness costs. 
Together, these data are the first observation of an ExoN(-) CoV genotype-fitness landscape and 
identify multiple genetic barriers underlying ExoN(-) motif I stability in MHV. Further, they 
suggest extensive coevolution between MHV replicase proteins during adaptation and reveal 
potential strategies for stabilizing ExoN mutant CoVs. 
 
RESULTS 
Primary reversion of ExoN(-) motif I. MHV-ExoN(-), hereafter ExoN-AA, contains two 
engineered substitutions in each codon of motif I, such that complete reversion to WT-ExoN-DE 
requires mutations to all four sites (Figure 1A). Viral mutation rates in the absence of 
proofreading range from 10-4 to 10-6 mutations per nucleotide per round of replication (µ) (1). 
Assuming an ExoN-AA mutation rate of 10-4 µ and accounting for codon degeneracy, the 
probability of restoring the native amino acid sequence in a single round of replication is 10-18. 
Only rarely do ExoN-AA titers exceed 106 PFU/mL, so it is unlikely that ExoN-AA could 
navigate this genetic barrier in a single infectious cycle. Thus, we hypothesized that ExoN-AA 
reversion, if possible, would proceed incrementally. To identify potential pathways towards 
ExoN-AA reversion, we examined the possible single-nucleotide substitutions surrounding A89 
and A91 (Figure 1B). Three mutations are synonymous, and five mutations yield amino acids 
unlikely to coordinate with the positively-charged metals required for ExoN catalysis (glycine, 
valine, proline, threonine, and serine) (16, 19, 21, 22). One mutation per site can restore the 
acidic charge (i.e. AA-to-ED) but not the native amino acid. These variants have not been tested 
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in a CoV ExoN, but biochemical studies of E. coli DNA polymerase I ExoN mutants suggest that 
these conservative substitutions would not restore WT-like ExoN activity (23). We predicted 
stepwise pathways to ExoN-AAàDE reversion based on restoration of acidic charge followed 
by reversion to native amino acids (Figure 1C). We engineered and recovered variants in ExoN-
AA requiring three mutations (3nt; ExoN-AD, ExoN-EA), two mutations (2nt; ExoN-DA, ExoN-
ED, ExoN-AE), or one mutation (1nt; ExoN-DD, ExoN-EE) for reversion to WT-ExoN-DE 
(Table 1). We will hereafter refer to these mutants as intermediate revertants. All intermediate 
revertants generated viable progeny during recovery, demonstrating that reversion to WT-ExoN-
DE along these pathways is theoretically possible. The 3nt and 2nt mutants were genetically 
stable during recovery, as confirmed by dideoxy sequencing. However, both 1nt mutants (ExoN-
DD and ExoN-EE) reverted to WT-ExoN-DE during three independent recovery attempts, 
suggesting that these two variants are less fit than WT-ExoN-DE and demonstrating that 
reversion by 1nt mutation is readily accessible. To test whether the 3nt or 2nt mutants would 
revert more rapidly than ExoN-AA (4nt), we passaged three lineages of each mutant 10 times at 
multiplicities of infection (MOI) of 0.5 and 0.01 PFU/cell. We harvested supernatants and 
screened for reversion by visual inspection of plaque phenotypes at each passage. WT-ExoN-DE 
and WT-like viruses produce uniform, large plaques, while ExoN-AA-like viruses yield small, 
variably-sized plaques (13). When we observed mixed plaque phenotypes, we sequenced three 
large plaques from each lineage to confirm reversion. The 3nt (ExoN-AD and ExoN-EA) and 2nt 
(ExoN-DA and ExoN-ED) intermediate revertants showed no evidence of reversion over 10 
passages at either MOI (Table 1). In contrast, the 2nt ExoN-AE contained WT-revertants by P2 
in all lineages at MOI = 0.5 PFU/cell and by P8 in one lineage at MOI = 0.01 PFU/cell. Once 
observed, WT-revertants dominated the ExoN-AE population for the remaining passages. These 
data indicate that at least one 2nt mutation pathway can lead to full reversion in tissue culture. 
The probability of ExoN-AE arising during a single infectious cycle of ExoN-AA is low but 
theoretically achievable (~10-9), so ExoN-AA could conceivably revert within just two infectious 
cycles. However, complete reversion has never been observed even during prolonged passage or 
persistent infections, suggesting that additional barriers to the replication, fitness, or maintenance 
of intermediate revertants exist. 
 
Partial reversion of MHV-ExoN(-) motif I does not confer a selective advantage. Because 
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the intermediate revertants are viable as recombinants but are not found in ExoN-AA 
populations, we hypothesized that they confer no selective advantage over ExoN-AA (8, 9, 13). 
To test this hypothesis, we first analyzed replication of the 3nt and 2nt intermediate revertants 
(Figure 2A). All variants achieved similar peak titers to ExoN-AA, but detailed examination of 
their kinetics suggested a potential delay of up to 1.5 hours for all intermediate revertants 
compared to ExoN-AA. Of note, ExoN-AE was the most delayed, and we detected WT-ExoN-
DE revertants in two of three replicates, suggesting increased selective pressure against this 
variant. We next measured the competitive fitness of each intermediate revertant relative to a 
recombinant ExoN-AA containing seven silent mutations in the nsp2 coding region (ExoN-AA-
reference). Intermediate revertants were mixed with an equal titer of ExoN-AA-reference at a 
combined MOI = 0.05 PFU/cell and passaged four times. The ratio of each intermediate revertant 
to ExoN-AA-reference was quantified at each passage by RT-qPCR, and the change in ratio over 
time was used to calculate their relative fitness. WT-ExoN-DE was significantly more fit than 
ExoN-AA, whereas the intermediate revertants (ExoN-AD, -EA, -DA, and -ED) had no 
increased fitness relative to ExoN-AA (Figure 2B). The apparent increased fitness of ExoN-AE 
resulted from all lineages reverting to WT-ExoN-DE during the experiment. Finally, our 
previous studies have shown that adaptation of ExoN-AA includes partial compensation for the 
replication fidelity defect, as measured by reduced susceptibility to the mutagen 5-fluorouracil 
(5-FU) (7-11, 24). None of the intermediate variants demonstrated statistically significant 
differences in 5-FU sensitivity as compared to ExoN-AA (Figure 2C). Thus, with the exception 
of the ExoN-AEàDE revertants, no 3nt and 2nt intermediate genotypes along our predicted 
pathway demonstrated an advantage in replication, fitness, or fidelity that would favor their 
maintenance or expansion in the viral population. Thus, natural selection is unlikely to drive 
ExoN-AA down these pathways towards reversion. 
 
Secondary adaptations outside of ExoN-AA motif I increase fitness along alternative 
pathways. Although we did not find fitness advantages to intermediate revertants, we also did 
not identify profound fitness costs that would drive their immediate loss from populations. We 
have previously demonstrated that during 250 passages (P250), ExoN-AA can adapt for 
increased replication, fitness, and fidelity via secondary mutations outside of motif I (7). We 
tested whether secondary adaptive mutations could exceed the fitness of ExoN-AA and its 
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intermediate revertants. To examine the early adaptation of ExoN-AA, we studied passage 10 
from the P250 passage series (Figure 3). ExoN-AA-P10 retains the ExoN-AA motif I genotype 
but has increased replication and reduced susceptibility to 5-FU, altogether manifesting in 
greater relative fitness (Figure 3) (7). We identified only six total mutations within ExoN-AA-
P10 by dideoxy sequencing (Table 2), indicating that rapid adaptation of and compensation for 
ExoN-AA requires relatively few genetic changes at the consensus level. To test whether 
interactions between multiple mutations or population level effects contribute to ExoN-AA-P10 
fitness, we isolated a plaque-purified clone of ExoN-AA-P10. The clone replicated to higher 
titers than the ExoN-AA-P10 population but had identical 5-FU sensitivity and relative fitness 
(Figure 3), indicating that genomes derived from a single virus plaque encode the adaptive 
changes required by the total population. Together, these data demonstrate that mutations outside 
of ExoN(-) motif I can confer greater fitness advantages than intermediate revertants even at 
early passages. These early adaptive mutations likely reduce the selective pressure for motif I 
reversion and place the intermediate revertants at a selective disadvantage. 
Adaptive mutations in nsp12 and nsp14 that increase ExoN-AA fitness confer significant 
fitness costs to WT-ExoN-DE. Mutational fitness effects are highly dependent upon the genetic 
background (25-27). In addition to reducing selective pressure for reversion, mutations 
conferring increased fitness to ExoN-AA might also reduce the benefits of motif I reversion. We 
previously reported that long-term passage of ExoN-AA selects for secondary adaptive 
mutations in the nsp12 RdRp and nsp14 (nsp12-P250 and nsp14-P250) (7). Nsp12-P250 contains 
7 nonsynonymous mutations that partially compensate for defective proofreading and increase 
ExoN-AA fitness. Nsp14-P250 contains 6 nonsynonymous mutations, including a conservative 
D-to-E substitution in ExoN motif III, and increases ExoN-AA fitness without compensating for 
defective proofreading. To test whether the fitness effects of passage-associated mutations in 
nsp12-P250 and nsp14-P250 depend upon the ExoN-AA genotype, we engineered a WT motif I 
(ExoN-DE) into viruses containing nsp12-P250 and nsp14-P250, alone and together, and 
analyzed replication, 5-FU sensitivity, and competitive fitness. Compared to WT-ExoN-DE, both 
ExoN-DE-nsp12-P250 and ExoN-DE-nsp14-P250 displayed delayed and decreased replication 
(Figure 4A). In 5-FU sensitivity assays, ExoN-DE-nsp14-P250 was indistinguishable from WT-
ExoN-DE, while both variants containing nsp12-P250 (ExoN-DE-nsp12-P250 and ExoN-DE-
nsp12/14-P250) were significantly more sensitive to 5-FU (Figure 4B). Finally, the nsp12-P250 
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and nsp14-P250 mutations significantly decreased fitness relative to WT-ExoN-DE (Figure 4C). 
We detected no statistical differences between the specific infectivity of WT-ExoN-DE and any 
of the nsp12-P250 and nsp14-P250 variants in isolated infections (Figure 4D). Thus, mutations 
in nsp12 and nsp14 that arose in the ExoN-AA background were detrimental to replication, 
mutagen sensitivity, and competitive fitness in the presence of a fully-reverted ExoN-DE. These 
results support the conclusion that the adaptive pathways available to ExoN-AA may stabilize 
the ExoN-AA genotype, reducing both the selective pressure for, and the potential benefits of, 
primary reversion. 
 
DISCUSSION 
In this study, we demonstrate that the stability of the ExoN(-) motif I genotype in MHV (ExoN-
AA) is a consequence of the limitations and opportunities of the genetic landscape it explores 
during replication (Figure 5). Our results support a model in which the viable adaptive pathways 
leading to direct reversion of motif I from AA-to-DE are relatively flat on a fitness landscapes, 
as intermediate revertants remain phenotypically ExoN(-) and confer no fitness advantage over 
ExoN-AA. In contrast, at least one alternative adaptive pathway is readily accessible and imparts 
immediate fitness gains over ExoN-AA. We propose that even minimal alternative pathway 
adaptive fitness gains reduce the likelihood and benefits of motif I reversion, until eventually the 
changing genetic background renders reversion detrimental. These data and this model suggest 
that selection during replication favors immediate, incremental fitness gains along the most 
accessible pathway rather than dramatic fitness increases across a larger genetic barrier. 
 
Our results also extend existing studies of CoV ExoN motif I. Motif I AAàDE mutations in the 
SARS-CoV nsp14-ExoN dramatically reduce nuclease activity in biochemical assays, but no 
study has examined the contributions of each residue independently (16, 18). Intermediate 
revertants of ExoN-AA did not display consistent or statistical differences in replication, 5-FU 
sensitivity, or competitive fitness relative to ExoN-AA, suggesting that they remain 
phenotypically ExoN(-) during infection and supporting previous studies that motif I DE is 
essential for WT ExoN function. Given these results, we were surprised to observe repeated 
reversion of the ExoN-AE but not the other two 2nt variants, ExoN-DA and ExoN-ED. One 
potential explanation is that the specific mutational bias of ExoN-AE makes the revertant 
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mutations more accessible than in ExoN-DA or ExoN-ED. Alternatively, if ExoN-AE has 
profound replication or fitness defects, selection could drive primary reversion more quickly 
away from this genotype. Consistent with this hypothesis, ExoN-AE reverted more quickly at a 
higher MOI, where natural selection acts more efficiently on a larger population size (Table 1) 
(28).  Biochemical studies would be valuable to understand how nsp14-ExoN-AE differs from 
the other intermediate revertants, with an eye towards understanding the catalytic constraints and 
functional interactions with nascent CoV RNA.  
 
CoV replication proceeds through the concerted action of multiple proteins proposed to resemble 
DNA replication holoenzymes (29). Due to the extensive interactions between CoV proteins, 
they must coevolve in a highly cooperative manner to maintain their essential functions. 
Consistent with this hypothesis, the fitness effects of mutations in nsp12-P250 and nsp14-P250 
differ based on the motif I genotype; they are beneficial in ExoN-AA but detrimental in the WT-
ExoN-DE background. In previous studies, it has been difficult to determine whether the fitness 
defects in ExoN(-) CoVs are directly linked to low-fidelity replication or through some other 
mechanism. Our data suggest that the proofreading function of nsp14-ExoN can be uncoupled 
from its more general role in replication (Figure 4), providing an opportunity to examine 
additional roles for this essential protein. Nsp12-P250 also will be an important tool for 
understanding the relationship between RdRp fidelity and ExoN proofreading during CoV 
replication and for studying replication complex assembly and interactions. Our studies suggest 
that compensatory mutations identified through long-term passage could stabilize the ExoN-AA 
genotype. In particular, the high-fidelity nsp12-P250 could reduce the probability of reversion by 
reducing mutational sampling within motif I (30), and both nsp12-P250 and nsp14-P250 render 
the MHV genome inhospitable to a WT-ExoN-DE. Together, these studies argue that 
experimental evolution can generate reagents to define critical interactions involved in CoV 
replication and can identify new strategies for stabilizing attenuated CoVs. 
 
MATERIALS AND METHODS 
Cell culture. Delayed brain tumor (DBT-9) cells (31) and baby hamster kidney 21 cells 
expressing the MHV receptor (BHK-R) (32) were maintained at 37°C in Dulbecco’s Modified 
Eagle Medium (DMEM, Gibco) supplemented with 10% serum (HyClone FetalClone II, GE 
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Healthcare or Fetal Bovine Serum, Invitrogen), 100 U/mL penicillin and streptomycin (Gibco), 
and 0.25 µM amphotericin B (Corning). BHK-R cells were further supplemented with 0.8 
mg/mL G418 selection antibiotic (Gibco). The infectious clone of the murine hepatitis virus 
strain A59 (MHV-A59; GenBank accession number AY910861) was used as the template for all 
recombinant viruses . 
 
Determination of viral titer by plaque assay. Virus samples were serially diluted and 
inoculated on subconfluent DBT-9 cell monolayers in either 6- or 12-well format. Cells were 
overlaid with 1% agar in DMEM and incubated overnight at 37°C. Plates were fixed with 4% 
formaldehyde and agar plugs were removed. The number of plaques per well was counted by 
hand and used to calculate titer (32). 
 
Plaque purification of viral populations. DBT cells were infected with serial dilutions of virus 
and overlaid with 1% agar in DMEM. Single plaques were isolated with glass Pasteur pipettes, 
resuspended in PBS containing calcium and magnesium, and inoculated onto fresh DBTs. This 
process was completed 3 times before generating experimental stocks. 
 
Cloning and recovery of recombinant viruses. Site-directed mutagenesis in MHV genome 
fragments was performed using “round the horn” PCR (originally described in (33)). Briefly, 
adjacent primers containing the mutation of interest were 5¢-phosphorylated using T4 
polynucleotide kinase (NEB, M0201S) using the buffer from the T4 DNA ligase, which contains 
ATP (M0202S). PCR was performed on a plasmid template using the Q5 High-fidelity 2x 
Master Mix (NEB, M0492L), with primers at final concentration of 500nM. The linear 
amplification product was purified using the Promega Wizard SV Gel and PCR Clean-up System 
(Promega Corporation, A9282), and 4 µL was ligated at 16°C overnight with the T4 DNA ligase 
(NEB M0202S). After transformation into chemically-competent Top10 E. coli (lab-derived) and 
expansion in liquid culture, the MHV segment of each plasmid was sequenced. Viruses were 
constructed, rescued, and sequenced as described previously (7, 13, 32). Experimental stocks 
were generated by infecting a subconfluent 150 cm2 flask of DBT-9 cells at MOI of 0.01 
PFU/cell. Flasks were frozen at -80°C when monolayers were fully involved, approximately 20-
28 hours post-infection depending on the variant. After thawing, the supernatant was clarified by 
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centrifugation at 4,000 x g (Sorvall RC 3B Plus; HA-6000A rotor) for 10 min at 4°C. For 
intermediate revertants, stocks were generated in serum-free DMEM and processed as above 
before being concentrated roughly 10-fold by centrifugation at 4,000 x g using Amicon Ultra-15 
Centrifugal Filter Units, 100kDa (EMD Millipore, UFC910008). The virus titer of each stock 
was determined by plaque assay using DBT-9 cells as described above. 
 
Passage of ExoN intermediate revertants. Intermediate revertants of ExoN-AA were passaged 
10 times on subconfluent DBT-9 cell monolayers in 24-well plates at an estimated MOI of either 
0.01 or 0.5 PFU/cell. Supernatants were harvested at 24 and 20 hours post-infection for MOI = 
0.01 and 0.5 PFU/cell, respectively, and screened for WT reversion by plaque assay. At least 
three WT-like plaques were sequenced for each lineage to confirm motif I reversion. 
 
Replication kinetics. Viral replication kinetics in DBT-9 cells were determined at indicated 
MOIs as described previously (11). Replicates were synchronized by 30-minute incubation at 
4°C before transferring to the 37°C incubator. Supernatant (300 μL) was harvested at the 
indicated time points and titered by plaque assay. 
 
Determination of specific infectivity. Subconfluent monolayers of DBT-9 cells in 24-well 
plates were infected with the indicated virus at MOI = 0.05 PFU/cell, and supernatant was 
harvested at 16 hours post-infection. Genomic RNA in supernatant was quantified using one-step 
reverse transcription quantitative RT-PCR (RT-qPCR) on TRIzol-extracted RNA as described 
previously (9). Briefly, genomic RNA was detected with a 5’ 6-carboxyfluorescein (FAM) and 
3’ black hole quencher 1 (BHQ-1) labeled probe targeting nsp2 (Biosearch Technologies, 
Petaluma, CA), and RNA copy number was calculated by reference to an RNA standard derived 
from the MHV A fragment. Samples were plated in technical duplicate to minimize well-to-well 
variation. Titers were determined by plaque assay in DBT-9 cells, and specific infectivity was 
calculated as PFU per supernatant genomic RNA copy. 
 
5-fluorouracil sensitivity assays. Stock solutions of 5-fluorouracil (Sigma F6627) were 
prepared in dimethyl sulfoxide (DMSO). Sensitivity assays were performed in 24-well plates at 
MOI = 0.01 PFU/cell, as previously described (7). Cells were incubated with drug for 30 minutes 
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prior to infection. Supernatants were harvested at 24 hours post-infection, and titers were 
determined by plaque assay. 
 
Competitive fitness assays. ExoN-AA-reference and WT-ExoN-DE-reference viruses were 
marked with 7 consecutive silent mutations within nsp2 (wild-type: 1301-TTCGTCC-1307; 
reference: 1301-CAGCAGC-1307) by round the horn PCR, as described above. Competitions 
were performed in triplicate on DBT-9 cells in 12-well plates, plated at a density of 1 x 105 cells 
per well 24 hours prior to infection. Cells were infected at a total MOI of 0.1 PFU/cell (MOI = 
0.05 PFU/cell each for competitor and reference virus). Supernatants were harvested 15 and 16 
hours post-infection for experiments with ExoN-AA-reference and WT-ExoN-DE-reference, 
respectively, and passaged 4 times. Samples were titered between all passages to maintain total 
MOI of 0.1 PFU/cell. RNA was extracted from 70 μL of supernatant using QIAamp 96 virus 
QIAcube HT kit on the QIAcube HT System (Qiagen). Each RNA sample was analyzed by one-
step RT-qPCR with two SYBR Green assays. Reference viruses were detected with forward 
primer SS-qPCR-Sil-F (5¢-CTATGCTGTATACGGACAGCAGT-3¢; 200nM final) and reverse 
primer SS-qPCR-R2 (5¢-GGTGTCACCACAACAATCCAC-3¢, 200nM final). Competitors were 
detected with forward primer SS-qPCR-WT-F (5¢-CTATGCT-GTATACGGATTCGTCC-3¢, 
450 nM final) and reverse primer SS-qPCR-R2 (5¢-GGTGTCAC-CACAACAATCCAC-3¢, 450 
nM final). RNA samples were diluted 1:100 prior to RT-qPCR with Power SYBR Green RNA-
to-Ct 1-step kit (Applied Biosystems) according to the manufacturer’s protocol. Duplicate wells 
were averaged, and values were excluded from subsequent analysis if the duplicate wells differed 
by > 0.5 Ct. The relative abundance of competitor and reference were determined by subtracting 
Ct thresholds (DCtcompetitor = Ctcompetitor – Ctreference) and converted to reflect the fold-change in 
ratio (Dratio = 2-DCt competitor). The log10Dratio was plotted against passage number, and the change 
in log10Dratio (i.e. slope of linear regression) is the relative fitness. Note that regressions were fit 
only through P1-P4, as slight deviations in 1:1 ratio in the input (P0) can skew the slope. 
 
Statistical analysis. GraphPad Prism 6 (La Jolla, CA) was used to perform statistical tests. Only 
the comparisons shown [e.g. ns or asterisk(s)] within the figure or legend were performed. In 
many cases the data were normalized to untreated controls. This was performed using GraphPad 
Prism 6. The number of replicate samples is denoted within each figure legend.  
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Figure 1. Sequence landscape around ExoN-AA motif I. (A) ExoN motif I nucleotide sequences. 
(B) Landscape of single-nucleotide substitutions within ExoN-AA motif I. (C) Predicted pathways to 
reversion of ExoN-AA. Variants marked with # reverted to WT during three independent recovery 
attempts. 
D89 E91
GAT GAA
A89 A91
GCA GCT
WT-ExoN-DE
ExoN-AA
A BExoN Motif I
C
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Figure 2. Intermediate revertants of ExoN-AA motif I do not have selective advantages. (A) 
Replication kinetics at MOI = 0.01 PFU/cell plotted as mean ± SD of n = 3. (B) Competitive fitness of 
each variant relative to ExoN-AA. Viruses were competed with a tagged ExoN-AA-reference strain, 
and relative fitness was normalized to the mean of ExoN-AA. (C) 5-fluorouracil sensitivity at MOI = 
0.01 PFU/cell. Statistical significance of each variant relative to ExoN-AA was determined by one-
way ANOVA with multiple comparisons (Panel D) two-way ANOVA with Dunnett’s multiple 
comparisons (panel C). ****p<0.0001; ns = not significant. Data in (B) and (C) represent mean ± SD 
of n = 6. Boxed values have the same significance. #All lineages of ExoN-AE reverted to WT-ExoN-
DE during the experiment. 
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Figure 3. ExoN-AA adapts for increased fitness within 10 passages. (A) Replication kinetics of 
indicated viruses at MOI = 0.01 PFU/cell plotted as mean ± SD of n = 3. (B) 5-fluorouracil sensitivity 
at MOI = 0.01 PFU/cell. (C) Competitive fitness of individual recombinants relative to ExoN-AA. 
Viruses were competed with a tagged ExoN-AA-reference strain, and relative fitness was normalized 
to the mean of ExoN-AA. Statistical significance of each virus relative to ExoN-AA was determined 
by two-way ANOVA with Dunnett’s multiple comparisons (panel B) or by one-way ANOVA with 
multiple comparisons (Panel C). ****p < 0.0001, ns = not significant. LOD = limit of detection. Data 
in (B) and (C) represent mean ± SD of n = 6. Boxed values have the same significance. 
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Figure 4. Mutations that increase ExoN-AA fitness are detrimental in the presence of WT-ExoN-
DE. (A) Replication kinetics of indicated viruses at MOI = 0.01 PFU/cell plotted as mean ± SD of n = 
3. (B) 5-fluorouracil sensitivity at MOI = 0.01 PFU/cell, mean ± SD of n = 6. (C) Competitive fitness 
of individual recombinants relative to WT-ExoN-DE. Viruses were competed with a tagged WT-
ExoN-DE reference strain, and relative fitness was normalized to the mean of WT-ExoN-DE, mean ± 
SD of n = 6. (D) Specific infectivity (genomes per PFU) from isolated infections, mean ± SD of n = 4.. 
Statistical significance of each virus relative to WT-ExoN-DE was determined with two-way ANOVA 
with Dunnett’s multiple comparisons test (panel B) or by ordinary one-way ANOVA with Dunnett’s 
multiple comparisons test (panels C and D). **p < 0.01; ***p < 0.001; ****p < 0.0001; ns = not 
significant. 
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Figure 5. Model for the in vitro evolution of MHV-ExoN-AA. MHV-ExoN-AA(black dot) is a low-
fitness variant. Reversion to WT-ExoN-DE would dramatically increase fitness but can only be 
achieved by traversing a flat landscape and climbing a steep fitness cliff (dotted white arrows). 
However, secondary mutations that incrementally increase fitness are more accessible (solid white 
arrow). Eventually, the genetic background changes enough that reversion becomes detrimental 
(dotted yellow line). 
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Table 1. Recovery and passage of intermediate revertants.  
n.d.: not done. 
aBolded nucleotides must mutate to reach WT-ExoN-DE genotype. 
bRecovered viruses were subjected to 10 passages at the indicated MOI. Samples were screened for 
wild-type revertants by plaque assay, and revertant lineages were sequence-confirmed. 
 
Virus
# of mutations to 
WT-ExoN-DE Motif I sequencea
# of reverted lineages by passage 10b
MOI = 0.01 MOI = 0.5
ExoN-AA 4 GCA…GCT 0/3 0/3
ExoN-AD 3 GCA…GAT 0/3 0/3
ExoN-EA 3 GAA…GCT 0/3 0/3
ExoN-DA 2 GAT…GCT 0/3 0/3
ExoN-AE 2 GCA…GAA 1/3 (by P8) 3/3 (by P2)
ExoN-ED 2 GAA…GAT 0/3 0/3
ExoN-EE 1 GAA…GAA n.d. n.d.
ExoN-DD 1 GAT…GAT n.d. n.d.
WT-ExoN-DE 0 GAT…GAA n.d. n.d.
Table 2. Mutations in ExoN(-) P10. Data derived from dideoxy sequencing. 
aMutation present at approximately 50% of population. 
bMHV HE is not transcribed in tissue culture. 
cAmino acid numbers designate positions within cleaved nsps, not the polyprotein. 
 
 
 
Mutation 
number
Nucleotide 
change
Protein Amino acid 
changec
1 G2520Aa nsp2 D524N
2 A3080Ga nsp3 silent
3 T16017A nsp12 M814K
4 A17836Ga nsp13 I492M
5 G22673Aa HEb noncoding
6 A29298Ca M silent
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